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Abstract
The tumour suppressor protein p53 is inactivated in a large proportion of human 
cancers. p53 controls growth and proliferation, through multiple mechanisms, 
including the ability to regulate transcription. p53 can function as a general repressor 
of RNA polymerase (pol) III transcription. Pol III is responsible for transcribing a 
variety of small stable RNAs including tRNA, 5S rRNA, and the adenoviral VAl 
RNA. p53 targets TFIIIB, a TBP-containing factor that is essential for recruitment of 
pol III to its templates. This study investigates the TFIIIB-p53 interaction, and how it 
serves to regulate pol Ill-transcribed genes. p53 does not disrupt the interaction 
between the TFIIIB subunits, TBP and B rfl. It does, however, prevent association of 
TFIIIB with the pol III specific factor TFIIIC2, and pol III itself. Immobilised 
template and chromatin immunoprécipitation analysis show that p53 prevents the 
recruitment of TFIIIB, but not TFIIIC2, to the tRNA promoter. Pol III repression 
camiot be attributed to one clearly defined region of p53. Sequence within both the 
N- and C-termini are essential, and the central core domain is also implicated in 
playing a role. Evidence is provided here that p53-mediated repression of tRNA 
genes occurs via a trichostatin A-sensitive histone deacetylase independent 
mechanism.
p53 is deregulated or mutated in the vast majority of human cancers. Individuals who 
inlierit mutant forms of p53 can suffer from Li-Fraumeni Syndrome (LFS), a familial 
cancer syndrome associated with a range of malignancies. Here is shown that pol III 
transcriptional activity is often highly elevated in primary fibroblasts from Li- 
Fraumeni patients, especially if the germline p53 mutation is followed by loss of the 
remaining allele. Deregulation of p53 function tlnough the action of various
II
Ï
oncoproteins can also contribute to carcinogenesis. E6 from human papilloma virus 
can bind to p53 and neutralise its function and E6 releases pol III from p53-mediated 
repression. Induction of the Mdm2 regulating protein p i4^^^ results in a p53- 
mediated repression of pol III activity. p53 does not interfere with nonnal cellular 
growth and development; it is, however, rapidly induced in response to cellular 
stress. Here it is shown that the DNA-damaging agent MMS provokes a p53 
response that correlates with a dramatic pol III transcriptional repression.
Collectively the data presented here support the idea that p53 can directly repress pol 
III transcription through interactions with the basal pol III machinery. p53 status can 
have a profound effect upon pol III activity; the precise circumstances under which 
such control becomes physiologically important however, remains to be detemiined.
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Chapter 1 
Introduction
1.1 p53-‘Guardian of the Genome’
The tumour suppressor protein, p53, aptly named the ‘Guardian of the Genome’ 
(Lane 1992), is mutated in over 50% of all human cancers (Hollstein et al. 1994). 
Furthennore, in many tumours which do not harbour a p53 mutation, deregulation 
events occur frequently at other points in the p53 activation or response pathways 
(Sherr and Weber 2000). Deregulation of p53 provides a selective advantage for the 
clonal expansion of genetically damaged cells, ultimately leading to tumour 
progression (Hollstein et al. 1991). The discovery of p53, in 1979, was the 
culmination of two studies. Initially, studies of simian virus 40 (SV40) transformed 
cells demonstrated that a 54kDa protein coprecipitated with the large T-antigen of 
SV40 (Chang et al. 1979;Ki-ess et al. 1979; Lane and Crawford 1979; Linzer and 
Levine 1979). In addition, it was shown that the 541cDa protein was over expressed in 
a wide variety of murine SV40 transformed cells and uninfected embryonal 
carcinoma cells (Linzer and Levine 1979). At the same time, but independently from 
the above studies, the p53 protein was identified due to its high expression level in 
chemically induced tumours (DeLeo et al. 1979).
Early observations suggested that p53 might function as an oncogene, since 
overexpression of p53 appeared to cause oncogenic transfomiation of cells (Jenldns 
et al. 1984; Parada et al. 1984; Eliyahu et al. 1985). However, once p53 cDNA was
1
cloned (Zakut-Houri et al. 1985), a variety of studies demonstrated the normal 
function of p53 to be anti-oncogenic. This conclusion was also based on the findings 
that rearrangement and functional inactivation of the p53 gene was observed at high 
frequency in mouse spleen tumours induced by the Friend erytluoleukaemia virus 
(Mowat et al. 1985; Chow et al. 1987; Rovinski et al. 1987; Mumne et al. 1988). 
Furthermore introduction of wild-type p53 was found to be growth suppressive 
(Mercer et al. 1990; Michalovitz et al. 1990; Martinez et al. 1991; Crook et al. 1994). 
p53 is not an essential gene; mice that are homozygously null for the p53 gene 
develop normally; they do, however, display a strong disposition to cancer such that 
74% develop tumours by the age of 6 months (Donehower et al. 1992). The 
importance of p53 is also displayed in individuals with Li-Fraumeni syndrome 
(LFS), a rare familial cancer disorder (Li 1969).
The genetic basis of LFS is an inherited mutation in the gene encoding p53 (Malkin 
et al. 1990). Unusual characteristics of this syndrome are the young age at which 
individuals develop cancer, the fact that individuals often develop multiple primary 
tumours, and the overall high frequency of cancer in the family. Many different types 
of cancer develop in families with LFS; the most common of which are sarcomas, 
breast cancer, leukaemia, brain tumours and adrenocortical carcinoma (Li 1969; 
Kleihues and al 1997). In LFS, an infected individual is heterozygous for the TP53 
mutant allele, having one wild-type and one defective TP53 gene. The TP53 
germline mutation and the cancer phenotype caused by the mutation are inlierited in 
an autosomal-dominant fashion (Lustbader and al 1992); therefore, an individual 
with cancer inlieriting the TP53 mutation will have a 50% chance of producing 
offspring with cancer. The penetrance of cancer is also high in LFS; an individual
who inlierits a TP53 mutation has a very high risk of developing cancer (Lustbader 
and al 1992).
1.2 p53 structure
The p53 protein can be divided roughly into thirds (Figure 1.1). The acidic activation 
domain at the amino terminus, mediates transcriptional activation. This domain, 
which constitutes the first 42 amino acids of p53, is capable of interacting with 
several proteins. It binds directly to the TBP-TAF complex in TFIID (Martin et al. 
1993; Thut et al. 1995b), directly regulating pol II gene expression. Amino acids 
F 19, L22 and W23 have been shown to be required for transcriptional activation in 
vivo (Lin et al. 1995). These amino acids make contacts with the TATA-associated 
factors TAFiiVO and TAFn31 (Lu and Levine 1995; Thut et al. 1995a). The 
adenovirus ElB-55kD protein and the human Mdm2 protein negatively regulate 
transcriptional activation. In both cases, amino acids 22 and 23 play a key role in 
binding of p53 to ElB-55Kd or Mdm2 (Lin et al. 1995).
The central core domain encompasses amino acids 102-292, and contains the 
sequence specific DNA-binding domain. This portion o f the protein forms a 
protease-resistant and independently folded domain containing an essential Zn+ ion 
required for sequence specific DNA binding activity. Tetrameric p53 binds to four 
repeats of a consensus DNA sequence 5’-PuPuPuC(A/Y)-3’. This sequence is 
repeated as a pair of inverted repeats. An extensive analysis of thousands of tumours 
and tumour cell lines has revealed the extraordinary extent to which p53 mutations 
are found (Hollstein et al. 1994). Approximately half the major forms of cancer
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contain p53 missense mutations, 90% of which reside in the sequence specific DNA 
binding domain, and more than 40% of these mutations are localised to residues 
R175, G245, R249, R273 and R282 (Figure 1.2). These are Icnown as the ‘hot-spof 
mutation sites (Cho et al. 1994). Mutations generally fall into two classes. Mutation 
at amino acid residues such as R248 or R273, result in defective contacts with the 
DNA and consequently loss in the ability of p53 to function as a transcription factor. 
The second class of mutation disrupts the structural integrity of the protein. The 
resultant altered confonnation produces a protein that is reactive with the monoclonal 
antibody pAb240. The epitope recognised by this antibody is not accessible in the 
native or wild-type p53 conformation (Cho et al. 1994; Hollstein et al. 1994).
The carboxy terminus is a multifunctional domain and comprises the remainder or 
the protein (K.o and Prives 1996). Native p53 exists as a tetramer in solution, and 
amino acids 324-356 are required for oligomerisation of the protein. The 26 extreme 
C-terminal residues form a protease-sensitive domain rich in basic amino acids. 
There is substantial evidence that the p53 protein requires a stmctural change to 
activate it for sequence-specific DNA binding. This latent, non-DNA binding, form 
of p53 can be regulated by the C-terminal amino acids. Deletion of this domain, 
phosphorylation at residue S378 by protein kinase C or residue S392 by casein 
kinase II, or binding of antibody pAb421 all activate the specific DNA binding 
activity of the central core domain (Hupp et al. 1992; Hupp and Lane 1994). 
Acétylation of sites within the C-terminus or the adjacent linking region has also 
been shown to stimulate the ability of p53 to bind DNA (Gu and Roeder 1997; 
Sakaguchi et al. 1998). Based on these observations it was assumed that the C- 
terminus of p53 serves as a negative regulator of the central core domain’s sequence-
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specific DNA binding activity, This hypothesis was, however, challenged recently by 
Espinosa and Emerson. The authors showed that while acétylation of p53 by p300 
can stimulate its ability to bind to short oligonucleotides containing a binding site 
from the p21 promoter, it had no effect on the ability of p53 to bind its sites within 
the p21 promoter when they are present in a much longer DNA molecule. It was also 
shown that a p53 protein deleted of its C-terniinus is actually less effective in 
interacting with the p21 promoter when present in naked or clnomatinised DNA 
(Espinosa and Emerson 2001). These experiments therefore challenge the notion that 
the p53 C-terminus serves in an autoinhibitory role. They also provide evidence that 
acétylation has no significant effect on the interaction of p53 with DNA. These 
findings are supported by clrromatin immunoprécipitation (ChIP) assays 
demonstrating that wild-type p53, or p53 containing several mutated acétylation 
sites, bind similarly to the p21 promoter in U20S cells (Bariev et al. 2001).
1.3 Activation of p53
Nonnally in a cell, the p53 protein is kept at low levels, in a latent inactive form. 
Consequently, it does not interfere with cell cycle progression or cell survival. A 
variety of conditions can lead to the rapid induction of p53 activity (Figure 1.3). 
Each condition represents a different form of cellular stress. Several different type of 
DNA damage can activate p53. These include double DNA stand breaks, produced 
by y-irradiation, the presence of DNA repair intermediates, after ultraviolet 
irradiation, or chemical damage to DNA. It has been predicted that even a single 
double-stranded break is enough to induce p53 (DiLeonardo et al. 1994). Damage to
Oncogene
Activation
Hypoxia
DNA
Damage
Mitotic Spindle 
Damage
i
Biological Effects
Ribonucleotide
Depletion
Other Stresses
Activation 
and amplification
Figure 1.3. Signals that activate p53. Multiple stress induced signals can activate 
p53. These include DNA damage, hypoxia, ribonucleotide depletion, oncogenic 
stresses and mitotic spindle damage. Both p53 activity and protein levels. Are 
increased. Activated p53 can then elicit its biological effects.
cellular components such as the mitotic spindles can also induce a p53 response 
(Cross et al. 1995).
In addition to cellular damage, exposure of cells to sub optimal growth conditions 
such as hypoxia (Graeber et al. 1994) can stimulate p53 levels and activate the p53 
protein. This process may represent another way that p53 may act as a gatekeeper 
against the formation of cancers. Many tumours begin to replicate and reach a critical 
size when the blood supply becomes limiting. The resultant hypoxia might trigger 
p53 activity and kill such cells (Levine 1997). Another signal reported to activate 
p53 is ribonucleotide depletion (Linke et al. 1996). Oncogenic proteins such as Myc, 
Ras, adenovirus E lA  and (3-catenin can also induce a p53 response (D ebb as and 
White 1993; Hermeking and Eick 1994; Serrano et al. 1997; Damalas et al. 1999).
1.4 Regulation of p53 activity
Induction of p53 tlirough stress occurs via several mechanisms. Stress-induced 
increases in the transcription of p53 have been described (Oren 1999). Furthermore, 
an increase in p53 niRNA translation may play a minor role in activating p53 in 
response to stress. There is evidence that this may be achieved tlnough relief of 
translational repression, operating through the 3’-untranslated region of the p53 
niRNA (Fu et al. 1996). Despite these observations, it is generally accepted that 
accumulation of active p53, in response to stress, occurs mainly tlnough post- 
translational mechanisms.
p53 generally exists in an inactive, labile state, with a very short half-life. In response 
to stress the p53 protein is markedly stabilised (Kastan et al. 1991). Additionally, 
there is also a conversion of p53 from the latent to active form. (Hupp et al. 1992; 
Bayle et al. 1995; Lambert 1998). It is becoming increasingly apparent that post- 
translational modifications such as phosphorylation and acétylation play a major role 
in the rapid stabilisation and activation of the p53 protein.
1.4.1 Regulation of p53 by post-translational modifications
Phosphorylations within the N-terminus of p53 are clearly involved in the regulation 
of p53 stability. Such modifications can interfere with the ability of p53 to bind 
Mdm2. By phosphorylating serine-15 and serine-37, both ATM and ATR kinases can 
activate p53 transcriptional activity, in response to DNA damage (Dumaz and Meek
1999). ATM can also phosphorylate Chk2, a kinase that phosphorylates p53 directly 
within the Mdm2 binding domain (Chehab et al. 2000; Hirao et al. 2000; Shieh et al.
2000). ATM also induces déphosphorylation of the C-tenninus of p53 (Waterman et 
al. 1998). Many other kinases have been shown to be capable of phosphorylating the 
N-terminus of p53 in vitro. These include DNA-PK, INK, p38, CKI and CAK 
(Ljungmaii 2000), although in many cases the physiological relevance of such 
modifications remains to be clarified (Woods and Vousden 2000).
A series of C-temiinal residues undergo phosphorylation resulting in the activation of 
the p53 protein. Phosphorylation of serine-392, by CK2 or PDK can efficiently 
activate DNA binding and transcriptional activity (Hupp et al. 1992; Blaydes and 
Hupp 1998; Cuddihy et al. 1999). A similar effect has been described for 
phosphorylation of serine-315, by cyclin-dependent kinases (Wang and Prives 1995;
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Blaydes et al. 2000). It has also been suggested that sub cellular localisation of p53 
might be regulated tlnough the coordinate effect of these two kinases, with CK2 
phosphorylation favouring nuclear localisation and CDK phosphorylation driving 
nuclear export (Ljungman 2000).
Acétylation of lysine residues within p53 has been demonstrated to modulate its 
function. p300/CBP can enhance the transcriptional function of p53 by interacting 
with the N“tenninus and acetylating lysine-382 located in the C-tenninus (Sakaguchi 
et al. 1998). The precise function of p53 acetylation/deacetylation unfortunately 
remains unclear at present (Prives and Manley 2001). Acétylation of this site was 
believed to activate the DNA-binding activity of p53 in a mamier similar to that of 
phosphorylation of the C-terminus (Gu and Roeder 1997). This idea has, however, 
been challenged (Bariev et al. 2001; Espinosa and Emerson 2001), and it seems 
unlikely that acétylation of p53 has a significant effect on its ability to bind to sites 
within promoters of target genes. Possible roles for p53 acétylation include 
transcriptional activation, mediated tlnough the recruitment of the coactivators 
p300/CBP, and the PCAF complex (Bariev et al. 2001). Acétylation of p53 may also 
serve to recruit deacetylases inorder to down regulate gene expression. There are 
several lines of evidence that interactions of p53 with deacetylases play a role in p53 
regulation (Murphy et al. 1999; Juan et al. 2000).
Phosphorylation of p53 within the N-terminus has been shown to entrance p300 
binding and p53 acétylation of lysine 382 (Sakaguchi et al. 1998). This finding is 
supported by reports showing that phosphorylation of p53 at N-terminal residues 
indeed increases its interactions with p300 (Dumaz and Meek 1999; Doman and
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Hupp 2001). A similar stress-induced phosphorylation-dependent interaction with 
PCAF has been shown to result in acétylation of lysine 320 (Sakaguchi et al. 1998; 
Liu et al. 1999). In contrast to phosphorylation, Mdm2 blocks the ability of p300 to 
acetylate p53 (Kobet et al. 2000; Ito et al. 2001).
1.4.2 Regulation of p53 by Mdm2
One of the central components in regulating p53 is the p53-interacting protein, 
Mdm2 (Lolmiin and Vousden 1999). Mdm2 is a transcriptional target of p53. hi this 
feedback loop, p53 drives the expression of its own negative regulator (Figure 1.4) 
(Wu et al. 1993). This mechanism may serve to keep check on p53 activity in normal 
unstressed cells or may contribute to limiting or reversing the p53 response following 
removal of the initiating stress (Bar-Or et al. 2000). Mdm2 is essential in the 
prevention of p53 activation during development. This is exemplified by the 
consequences of deleting the Mdm2 gene in mice. Homozygous deletion of Mdm2 
results in a very early embryonic lethality, resulting from excessive apoptosis (de 
Rozieres et al. 2000). This lethality is completely rescued however by the 
simultaneous deletion of p53, allowing entirely normal growth and development 
(Jones et al, 1995; Montes de Oca Luna et al. 1995).
Mdni2 interacts with the N-terminal transcriptional activation domain of p53 
(Momand et al. 1992) Binding of Mdm2 can therefore inlribit p53’s transcriptional 
activity by interfering with the recruitment of coactivators such as p300/CBP (Oliner 
et al. 1993; Wadgaonkar and Collins 1999). Mdm2 also regulates the stability of p53 
(Haupt et al. 1997; Kubbutat et al. 1997a). Mdm2 is a RING-fmger protein that 
functions as a ubiquitin ligase for both p53 and itself
12
Transcriptional
activation
i
Degradation
pl4A R F
1
Mdm2
Ub
Ub
p53
Figure 1.4. The p53-lMdm2 auroregulatory loop. Activated p53 protein binds to 
the Mdm2 gene and activates its expression. The resultant Mdm2 protein binds to 
p53 and blocks its activity. Binding of Mdm2 to p53 promotes the ubiquitination of 
p53 and its subsequent degradation. Deregulated oncogenic signals can also induce 
the synthesis of pi which binds to Mdm2 and blocks its action. Ub, ubiquitin.
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(Honda et al. 1997; Fang et al. 2000; Midgley et al. 2000). Mutations within the 
RING-fingers domain of Mdm2 inhibit ubiquitination and result in stabilization of 
both proteins. The ability of Mdm2 to regulate p53 activity can be modulated by 
other factors. A role for p300 has been described in supporting efficient degradation 
of p53 (Grossman et al. 1998).
p53 activation may also involve a change in subcellular localisation. Both nuclear 
import and export are tightly regulated (Vousden and Woude 2000). Nuclear import 
of p53 depends on its interaction with the microtubule network (Giannakakou et al. 
2000), although nuclear localisation signals located on the C-temiinus of p53 (Figure 
1.1) mediate this response. p53 also contains a nuclear export signal in the carboxy 
terminus (Stommel et al. 1999); however, efficient export of p53 to the cytoplasm 
depends on Mdm2 function. Studies have shown that the ubiquitin ligase function of 
Mdni2 is essential for p53 export (Boyde et al. 2000; Geyer et al. 2000). Some 
studies have suggested that efficient degradation of p53 requires nuclear export 
(Freedman and Levine 1998; Boyde et al. 2000; Geyer et al. 2000).
Like p53, Mdni2 is subject to extensive regulation. Mdm2 expression can be directly 
inlhbited in response to various stress signals (Freedman et al. 1999; Ashcroft et al.
2000). Mdm2 is subject to post-translational modifications (Hay and Meek 2000). 
Phosphorylation within the N-terminal p53-binding region of Mdm2, reduces the 
interaction between p53 and Mdm2 (Mayo et al. 1997). Sumoylation and 
ubiquitination of Mdm2 has also been reported to modulate its function. Stress- 
induced loss of SUMO-1 modification allows autoubiquitination of lysine 446 and 
subsequent degi'adation of Mdm2 (Busclmiann et al. 2000).
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Disruption of Mdm2 function can also be achieved by p i4^^^. This small protein 
arises tlii'ough the translation of an alternate reading frame derived from the INIC4A 
tumour suppressor gene (Kamijo et ah 1997). pld"^ *^^  can act directly to inhibit the 
p53-directed ubiquitin ligase activity of Mdm2 (Honda and Yasuda 1999; Midgley et 
al. 2000). Abnormal oncogenic signals, such as E lA  and Myc, have been shown to 
lead to the activation of p53 thiough induction of p i 4^^^ (Weber et al. 1999; Lohrum 
et al. 2000). In some cells, the expression of also alters the subcellular
localisation of Mdm2, targeting itself and Mdni2 to the nucleolus (Weber et al. 1999; 
Lolmmi et al. 2000). Under these circumstance, p53 remains in the nucleoplasm, 
releasing p53 from the inliibitory effect of Mdm2 interaction.
1.5 Oncogenic deregulation of p53
Mechanisms other than point mutation can also functionally inactivate p53. Several 
oncoproteins can bind and neutralise p53 (Vousden 1995; Levine 1997). Although 
over 50% of all human cancers harbour p53 mutations, this is not the case in cancers 
of the cervix. More than 90% of ceiwical carcinomas contain DNA from a high risk 
Human Papillomavirus (HPV), most notably HPV-16 and 18. HPV is associated with 
a range of clinical conditions, the most serious of which is cervical carcinoma. The 
E6 oncoprotein from HPV-16 and 18 has been shown to complex with and target p53 
for rapid proteosome-niediated degradation (Scheffiier et al. 1990). As a 
consequence, the functions of p53 are abrogated (White et al. 1994a). Since p53 is 
frequently wild-type in cervical cancers, it is proposed that the activity of E6 is
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equivalent to an inactivating p53 mutation found in many other tumours (Crook et al. 
1992).
Other small DNA tumour viruses can target and inactivate p53. Adenovirus ElB 
protein binds directly to the N-teiminal activation domain of p53 (Kao et al. 1990), 
blocking its transcriptional activation function (Yew et al. 1994). Simian virus 40 
(SV40) can also inactivate p53 function. SV40 Large T antigen interacts with the 
central core domain of p53, inliibiting sequence specific DNA binding activity 
(Marston et al. 1994).
Some tumours inactivate p53 by amplification of the Mdm2 gene. Currently it is 
estimated that Mdm2 is over expressed in 30-40% of human sarcomas (Oliner et al. 
1992). Conversely, p l4  ARF, which binds to and functionally inactivates Mdm2 
(Figure 1.4), is deleted or methylated in many human cancers (Ruas and Peters 
1998). Several other mechanisms exist to compromise p53 function. For example, in 
a small number of breast tumours and neuroblastomas, p53 is inactivated by 
localisation of the protein in the cytoplasm. (Levine 1997).
1.6 p53 function
The p53 protein is a key regulator in a wide range of cellular processes including cell 
cycle control, DNA repair, genome stability, programmed cell death, differentiation, 
senescence and angiogenesis (Figure 1.5) (Ko and Prives 1996; Levine 1997). p53 
mediates many of these effects tlu'ough its ability to regulate transcription (Figure 
1.5) (Cox and Lane 1995; Haffner and Oren 1995; Ko and Prives 1996;
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Levine 1997). p53 can bind to DNA, as a tetramer, in a sequence-specific fashion, 
and stimulate expression of genes carrying p53 recognition elements in their 
promoters (Bargonetti et al. 1991; Kem et al. 1991; Farmer et al. 1992; Zambetti et 
al. 1992). A huge an*ay of p53 target genes have been described, and the coordinate 
expression of sub sets of these genes, depending on cell type, environment and 
stimulating signal, is likely to determine the outcome in response to cellular stress 
(Woods and Vousden 2000).
The p21/W AFl/Cipl gene (El-Deiry et al. 1993; Harper et al. 1993; Xiong et al. 
1993a) is one of the most studied p53 response genes (El-Deiry et al. 1993). Deletion 
of this gene significantly reduces the cell cycle response to p53 (El-Deiry 1998). The 
encoded protein forms part of a quaternary complex found in normal cells along with 
cyclin/CDKs and the DNA polymerase processivity factor PCNA (Xiong et al. 
1993a). In response to iinadiation, G1 arrest is mediated, at least in part, tlnough 
induction of p21/W AFl/Cipl by p53 (El-Deiry et al. 1994), which at high protein 
concentrations, inliibits the function of CDKs (Gu et al. 1993; Harper et al. 1993; 
Xiong et al. 1993b). Recently, it has been demonstrated that p53 can directly 
participate in DNA repair tlnough induction of a ribonucleotide reductase, p53R2 
(Nakano et al. 2000; Tanaka et al. 2000).
Induction of apoptosis is one of the most extensively studied functions of p53. p53 
has been shown to induce the expression of several genes that participate in the 
apoptotic response (Vousden 2000). Bax, a protein with homology to the survival 
factor Bcl-2, is upregulated in response to p53 (Miyashita and Reed 1995). Bax, in 
cooperation with other p53 inducible genes such as NOXA (Oda et al. 2000a),
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PUMA (Nakano and Vousden 2001) and p53AIPl (Oda et al. 2000b), trigger 
cytodn'ome c release fioin the mitochondria and induce activation of the Apaf- 
l/caspase9 apoptosome. p53 also induces expression of death receptors, such as Fas 
and Killer/DR5 and the death domain containing protein PIDD (Lin et al. 2000).
Control of gene expression is clearly an important function of p53, indeed, a recent 
study indicated that substitution of a gene encoding a transcriptionally inactive 
mutant p53 for the wild-type gene in mice, lead to loss of growth inliibitory activity 
(Chao et al. 2000; Jimenez et al. 2000). Despite this, transcriptionally independent 
activities of p53 play a role in mediating some of its downstream effects (Figure 1.5). 
For example, p53 has been implicated in the relocalisation of death receptors to the 
cell surface (Bennett et al. 1998).
1.7 Transcriptional repression by p53
In addition to activating genes whose promoters contain p53 binding sites, p53 can 
also repress expression of an ever increasing array of genes (Ginsberg et al. 1991; 
Mercer et al. 1991; Santhanam et al. 1991; Seto et al. 1992; Subler et al. 1992; Mack 
et al. 1993; Ragimov et al. 1993; Crook et al. 1994; Horikoshi et al. 1995; 
Chesnokov et al. 1996; Caims and White 1998). A microarray analysis of -6000 
RNA polymerase Il-dependent genes, revealed that 1.8% were induced by p53 
whereas 0.9% were repressed (Zhao et al. 2000). Genes repressed by p53 include c- 
fos, IL-6, PCNA, cyclin A and Bcl2. Many of the gene products suppressed by p53 
are involved in promoting cell cycle progi'ession. It has therefore, been proposed that 
the transcriptional repression function of p53, may contribute to its tumour
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suppression function (Ko and Prives 1996). This is underscored by the fact that many 
tumour derived p53 mutants have lost the capacity to inhibit transcription (Ginsberg 
et al. 1991; Mercer et al. 1991; Subler et al. 1992; Ragimov et al. 1993; Crook et al. 
1994). In addition, two oncoproteins have been shown to block p53-mediated 
repression without affecting activation (Crook et al. 1994).
The requirements for repression by p53 are not well established. p53 has been shown 
to associate with histone deacetylase complexes (HDACs). HD AC complexes 
function by deacetylating histone tails. Such modifications generally produce 
clnomatin structures that are not conducive to transcription. By utilising this 
mechanism, p53 was shown to inliibit the expression of Map4, a gene linked to the 
control of apoptosis (Murphy et al. 1996). Other proposed methods of transcriptional 
repression by p53 include p53 interacting with TBP-associated factors (TAPs) 
(Fanner et al. 1996b). Interestingly, a p53g]„22,sei-23 mutant, which retains the ability to 
interact with TBP but is unable to bind to TAFs is unable to repress transcription 
(Sabbatini et al. 1995). Therefore, although p53 has been shown to interact with TBP 
in vitro and in vivo (Seto et al. 1992; Liu et al. 1993; Truant et al. 1993a; Chang et al. 
1995; Horikoshi et al. 1995; Faimer et al. 1996a), the biological relevance of this 
interaction has not yet been fully established.
In one case transcriptional repression by p53 was shown to act tlnough interaction 
with a transcriptional activator. Repression of hsp70 by p53 is mediated thiough 
interaction with CCAAT binding factor (CBF), a transcriptional activator of the 
hsp70 promoter (Agoff et al. 1993). All the genes mentioned so far are transcribed by 
the RNA polymerase II. There are however three nuclear RNA polymerases in
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eukaryotic cells, and recently, it was demonstrated that p53 can also repress pol I and 
pol III transcribed genes (Chesnokov et ah 1996; Cairns and White 1998; Budde and 
Grummt 1999; Zhai and Comai 2000).
1.8 RNA polymerase III
RNA pol III is the largest and most complex of the tlnee nuclear RNA polymerases. 
It has an aggregate mass of 600-700 kDa and contains 17 subunits in both humans 
and yeast. Pol III has been purified foiin a variety of organisms, including humans 
(Jaehning et al. 1977; Wang and Roeder 1997), mouse (Sklar and Roeder 1976), frog 
(Engelke et al. 1983), silkworm (Sklar and Roeder 1976), fruitfly (Gundelfmger et al.
1980), wheat (Jendiisak 1981) and yeast (Valenzuela et al. 1976), and there has 
proved to be significant similarity in composition of pol III subunits between these 
species.
Each of the three nuclear RNA polymerases consist of two large subunits and a 
complex array of smaller components, which range in size from lOkDa to 90kDa. All 
three polymerases share five common subunits, ABClOa, ABClOp, ABC14.5, 
ABC23 and ABC27: A denotes a subunit found in pol I, B a subunit in pol II and C a 
subunit in pol III and the number indicates its size in kDa. Pols I and III additionally 
share subunits AC19 and AC40 (Mami et al. 1987). These subunits are not found in 
pol II, but B12.5 and B44 are functionally equivalent (Martindale 1990). The two 
largest polypeptides of each polymerase are homologous to the equivalent 
polypeptides of the other enzymes (Breant et al. 1983). Furthermore, these subunits 
are also homologous to the |3’ and (3 subunits of prokaryotic polymerases (Allison et
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al. 1985; Sweetser et al. 1987). The presence of common subunits may offer the 
opportunity for coordinate regulation (Paule 1998), although evidence for such a 
mechanism has remained elusive.
Although pol 1, II and III share several common subunits, they do not display 
functional redundancy. Each polymerase is responsible for transcribing its own 
specific set of templates. These are commonly termed class I, II and III genes, 
respectively. Within the nucleus, pol I synthesises only a single RNA species, the 
large ribosomal RNA (rRNA) precursor molecule. This large rRNA precursor is 
processed into the mature 5.8S, 18S and 28S rRNA components of the ribosomes. 
Although pol I synthesises only one product, it is estimated that pol I is responsible 
for 70% of all nuclear transcription.
Pol II alone is responsible for synthesising the majority of genes. These include all 
messenger RNAs (mRNAs), which encode protein, and most small nuclear RNAs 
(snRNA). hicredibly, however, only 20% of total nuclear transcription is ascribed to 
pol II. The remaining 10% of nuclear transcription is carried out by pol III. The 
products synthesised by pol III encode a variety of untranslated small stable RNAs, 
including 5S rRNA, transfer RNAs (tRNA) and U6 snRNA.
The tlnee polymerases are localised to distinct sites within the nucleus (Shaw et al. 
1995; Pombo et al. 1999). Pol I transcription is localised to discrete sites called 
nucleoli. These ‘ribosome factories’ are the sites at which rRNA is synthesised, 
processed and assembled into ribosomes (Shaw et al. 1995). Confocal and electron 
microscopy revealed that pol II and pol III function at their own spatially discrete
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sites. Each nucleus was estimated to contain approximately 8000 pol II sites per 
HeLa cell. Furthennore, pol III transcription was localised to around 2000 discrete 
sites within the nucleoplasm, with each site containing on average 5 molecules of 
active pol III (Pombo et al. 1999).
Ribosome synthesis requires equiniolar amounts o f —80 ribosomal proteins and 28S, 
18S, 5.8S and 5S rRNAs. It would therefore seem logical that the activity of all tlnee 
nuclear RNA polymerases, used to synthesise these products, is co-ordinately 
controlled. To a certain extent this does appear to be the case. In particular the rates 
of ribosome biogenesis and transcription by pols I and III are closely coupled to cell 
growth. An obvious way to coordinate transcription by pols I, II and III would be to 
target shared components. These three polymerases have five common subunits, but 
there is no evidence at present that these are used to coregulate activity. The TATA- 
binding protein, TBP, is shared by all three transcription systems. By targeting TBP, 
a repressor protein called DiT has been shown to coregulate pols II and III (White et 
al. 1994b). Additional regulatory proteins have also been shown to control the 
activity of other combinations of polymerases. For example, the retinoblastoma 
protein, RB, can repress pols I and III transcription, and to a lesser extent control pol 
II transcription. Factors such as these may provide a network of control mechanisms 
used to regulate and coordinate the activity of the tliree nuclear RNA polymerases.
1.9 Pol III transcripts
The genes transcribed by pol III encode a variety of small stable RNA molecules that 
do not get translated into protein. Many of these have essential functions in cellular
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metabolism. The tRNAs range between 70 and 90 nucleotides in length and are 
essential in the process of translation. tRNAs serve as adaptor molecules, translating 
the genetic information contained within mRNA into a specific sequence of amino 
acid residues. A three-residue anticodon sequence of a particular tRNA is specific for 
a particular amino acid. By base pairing of the tRNA anticodon with the 
complementary codon of the mRNA nucleotide sequences facilitates accurate 
synthesis of a polypeptide chain. The human genome contains around 500 tRNA 
genes, which give rise to 60 to 90 tRNA species (Lander 2001; Venter 2001; Hatlen 
and Attardi 1971). This considerable redmidancy results in an average copy number 
of 10 to 20 genes per amino acid adaptor molecule.
5S rRNA is the smallest (120 nucleotides) of all the ribosomal RNAs. It is the only 
rRNA transcribed by pol III, and like tRNAs has an essential role in translation. 5S 
rRNA is found associated with the large ribosomal subunit in all eukaryotic 
organisms. The haploid genome contains 200 to 300 copies of the 5S gene, many of 
which occur in clusters of tandem repeats (Sorensen and Frederiksen 1991).
The U6, HI and MRP RNAs, which also fall into the class III gene family, play 
important roles in the processing of RNA transcripts. The 106 nucleotide U6 
transcript is the most highly conserved of the spliceosomal RNAs (Brow and Gutlnie
1988). It is also the only spliceosomal RNA transcribed by pol III. U6 is the smallest 
of five snRNA species that make up a ribonucleprotein (RNP) complex termed a 
spliceosome (Kunlcel et al. 1986; Moenne et al. 1990). The essential function of the 
spliceosome, is to post-transcriptionally modify pre-mRNA molecules (Maniatis and 
Reed 1987). Intronic sequences are removed and regions encoded by exons are
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religated to form mature mRNA. HI is a 369 nucleotide RNA which forms part of 
RNase P, an endoribonuclease involved in processing of the 5’-termini of pre-tRNA 
(Bartkiewicz et al. 1989; Lee and Engelke 1989; Morrissey and Tolleiwey 1995). 
MRP, a 265 nucleotide transcript, which shares several regions of sequence 
homology with HI (Gold et al. 1989), fonns part of RNase MRP, another 
endoribonuclease. Rnase MRP serves an important role in the endonucleolytic 
processing of pre-rRNA (Morrissey and Tollervey 1995).
7SL RNA fonns the scaffold of the signal recognition particle (SRP), which plays an 
essential role in the intracellular localisation of proteins (Walter and Blobel 1982). 
There are four 7SL genes, all of which are transcribed by pol III. Each gene encodes 
a highly conserved, 300 nucleotide transcript (Ullu and Tschudi 1984; Ullu and 
Weiner 1984).
Two recent studies have shown that the evolutionarily conserved 7SK RNA acts as a 
negative regulator of the RNA polymerase II elongation factor P-TEFb (Nguyen et 
al. 2001; Yang et al. 2001). The transcription-dependent interaction of P-TEFb with 
7SK may well contribute to an important feedback loop modulating the activity of 
Pol II (Nguyen et al. 2001; Yang et al. 2001).
The VA RNAs encoded by adenovirus are also synthesised by pol III. These serve to 
divert the translational machinery of an infected cell towards the more effective 
production of viral proteins. Many other class III genes encode transcripts of 
unlmown function. This category includes various gene families of repetitive short 
interspersed elements (SINEs). SINE DNA accounts for a substantial proportion of
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the mammalian genome and therefore constitutes a quantitively important class of 
pol III template (Jelinek and Sclunid 1982; Singer 1982). The principle SINE in 
primates is the Alu family. It is estimated that Alu sequences comprise around 10% 
of the total human genome and that there are in the region of one million copies 
(Jelinek et al. 1980; Rubin et al. 1980; Britten 1994). Alu genes consist of two 
imperfect repeats separated by an 18bp spacer (Rubin et al. 1980; Deininger et al.
1981) with a functional pol III promoter located in the upstream repeat (Paolella et 
al. 1983).
The B1 and B2 SINEs are the most abundant SINE family found in rodents. There 
are estimated to be approximately 100 000 and 80 000 copies of BI and B2 per 
haploid mouse genome, respectively (Kmyev et al. 1980; Bennett et al. 1984; Rogers 
1985). B l genes show 80% homology with human Alu genes, while the B2 family is 
specific to rodents and alone constitutes -0.7%  of total mouse genomic DNA. SINEs 
are frequently clustered together and Alu or B l genes are found immediately 
downstream of 7SK, HI and MRP genes (Murphy et al. 1986; Chang and Clayton 
1989; Baer et al. 1990).
Retrotransposition, where pol III transcripts are reverse transcribed into DNA and 
subsequently integrated into new genomic sites is thought to allow the dispersal and 
amplification of SINESs (Weiner et al. 1986). SINEs do not have a clearly defined 
function (Howard and Sakamoto 1990). The principle SINE families appear to be 
derived from class III genes of laiown physiological significance. The B2 family 
seems to have evolved from tRNA genes (Daniels and Deininger 1985). It is also 
likely that the B l and Alu families evolved from the 7SL genes (Ullu and Tschudi
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1984). It is possible that the SINEs exist as pseudogenes of no functional 
significance, but during the course of evolution some SINE transcripts may have 
acquired roles. Such roles include the regulation of adjacent gene expression (Britten 
and Davidson 1969), splicing (Ki'ayev et al. 1982), translation (Chang et al. 1994), 
DNA replication (Anachkova et al. 1984; Ariga 1984; Anaclikova et al. 1985), cell 
stress response (Fornace and Mitchell 1986; Liu et al. 1995) and regulation of growth 
(Sakamoto et al. 1991) or the turnover of specific mRNAs (Clemens 1987).
Despite possessing no clear functional role, the insertion of SINEs into new genomic 
locations has a significant impact on the stmcture and evolution of the genome. 
SINEs have a huge capacity to disrupt genomic sequences tlnough multiple 
recombination events, however, since SINEs are generally expressed at low levels, 
this mutagenic potential is limited.
1.10 Pol III promoters
There are tlnee promoter types used by pol III, namely types I, II and III, which are 
presented in Figure 1.6. The most unusual and striking feature of pol III promoters is 
that the majority require sequence elements down stream of the transcriptional start 
site. These control regions, which lie within the transcribed region, are discontinuous 
structures composed of essential blocks of sequence separated by non-essential 
regions (Paule and White 2000). A small minority of pol III promoters, namely those 
of type III, lack these intragenic control regions. These promoters are similar to those 
utilized by pol I and pol II in that they rely on 5’ flanking sequences to direct 
transcription (Murphy et al. 1987).
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Type I promoter
e.g. Xenopus somatic 5S rRNA genes
A-block —  IE
+ 1 +50 +64 +70
Tn
C-block
+80 +97 + 120
Type II promoter
e.g. Saccharomyces SUP4 tRNA gene
Tn
A-biock TB-block
+ 1 + 8  +19 +52 +62 +73
Type III promoter
e.g. Human U6 snRNA gene
J2SE. PSE TATA
-244 -214 -66 -47 -30 -25 + 1
Figure 1.6. Class III genes utilize three types of promoter arrangement. The sites 
of transcription initiation are indicated by +1 and the sites of termination are 
indicated by Tn. Promoter elements are shown as boxes. A-block, yellow; B-block, 
orange; C-block, blue.
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1.10.1 Type I promoters
The Xenopus laevis somatic 5S rRNA gene seiwes as a classical type I promoter. It 
requires three internal elements for efficient transcription. An A block is situated 
between +50 and +64, an intermediate element at +67 to +72 and a C block from +80 
to +97 (Pieler et al. 1987). Although the sequence separating these elements does 
not influence transcription efficiency, variation in distance between the essential 
blocks of sequence is poorly tolerated (Pieler et al. 1987). Studies have also 
demonstrated that the region between the A-block and the transcriptional start site is 
an important determinant of 5S rRNA expression (Fradkin et al. 1989; Keller et al.
1990).
1.10.2 Type II promoters
The most common promoter arrangement used by pol III is found in the tRNA genes, 
the adenovirus VA genes and many middle repetitive gene families. It is called the 
type II promoter and consists of two highly conserved sequence blocks, A and B. 
Each block is -lObp and they are separated by 30-40 bp (White 1998a). The A 
blocks of type I and II promoters are homologous and sometimes interchangeable, 
although they differ in their location relative to the start site of transcription 
(Ciliberto et al. 1983b). The A-block of the type II promoter is located at 
approximately +10 to +20, whereas on type II promoters it is typically foimd -40bp 
fiirther upstream (Galli et al. 1981). The location of the B-block is extremely 
variable. This is in part due to the fact that some tRNA genes possess short introns 
within their coding region. A distance of -30-60 bp between the A and B-blocks is 
optimal for transcription, although a separation of 365 bp can be tolerated (Baker et
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al. 1987; Fabrizio et al. 1987). This flexibility is particularly remarkable since a 
single transcription factor, TFIIIC, binds simultaneously to both the A- and B-blocks 
(Schultz et al. 1989).
The A- and B-block have the consensus sequences TGGCNNAGTGG and 
GGTTCGANNCC, respectively. Both these elements are essential for transcription 
and point mutations within the A- and B-blocks have been found to have a 
substantial effect on transcription efficiency (Newman et al. 1983; Traboni et al. 
1984; Nichols et al. 1989). Additional internal or flanking sequences often confer 
modulatory effects. For example, although the start site at which transcription can 
commence is dictated primarily in relation to the A-block (Ciliberto et al. 1983a; 
Baker et al. 1987), the precise start site is determined by local sequence. Pol III 
favours initiation at a purine preceded by a pyrimidine (Ciliberto et al. 1983b; 
Fruscoloni et al. 1995). In addition, the upstream fianlcing region can be influential. 
In most cases, the 5 ’ flanking sequences have an overall stimulatory influence upon 
transcription, although repressive effects can also occur (DeFranco et al. 1981; 
Dingermann et al. 1982; Hipskind and Claikson 1983). Despite their modulatory 
effects, 5’ flanking regions display little or no homology even between different 
genes encoding the same tRNA iso acceptor (White 1998a). This variation may, 
however, provide a mechanism for differential regulation of tRNA genes in response 
to differing codon and amino acid demands in various cell types (White 1998a). It is 
also believed that internal block and external sequences may account for the 
differential promoter strengths of distinct class III genes with type II promoters.
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1.10.3 Type III promoters
A small proportion of vertebrate pol III templates lack any requirement for intragenic 
promoter elements, these are refeiTed to as type III promoters. Human and mouse U6 
snRNA promoters have been identified that retain full activity following deletion of 
all sequence downstream of the transcription start site (Das et al. 1988; Kuiilcel and 
Pederson 1989; Lobo and Hernandez 1989). This was also found to be the case for 
human 7SK and MRP RNA genes (Murphy et al. 1987; Yuan and Reddy 1991). 
Although this feature of type 111 promoters is an anomaly for class III genes, it is the 
normal occurrence for class 1 and II genes as well as bacteria.
The best characterised type 111 promoter belongs to a human U6 gene. Efficient 
expression relies upon a TATA box between -30 and -25, a proximal sequence 
element (PSE) between -66  and -47 and a distal sequence element (DSE) between -  
244 and -214 (Bark et al. 1987; Carbon et al. 1987; Das et al. 1988; Kunkel and 
Pederson 1988). These control regions display considerable homology to regions 
within the promoters of the U2 snRNA gene, transcribed by pol 11. Indeed, the PSE 
and DSE sequence elements are interchangeable between the U6 and U2 snRNA 
promoters (Bark et al. 1987; Carbon et al. 1987; Kunkel and Pederson 1988; Lobo 
and Hernandez 1989). Although TATA sequences are a classical feature of class 11 
genes, the U2 gene does not contain this element. Indeed, the fact that the U6 snRNA 
promoter contains a TATA box presents a curious anomaly, since TATA sequences 
are not a nomial occurrence in class 111 genes. Paradoxically, insertion of a TATA 
box can convert U2 it into a pol 111 template, while inactivation of the U6 TATA box 
allows U6 to be transcribed by pol 11 (Mattaj et al. 1988; Lobo and Hernandez 1989)
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1.10.4 Other promoter types
Several of the class III genes do not fall neatly into any of the tliree promoter types. 
For example the EBER2 gene of Epstein-Barr vims has A and B blocks that are 
typical of type II promoters and are essential for its transcription (Howe and Shu 
1989). However, deletion of sequence upstream reduces expression (Howe and Shu 
1989). Upstream binding site for Spl and ATF are thought to be responsible for this 
effect (Howe and Shu 1989). The EBER2 promoter also has a TATA box located 
between -28 and -23 that can stimulate transcriptional activity 5-fold (Howe and 
Shu 1989).
Transcription of the human 7SL gene also depends on internal and external promoter 
elements. It possesses A- and B-blocks, although they do display sequence variation 
to those of type 11 promoters (Allison et al. 1983). Like the EBER2 promoter, 
efficient expression requires upstream sequences including a ATF binding site at -51 
to -44 and a putative TATA box between -28 to -24 (Bredow et al. 1990; Howe and 
Shu 1993). Other examples of pol 111 promoters that rely on both internal and 
upstream sequences for efficient expression include silkworm tRJMA^ ''^  genes 
(Sprague et ah 1980), the Xenopus tRNA^^^ gene (Carbon and Krol 1991) and the rat 
vault RNA gene (Vilalta et al. 1994).
1.11 Transcription factors and complex assembly on class III genes
The process of transcription by pol 111 involves a complex array of trans-acting 
factors that work in concert with cis-acting DNA elements. Multiple transcription 
factors cooperate in order to recmit pol 111 to the start site of transcription on class 111
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genes (Parker and Roeder 1977). Without these factors, pol 111 will initiate randomly 
(Weil et al. 1979; Cozzarelli et al. 1983). Many of these essential transcription 
factors are common to all pol 111 templates, but some are required for the 
transcription of certain promoter sub types.
1.11.1 Type I and II promoters
The A- and B-blocks in type 11 promoters are initially recognised by TFlllC (Figure 
1.7A). TFlllC is one of the largest and most complex transcription factors known, hi 
S. cerevisiae, TFlllC consists of two globular domains, each approximately lOmn in 
diameter and -300 kDa (Schultz et al. 1989). TFlllC is composed six subunits, none 
of which are capable of binding DNA specifically on their own. Photocrosslinking 
studies have revealed that the various subunits of TFlllC extend across the entire 
length of the tRNA^^' gene (Figure 1.8) (Bartholomew et al. 1990; Braun et al.
1992). TFlllC contacts both the A and B blocks, although the B block is the major 
determinant of binding affinity (Baker et al. 1986). The relative helical orientation of 
the A and B blocks is not important for transcription efficiency (Baker et al. 1987). 
Electron microscopic studies suggest that the two domains of TFlllC can stretch, 
giving the protein the appearance of a dumb-bell when bound to DNA (Schultz et al.
1989). This finding can account partially for the fact that the distance between the A 
and B block can vary substantially. On promoters with very long inter block 
separations, the inteiwening DNA is looped out so that both sequence elements can 
be contacted efficiently by TFlllC (Schultz et al. 1989).
Human TFlllC varies significantly fi'om the yeast factor. It can be resolved by ion 
exchange chromatography into two components, TFlllC 1 and TF111C2 (Yoshinaga et
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A tDNA TFIIIC
TFIIIC/tDNATFIIIB
TFIIIB/TFIIIC/tDNA 
Pol III
Pol III/TFIIIB/TFIIIC/tDNA
B 5S rDNA
TFIIIA
TFIIIA/5S rDNA
TFIIIC
TFIIIC/TFIIIA/5S rDNA 
TFIIIB
TFIIIB/TFIIIC/TFIIIA/5S rDNA
Pol III
Pol III/TFIIIB/TFIIIC/TFIIIA/5S rDNA
Figure 1,7. Order of transcription factor assembly on type I and II pol III 
promoters. Flow chart indicates the order of interaction of factors and polymerase 
on (A) a typical type II promoter such as a tRNA gene. (B) the promoter of a 5S 
rRNA gene.
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al. 1987; Wang and Roeder 1996; Oettel et al. 1997). Both components are required 
for the transcription of 5S rRNA, VAl and tRNA genes, but U6 and 7SK 
transcription requires only TFIIIC 1 (Lagna et al. 1994; Yoon et al. 1995; Oettel et al.
1997). Sedimentation analysis has suggested that TFIIIC 1 has a mass of up to 200 
kDa (Yoshinaga et al. 1987). However, little progress has been made to further 
characterise this factor. On the other hand, TFIIIC2 has been purified and shown to 
consist of five polypeptides of 220, 110, 102, 90 and 63 IcDa, with a total mass of 
~600kDa (Dean and Berk 1988; Yoshinaga et al. 1989; Wang and Roeder 1996). 
TFIIIC2 can be isolated in two foiins designated TFIIIC2a and TFIIIC2b (Floeffler et 
al. 1988; Sinn et al. 1995). Both forms share the 220, 102, 90 and 63kDa subunits, 
and can bind DNA producing identical footprints on VAl. Transcriptional activity is, 
however, only associated with TFIIIC2a, which contains the llOkDa subunit 
(Hoeffler et al. 1988).
All five of the TFIIIC2 subunits have been cloned (Lagna et al. 1994; L'Etoile et al. 
1994; Simi et al. 1995; Hsieh et al. 1999a; Hsieh et al. 1999b). HTFIIIC220, 
liTFIIICllO and hTFIIIC90 show no significant homology to any of the subunits of 
yeast TFIIIC. HTFIIIC102 and hTFIIIC63 display only a weak homology to t131 
and x95 respectively (Hsieh et al. 1999b). This apparent lack of homology is 
particularly surprising since A and B blocks, contacted by TFIIIC220 in humans, are 
well conseiwed between mammals and yeast (Yoshinaga et al. 1987)
Productive recruitment of TFIIIC to the 5S rRNA promoters requires TFIIIA (Figure 
1.7B). TFIIIA serves as an adaptor, providing a platform that allows TFIIIC to be 
recruited onto the 5S rRNA genes for which it has little affinity. Xenopus laevis
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TFIIIA was the first eukaryotic transcription factor to be purified to homogeneity 
(Engelke et al. 1980) and the first to have its cDNA cloned (Ginsberg et al. 1984). 
TFIIIA is a gene-specific factor that is only required for the expression of 5S genes 
(Engelke et al. 1980). The 334 amino acid sequence of TFIIIA is predominantly 
composed of nine tandem, zinc-dependant DNA binding protein domains (Miller et 
al. 1985). NMR and crystal stmctine analysis has revealed that the C block on type I 
promoters is recognised by the tlnee N-terminal fingers. These fingers wrap 
smoothly around the DNA major groove, and constitute 95% of the total binding 
energy of full length TFIIIA (Clemens et al. 1992; Foster et al. 1997; Nolle et al.
1998). The C-temiinal tliree fingers are thought to contact the A block in a similar 
manner, albeit with a lower affinity (Clemens et al. 1992). The middle three fingers 
span the intermediate region. This region is twice as long as the regions bound by 
fingers 1-3 and 7-9, and these fingers adopt a completely different configuration in 
order to cover this area. Finger 5 makes base contacts in the major groove, at the 
intermediate element, whereas finger 4 and 6 straddle the neighbouring minor 
gi'ooves and function primarily as spacer elements (Nolle et al. 1998).
Photocrosslinking studies have revealed that the positioning of the various TFIIIC 
subunits relative to each other, and to the initiation site, is similar on both a yeast 5S 
rRNA gene and a tRNA gene (Figure 1.8) (Braun et al. 1992). This finding is quite 
remarkable since, although, type I and II promoters both contain an A-block, it is 
bound by TFIIIA in the former case and by TFIIIC in the later case. Regardless of 
promoter type, the primary function of TFIIIC is to recmit TFIIIB (Figure 1.7).
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TFIIIB has been characterised extensively (Kassavetis et al. 1995; Roberts et al. 
1996; Ruth et al. 1996). It is a complex of tlnee components, one of which is the 
TATA-binding protein, TBP. TBP is a central transcription factor utilized by all 
three nuclear RNA polymerases (White and Jackson 1992b; Hernandez 1993; Rigby
1993). Although the majority of pol III templates lack TATA-like sequences (White 
and Jackson 1992b; Wliite et al. 1992b), TBP fonns an integi'al part of the 
transcription initiation complexes formed on these genes.
TBP is the most conserved eukaryotic transcription factor known. All TBP genes 
encode a small (27-38kDa) polypeptide. The DNA-hinding domain of TBP is 180 
residues long and displays an extraordinary level of evolutionary conservation. This 
C-terminally located domain is identical between man and mouse, and is 81% 
identical between humans and the yeast S. cerevisiae. hi contrast, the N-terminal 
region of TBP varies tlmough evolution, in both its length and sequence. It has been 
suggested that it may modulate the activity of the highly consei*ved C-temiinus 
(Kuddus and Schmidt 1993; Lescure et al. 1994; Mittal and Hernandez 1997; Zhao 
and Herr 2002). The DNA-hinding domain of TBP is composed of two directly 
repeated halves. Although these halves are only 31% identical in sequence, they are 
virtually identical topologically (Reddy and Hahn 1991; Strubin and Struhl 1992; 
Heard et al. 1993). The a-carbon atoms of each polypeptide chain follow the same 
path through space in the two regions, forming a saddle stnicture that sits astride the 
DNA. The convex upper surface of the saddle consists of four a-helices, which make 
contact with other transcription factors (Nikolov et al. 1992). The concave under side 
contacts the DNA. This cuiwed face is composed of ten antiparallel (3-sheets, which 
fonns a surface wide enough to accommodate the DNA double helix (Nikolov et al.
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1992). TBP severely bends the DNA, creating an angle of approximately 80°. The 
minor grove is widened and flattenened, making extensive contacts with the 
underside of TBP tlirough many hydrophobic and some hydrophylic interactions 
(Nikolov et al. 1992).
TBP interacts with other polypeptides, termed TBP-associated factors (TAFs). The 
different TBP-TAF complexes provide the basis of polymerase specificity. These 
complexes, in conjunction with appropriate initiation factors, form class-specific 
complexes at promoters and facilitate recruitment of the coiTect RNA polymerase 
(White and Jackson 1992b; Hernandez 1993; Rigby 1993). Pol I is recmited via the 
TBP-containing complex SLl (Comai et al. 1992; Eberhard et al. 1993; Zonierdijk et 
al. 1994), and the equivalent complex in the pol II system, is TFIID (Greenblatt
1991).
TFIIIB, the pol III TBP-containing complex, has two TAFs. The largest of these is a 
90kDa polypeptide called Bdpl. Bdpl displays little homology to other known 
proteins except for a putative SANT domain (Kassavetis et al. 1995; Aasland et al. 
1996; Ruth et al. 1996). This subunit is unusually resistant to truncation and will 
continue to support U6  transcription after all but 176 of its 594 residues have heen 
deleted (Kumar et al. 1997). Two distinct domains (residues 270-305 and 390-460) 
are required for tRNA synthesis, whereas either alone is sufficient in the case of U6 
(Kumar et al. 1997). Footprinting suggested that Bdpl is folded such that these two 
domains are in close proximity when TFIIIB is assembled onto DNA (Kumar et al. 
1997). Bdpl makes multiple contacts with the transcription complex (Bartholomew 
et al. 1991; Kassavetis et al. 1991; Joazeiro et al. 1994; Roberts et al. 1996). This
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may possibly account for its resilience to deletion mutagenesis. If an individual 
contact is lost, it may be compensated by other interactions made by the protein.
The other component of TFIIIB is a 70 kDa suhunit that displays in its N-terminal 
320 residues 23% identity and 44% similarity to the pol II transcription factor TFIIB 
(Buratowski and Zhou 1992a; Colbert and Hahn 1992; Lopez-de-Leon et al. 1992). 
Because of this homology, it is often referred to as TFIIB-related factor, or Brfl, 
although it has also been called TDS4, PCF4 and TFIIIB70. The majority o f the 
homologous region is made up of a zinc rihhon at the extreme N-terminus and two 
imperfect repeats of 76 amino acids within the remainder of the amino-terminal half 
(Buratowski and Zhou 1992b; Colbert and Halm 1992; Lopez-de-Leon et al. 1992). 
The C-terminal half of yeast Brfl displays no obvious homology to any other know 
protein, and in contrast to the N-teiminal half, is poorly conserved. However, tlnee 
discrete regions of significant conseiwation have been identified, these are tenned 
yeast homology regions HI, HII and HIII (Klioo et al. 1994).
Extensive mutagenesis has revealed that Brfl contains two distinct TBP-hinding 
domains, which interact with opposite faces of the TBP-DNA complex (Colbert et al. 
1998; Kassavetis et al. 1998). The HII domain of the C-terminal half of Brfl is 
thought to mediate one interaction with TBP (Klioo et al. 1994; Colbert et al. 1998; 
Andrau et al. 1999). The second TBP-hinding site is located in the conserved direct 
repeat region in the N-temiinal half of B rfl. This region is also believed to directly 
contact pol III (Klioo et al. 1994) and interact with the largest suhunit of yeast 
TFIIIC (Chaussivert et al. 1995). A remarkable feature of Brfl is that it can be split
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down the middle to give two separate halves that continue to function when 
recombined (Kassavetis et al. 1998).
TFIIIB, reconstituted from recombinant TBP, Brfl and Bdpl, is able to support 
TFIIIC-dependent and TATA-dependent DNA binding and transcription (Roberts et 
al. 1996; Ruth et al. 1996). Nevertheless, this reconstituted factor was found to he 
less active than native TFIIIB (Kassavetis et al. 1995; Ruth et al. 1996). Although 
this could be due to mis-folding of recombinant polypeptides, or the lack of 
important post-transcriptional modifications, the possibility exists that a non- 
essential, hut stimulatory factor(s) is missing from the reconstituted TFIIIB 
preparation.
Human TFIIIB also contains TBP. Using anti-TBP antibodies, a TAF of 88-90 kDa 
was imniunoprecipitated from TFIIIB fr-actions (Wang and Roeder 1995; Mital et al.
1996). The N-terminal 280 residues of this 677 amino acid protein, share 24% 
identity to human TFIIB, and 41% identity with S. cerevisiae B rfl. On the hasis of 
this it was termed human TFIIB-related factor (hBrfl) (Mital et al. 1996). The N- 
terminal half of hBrfl also shares regions of extensive homology with other Brf 
species; these include a zinc ribbon motif and two direct repeats (Mital et al. 1996). 
In contrast, with the exception of yeast homology region II (HII), the C-temiinal half 
of hBrfl displays little homology to yBrfs (Mital et al. 1996).
Like yBrfl, liBrfl possesses two TBP-hinding sites. One is located in the N-terminal 
half, with a stronger site associated with the conserved HII domain in the C-tenninal 
domain of the protein (Wang and Roeder 1995). Transcription of VA and tRNA
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genes was found to be severely inliibited following immunodepletion of liBrfl and 
was restored by addition of recombinant TBP and liBrfl, proving it to be essential in 
human pol III transcription (Wang and Roeder 1995; Mital et al. 1996).
Recently a human homologue of yeast Bdpl was cloned (Sclrramm et al. 2000). It is 
significantly larger that yBdpl, with a calculated mass of 156 kDa. It contains three 
principle regions of sequence conservation. A putative SANT domain exists between 
residues 415-472, which shows 43% identity to that of yeast Bdpl. In addition, a 131 
amino acid region immediately upstream, and 151 amino acids downstream of the 
SANT domain, share 21% and 17% identity with yBdpl, respectively (Schramm et 
al. 2000). A striking feature of liBdpl is a region of 19 repeats of 26-28 amino acids 
in the C-terminal domain, which is absent from yBdpl. Immunodepletion of liBdpl 
from cell extracts severely impaired pol III gene expression. Addition of recombinant 
IrBdpl could restore this activity, confirming the functional significance of liBdpl in 
pol III transcription (Scluamm et al. 2000).
Since TFIIIB contains TBP, TFIIIB can bind independently to a TATA box (Joazeiro 
et al. 1994). However, since most type I and II promoters lack TATA sequences, 
they can not he recognised directly by TFIIIB (Kassavetis et al. 1989; Kassavetis et 
al. 1992; White and Jackson 1992b; Huet and Sentenac 1993). In these cases, TFIIIB 
is recruited by protein-protein contacts with DNA-hound TFIIIC (Lassar et al. 1983; 
Huet and Sentenac 1993). S. cerevisiae Brfl has been shown to interact with t131, 
the subunit of TFIIIC located furthest upstream along the promoter (Chaussivert et 
al. 1995; Kassavetis et al. 1998). It has been suggested that the TFIIIB-binding site 
may be masked prior to confonnational reaiTangements, since certain mutation in
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t131 can stimulate transcription complex assembly (Rameau et al. 1994; Chaussivert 
et al. 1995; Moir et al. 1997). Indeed xl31 becomes reoriented during TFIIIB 
assembly, indicated by changes in the efficiency of photocrosslinlcing (Kassavetis et 
al. 1992). Once recmited, yeast TFIIIB is situated approximately 40 bp upstream 
from the transcription start site (Kassavetis et al. 1989; Kassavetis et al. 1990; Braun 
et al. 1992; Kassavetis et al. 1998; Per singer et al. 1999). From this position, TFIIIB 
can efficiently recmit pol III to the initiation region (Kassavetis et al. 1990). 
Although all tlmee suhunits are required for pol III recruitment, direct interaction 
have only heen identified in the case of Brfl (Bartholomew et al. 1993; Werner et al. 
1993; Khoo et al. 1994).
Once assembled, transcription complexes on class III genes display considerable 
stability towards high salt concentrations that would prevent their fomiation entirely 
(Setzer and Brown 1985; Carey et al. 1986; Kassavetis et al. 1989; Kassavetis et al. 
1990). For example, after a 6.5 min exposure of the preformed human complex to 
IM KCl, -45%  of VAl transcriptional activity remains (Carey et al. 1986). In yeast, 
the interaction between TFIIIB and DNA is the most resistant to salt, whereas TFIIIC 
and TFIIIA are dissociated more readily (Kassavetis et al. 1989; Kassavetis et al. 
1990). Once recruited, TFIIIB will remain stably bound, even in IM KCl (Kassavetis 
et al. 1990). This is remarkable, since TFIIIB alone is incapable of recognising 
TATA-1 ess class III genes. It seems probable that interaction with TFIIIC unmasks a 
cryptic DNA-hinding capacity that locks TFIIIB onto the promoter (Huet et al.
1997). TFIIIA and TFIIIC can be regarded as assembly factors, as they can be 
stripped from fully assembled transcription complexes on tRNA and 5S rRNA 
promoters without compromising the efficiency of transcription (Kassavetis et al.
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1990). Under these circumstances, TFIIIB is sufficient on its own to recruit pol III 
and direct multiple rounds of accurately initiated transcription (Kassavetis et al. 
1990). This exceptional salt stability is not a feature of vertebrate pol III systems. 
Where the dissociation pathway is the reverse of the assembly pathway (Setzer and 
Brown 1985; Carey et al. 1986; Jahn et al. 1987).
1.11.2 Type III promoters
The assembly of transcription complexes on type III promoters differs due to the lack 
of ICRs. This consequently eliminates the need for TFIIIA and TFIIIC2 (Bernues et 
al. 1993; Lagna et al. 1994; Yoon et al. 1995). Although these promoters still utilize 
TFIIIC 1, they employ a fonn of TFIIIB chromatogi’aphyically separable from the 
form used by type I and II promoters (Lobo et al. 1992; Teiclimann and Seifart
1995). Recent analysis has demonstrated that a Brfl-like factor, Brf2 (BRFU) is 
required for transcription of the U6  snRNA genes instead of Brfl (Sclmamm et al. 
2000). The N-tenninal domain of Brf2 is related to hoth Brfl and TFIIB, whereas the 
C-teiminal region is divergent.
The PSE of type III promoters is recognised by SNAPc/PTF (Figure 1.9). 
SNAPc/PTF is essential for transcription of 7SK and some vertebrate U6  genes 
(Yoon et al. 1995). It associates with the PSE of type III promoters and can greatly 
enliance the recruitment of TFIIIB to the TATA box (Yoon et al. 1995). SNAPc/PTF 
is a complex of five subunits, with a native mass of approximately 350 kDa 
(Sadowski et al. 1993; Ftem*y et al. 1995). The largest suhunit, SNAP 190, contains a 
Myb DNA-hinding domain, and can be cross-linked to the PSE (Yoon et al. 1995; 
Wong et al. 1998). The second largest subunit, SNAP50, also associates with the
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Figure 1.9. PTF/SNAPc interactions with TFIIIB on the U6 promoter. Schematic 
diagram illustrates the interactions between PTF/SNAPc and TFIIIB that may occur 
on a vertebrate U6 promoter.
45
DNA (Henry et al. 1996). In contrast, the other subunits, SNAP45, 43 and 19, do not 
bind directly to the DNA (Yoon and Roeder 1996), but are found associated with the 
PSE-binding complex, hnmunodepletion of SNAP50, SNAP43 or SNAP45 
specifically repressed 7SK and U6 transcription, whilst having no effect on VAl and 
AdML expression (Hemy et al. 1996; Sadowski et al. 1996; Yoon and Roeder 1996). 
Transcription of the pol II transcribed U1 and U2 genes was also inhibited by 
immunodepletion of these factors. This repressive effect could be restored by 
addition of highly purified SNAPc/PTF, indicating that, SNAPc/PTF is required for 
transcription of both pol II and pol III U snRNA genes (Hemy et al. 1995; Bai et al. 
1996; Herny et al. 1996; Sadowski et al, 1996; Yoon and Roeder 1996). The distance 
separating the PSE and the TATA box is constrained very precisely on type III 
promoters (Lescure et al. 1991; Goomer and Kunlcel 1992). This suggests that 
PTF/SNAPc interacts with the TATA-bound TBP or TFIIIB. Both PSE and TATA 
recognition are relatively slow (Wanandi et al. 1993; Mittal et al. 1996). 
Transcription assembly can, however, be stimulated by Oct-1, which binds to the 
upstream DSE. Oct-1 interacts directly with SNAPcl90, and thereby stimulates PSE 
occupancy (Murphy et al. 1992; Mittal et al. 1996; Ford et al. 1998). Occupancy of 
the PSE is of primary importance for stable complex formation on the human U6 
promoter (Kunlcel and Danzeiser 1992). However, SNAPc/PTF and TBP enliance 
each other’s recmitment (Mittal and Hernandez 1997). Figure 1,9 illustrates the 
composition of TFIIIB on type III promoters. It remains to be determined how 
TFIIIC 1 is recruited, but this may be a late step in complex assembly on type III 
promoters (Paule and White 2000).
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1.12 TFIIIB; the p53 target
Expression of p53 has been shown to repress transcription of a wide range of pol III 
transcripts including Alu, U 6  (Chesnokov et al. 1996; Cairns and White 1998), 
tRNA, 5S rRNA, VA, B2 and EBER (Cairns and White 1998) and thus functions as 
a general regulator of pol III transcription. As yet, the mechanistic basis of pol III 
transcriptional repression by p53 has not been established.
It has been shown that an N-terminal fragment of p53, overexpressed as a GST 
fusion protein, can bind to TFIIIB in a ‘pull-down’ assay (Chesnokov et al. 1996). In 
addition, it has been demonstrated by immunoprécipitation and cofractionation 
experiments that endogenous p53 and TFIIIB associate at physiological ratios. It is 
proposed that TFIIIB is a specific target for repression by p53. This is supported by 
the finding that when p53 is present in excess, adding more purified TFIIIB can 
efficiently relieve VAl gene expression from repression by p53. It is well 
documented that TBP, one of the components of TFIIIB can bind to p53 (Seto et al. 
1992; Liu et al. 1993; Martin et al. 1993; Truant et al. 1993b; Horikoshi et al. 1995; 
Tansey and Flerr 1995; Chesnokov et al. 1996; Fanner et al. 1996a). It appears that 
this interaction is required for repression of TFIIIB, since heat inactivation of TBP 
abolishes the ability of TFIIIB to restore transcription in the presence of p53.
Fibroblasts derived from p53 knock out mice transcribe pol III templates at elevated 
levels, this is due to a specific rise in TFIIIB activity (Cairns and White 1998). It is 
proposed that TFIIIB is a target for repression by endogenous p53 and that this 
regulation may contribute to the proper control of pol III transcription in 
untransformed cells (Cairns and White 1998). Although it has been demonstrated
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that p53 can inactivate TFIIIB specifically, once TFIIIB has been assembled into a 
preinitiation complex it becomes far less susceptible to repression (Cairns and White
1998).
1.13 Regulation of Pol III transcription
Synthesis of pol III products is clearly an essential component of cellular metabolism 
and consequently pol III transcription is subject to a wide range of regulatory signals 
(Brown et al. 2000). It is tightly linked to growth conditions, increasing in response 
to mitogenic signals and falling when serum factors or nutrients are limiting. It is 
also subject to cell cycle control in vertebrates, being activated at the Gl/S transition 
and repressed at mitosis, hi addition, many vims es have potent effects upon the rate 
of pol III transcription. Furthermore, the majority of transformed and tumour cell 
types display abnormally elevated pol III products (Kramerov et al. 1982; Brickell et 
al. 1983; Scott et al. 1983; Majello et al. 1985; Ryskov et al. 1985; Lania et al. 1987; 
Kramerov et al. 1990). In each case, regulation is mediated through changes in 
activities of the pol III specific transcription factors, and not tlnough the polymerase 
itself (Brown et al. 2000).
p53 is not alone in its ability to target TFIIIB (Figure 1.10). This is perhaps not 
surprising, given the essential central role TFIIIB plays in mediating pol III 
transcription (White 1998a). TFIIIB is bound and regulated by the tumour suppressor 
RB, the product of the retinoblastoma susceptibility gene (Chu et al. 1997; Larminie 
et al. 1997; Lanninie et al. 1999; Sutcliffe et al. 1999; Sutcliffe et al. 2000). 
Overexpressing RB in transfected cells produces a significant decrease in pol III
48
Repressors of 
TFIIIB
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TFIIIB
RB
pl07
pl30
p53
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Figure 1.10. TFIIIB antagonistic influences. The gi'owth suppressors RB, p53 and
Drl can all repress TFIIIB. In contrast a variety of oncoproteins can stimulate TFIIIB 
activity. Activators of TFIIIB include the E l A protein of adenovirus, SV40 large T 
antigen, the Tax protein of HTLV-1, the X protein of HBV.
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activity (White et al. 1996; Chu et al, 1997). Recombinant RB also represses pol III 
transcription that has been reconstituted from partially purified factors (White et al. 
1996; Chu et al. 1997). Additionally, inactivation of endogenous RB results in a 
fivefold increase in the synthesis of tRNA and 5S rRNA (White et al. 1996). Extracts 
prepared from RB-lmockout mice show a specifrc increase in TFIIIB activity (White 
et al. 1996). RB coimmunoprecipitates with endogenous TFIIIB (Larminie et al.
1997). Indeed, such an association has been demonstrated to result in disruption of 
TFIIIB interactions with TFIIIC2 and pol III (Sutcliffe et al. 2000). pl07 and pl30, 
two RB relatives, also bind to TFIIIB (Sutcliffe et al. 1999). Like RB, recombinant 
p i 07 and p i 30 repress transcription of a wide range of pol III templates, both in vitro 
and in transfected cells (Sutcliffe et al. 1999). Collectively these tlrree proteins are 
referred to as the pocket protein, because most of their homology lies within a 
bipartite region called the pocket domain.
The functions of the pocket proteins are subject to cell cycle control (Figure 1.11) 
(Brown et al. 2000). They are found to be underphosphorylated, and hence in an 
active state, during GO and early G1 phases. As cells pass the restriction point in mid 
G l, the pocket proteins are inactivated tlmough hyperphosphorylation by the cyclin 
D- and cyclin E-dependent kinases (Heiwig and Strauss 1997; Taya 1997; Grana et 
al. 1998; Mittnacht 1998; Mulligan and Jacks 1998). For much of the mammalian 
cell cycle, there is an inverse correlation between the activity o f the pocket proteins 
and the level of pol III transcription (Jolmson et al. 1974; Mauck and Green 1974; 
White et al. 1995a). TFIIIB activity is also regulated strongly in cycling cells (White 
et al. 1995b; White et al. 1995a). Dining mitosis the activity of TFIIIB is severely 
limiting. This is achieved tlirough phosphorylation and inactivation of TFIIIB
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(Gottesfeld and Forbes 1997). As cells exit mitosis, TFIIIB liyperphosphorylation is 
rapidly reversed. The rate of pol III transcription increases gradually as cells pass 
through the Gl phase (White et al. 1995a; Scott 2001). RB hinds and represses 
TFIIIB during GO and early G l, hut this interaction decreases as cells approach S 
phase. Full induction of pol III coincides with mid- to late Gl phase, when RB 
becomes phosphorylated by cyclin D- and E-dependent kinases. TFIIIB only 
associates with the undeiphosphorylated form of RB, and overexpression of cyclins 
D and E stimulate pol III transcription in vivo (Scott et al. 2001). Pol III transcription 
is maximal tlnoughout S and G2 phases, where TFIIIB activity is in relative excess 
(White et al. 1995b; White et al. 1995a).
The 19 IcDa phosphoprotein Drl can also hind to and inliihit the activity of TFIIIB 
(White et al. 1994b). Drl was found to inactivate TFIIIB by binding to TBP and 
disrupting its interaction with Brfl (White et al. 1994b; Kim et al. 1997),
A variety of viruses have been shown to stimulate pol III transcription. This is most 
likely necessary to meet an increase in biosynthetic demands. Multiple mechanisms 
contribute to the regulation of pol III transcription in response to adenovirus 
infection. Adenovirus encodes two pol III products, VAl and YAH, which are 
synthesised at high levels during the late stages of infection (Weinmamr et al. 1974; 
Soderlund et al. 1976). These short RNAs are involved in subverting the host’s cells 
translational apparatus, in order to ensure the synthesis of viral proteins 
(Thimmappaya et al. 1982). Cells infected with wild-type adenovirus display a 
marked increase in TFIIIC activity (Hoeffler and Roeder 1985; Yoshinaga et al. 
1986; Floeffler et al. 1988; Sinn et al. 1995). Additionally, the E l A transforming
52
protein from adenovirus can also relieve TFIIIB from repression by RB (White et al.
1996). SV40, human T-cell leukaemia virus type I and hepatitis B virus also all 
possess the capacity to stimulate pol III transcription, which is mediated at least in 
part tlirough their action on TFIIIB (White 1998b).
1.14 Pol III transcription and cellular transformation
Many transformed cell lines overexpress pol III products (Brickell et al. 1983; Scott 
et al. 1983; Majello et al, 1985; Ryskov et al. 1985; Lania et al. 1987; Kramerov et 
al. 1990). Pol III responds to a variety of transforming agents, including DNA 
tumour viruses, RNA tumour viruses and chemical carcinogens (White 1998b). In 
situ hybridisation has also revealed this to be the case in vivo (Chen et al. 1997a). 
Elevated pol III transcripts were found in the neoplastic cells of breast carcinoma, 
colon adenocarcinoma and skin fibrosarcoma samples, relative to the sunounding 
tissue (Chen et al. 1997a).
In many cases the mechanistic basis of the elevation in pol III transcript levels has 
yet to be determined (White 1998b). It however seems likely that release of TFIIIB 
from repression by RB is a pivotal feature of tumour cells. RB function has been 
shown to be compromised in a broad range of human cancers (Strauss et al. 1995; 
Weinberg 1995; Whyte 1995). Most RB mutations that occur naturally in tumours lie 
within the pocket domain, the same region that is required for regulation of pol III 
transcription (White et al. 1996; Chu et al. 1997).
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Approximately half the major fonns of human cancer contain p53 mutations 
(Hollstein et al. 1991). Several such mutations can abrogate the ability of p53 to 
repress pol III transcription (Stein et al. 2002a). For example, in SAOS2 cells, 
transient transfection of a mutant p53 in which arginine 175 is substituted to proline 
(R175P), originally derived from an anogenital tumour, was severely compromised 
in its ability to repress pol III transcription (Stein et al. 2002a). Mutation R175H, in 
which arginine 175 was substituted to histidine, is one of the most common 
substitutions associated with human cancers. This mutation is also associated with an 
extremely poor prognosis in cancer patients (Goh et al. 1995). R175H was unable to 
repress pol III transcription in transient transfection assays (Stein et al. 2002a). 
Remarkably, this mutant actually activates pol III transcription in a dose-dependent 
manner (Stein et al. 2002a). The mechanistic basis of these effects are, however, still 
to be detennined.
A considerable weight of evidence indicates that the regulation of protein synthesis is 
an important aspect of growth control. It has been shown that a 50% reduction in the 
rate of protein synthesis is sufficient to cause proliferating cells to withdraw from the 
cell cycle and quiesce (Brooks 1977; Romiing et al. 1981).
There are many documented examples in which the translation machinery has 
become deregulated following transformation (Rosenwald 1996), providing strong 
support for the belief that the control of protein synthesis is an important aspect of 
growth regulation. Translation is clearly dependent on the availability of adequate 
supplies of tRNA and rRNA and thus active pol III transcription. These facts may
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therefore explain why pol III transcription is subject to deregulation by viruses, and 
frequent activation in transformed and tumour cells (White 1998b).
1.15 Aims and objectives
Clearly, p53 can repress pol III transcription. The mechanistic basis of this however, 
remains elusive. The principal aim of this project was to establish the means by 
which p53 can repress pol III transcription. Many lines of evidence indicate that 
TFIIIB is targeted by p53, the biochemical and functional consequences of this 
interaction were therefore investigated both in vitro and in vivo.
p53  is deregulated or mutated in a majority o f human cancers; the consequence of 
such deregulation was investigated with respect to pol III transcriptional control. 
Additionally, it was investigated whether DNA damage, a cellular stress known to 
activate p53, could stimulate endogenous p53 into repressing pol III gene expression.
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Chapter 2
Materials and methods
2.1 Cell culture
HeLa, primary mouse embryo fibroblasts (MEFs) and SA0S2 cells were cultured in 
DMEM (Dulbecco’s Modified Eagle Medium) containing 10% fetal calf serum 
(FCS, Sigma), 2mM L-glutamine, lOOU/ml penicillin and lOOpg/ml streptomycin. 
CHO cells, stably transfected with pcDNASHABrfl, expressing Haemaglutinin (HA) 
tagged BrfI (Johnston et al. 2002), were grown in Flam’s F-12 medium 
supplemented with 10% FCS lOOU/ml penicillin and lOOpg/ml streptomycin. 
NARF2 cells stably expressing inducible p i4^^^ (Stott et al. 1998) were maintained 
in DMEM containing 10% fetal calf serum, 150pg/ml hygromycin, 300pg/ml 
geneticin, 2mM L-gliitamine, lOOU/nil penicillin and lOOpg/ml streptomycin. For 
Methanesulfonic Acid Methyl Ester (MMS) treatment of HeLa cells, cells were 
gi'own to 80% confluency then treated with 0.04% MMS for 2 hours. Cells were 
routinely grown in a humidified atmosphere containing 5% CO2 at 2>TC. Cell 
culture was performed in a class II hood, using aseptic teclinique and sterile 
equipment and reagents.
Cells were passaged when subconfluent; approximately every 2 to 3 days. After 
media was aspirated from the flask, 2ml of buffered trypsin-EDTA (0.05% trypsin, 
0.02% EDTA) was added to the cells, then aspirated immediately. A further 2ml was 
added and left for approximately 2 minutes at 37°C. Following trypsinisation, fresh 
media was immediately added to the dissociated cells in order to neutralise the
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trypsin. Cells were centrifuged at 1200g for 2 minutes at 4°C and the media 
removed. The pelleted cells were then resuspended in fresh media at a ratio of 1:4 
for the NARF2 or wild-type MEFs or 1:8 for the HeLa or p53 knockout MEFs.
Cyi'o-freezing was used for storage of all cell lines. Cells were trypsinised as 
described and, following pelleting by centrifugation, cells were resuspended in a 
solution of 82% DMEM or Ham’s F12 (10% FCS), 10% neat FCS and 8 % 
dimethylsulphoxide (DMSO). Cells were aliquotted into cyi'o-tubes and frozen at -  
80°C overnight then transfeiTed to liquid nitrogen. Thawing of cells was performed 
rapidly by placing cyro-tubes in a waterbath at 37°C until just thawed. Cells were 
then mixed with fresh media, centrifuged and the supernatant aspirated off to ensure 
removal of DMSO prior to resuspension in 10% FCS DMEM.
2.2 Transient transfection of SAOS2 cells by calcium phosphate precipitation
Approximately 6 x 1 0 ^  cells were seeded onto 100mm tissue culture plates the day 
prior to transfection. Media was changed 2-3 hours preceding transfection. A total of 
20pg plasmid DNA (4pg HSV-p53, 6 pg pVAl, 6 pg HSV-CAT and 4pg PJ4Q16.E6 
or pG4-p300) in 225pl of 0.1 xTE was mixed with 25pl of 2.5M CaCb then added 
dropwise to 250pl of 2xHBS (50mM HEPES, 250mM NaCl, 1.5niM NaHP0 4  pH 
7.12) with vigorous mixing. DNA calcium phosphate precipitate was allowed to form 
for 30 minutes at RT then added dropwise to tissue culture plates. The precipitate 
was removed after 16 hours and the cells washed 2 x in PBS and fresh media added. 
Cells were haiwested 48 hours later.
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The plasmids used for transient transfection were as follows: pVAl contains the 
adenovirus VAl gene (White et al. 1989); HSV-CAT contains the CAT gene driven 
by the thymidine kinase promoter of Herpes Simplex Virus; HSV~p53 (Crook et al, 
1994); pJ4fH6.E6 (Storey et al. 1988); pG4-p300 was prepared by subcloning p300 
from Gal4-p300 into pCDNA3 (Shikama et al. 2000) and pcDNA3 (Invitrogen).
2.3 Preparation of whole cell extracts
All whole cell extracts were prepared from cells grown in 10cm tissue culture dishes 
to facilitate scraping and were harvested at approximately 80% confluency. 
Preparation was performed on ice as rapidly as possible and all solutions and tubes 
were kept ice-cold to maintain cell activity. Cells were washed twice with 5ml of 
PBS before being scraped with a plastic spatula into 5ml of ice-cold PBS. Cells were 
collected in 50ml Falcon tubes and pelleted by centrifugation at 1200g for 8 minutes 
at 4°C. 1ml of Eesh ice-cold PBS was used to resuspend the cell pellets and allow 
the cells to be transferred to eppendorf tubes. These were then microcentrifuged 
briefly at 4°C to re-pellet the cells and the PBS removed. The volumes of cell pellets 
were then measured by comparison with pre-measured volumes of water. 
Microextraction requires pellets to be between 50 - 150pl, giving approximately 0.5 
-  3 X 10  ^ cells; larger pellets were subdivided. An equal volume of freshly made 
cold micro extraction buffer (450mM NaCl, 50niM NaF, 20mM Hep es pH 7.8, 25% 
glycerol, ImM DTT, 0.5mM PMSF, 0.2mM EDTA, 40pg/ml bestatin, Ipg/ml 
trypsin inhibitor, 0.7|Lig/ml pepstatin, 0.5|ug/ml aprotinin, 0.5pg/ml leupeptin) was 
added to the cells and, following resuspension, the cells were immediately snap- 
frozen on dry ice. Cells were then placed in a 30°C water bath until just thawed
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before being immediately returned to dry-ice. This freeze-thaw procedure was 
perforaied a total of 3 times to ensure optimal cell lysis. Cells were then 
microcentrifuged at 7000g for 7 minutes at 4°C. The supernatant was removed, 
aliquoted and snap frozen. Whole cell extracts were stored at -70°C.
2.4 Preparation of total cellular RNA
Total cellular RNA was isolated from cells when approximately 80% confluent using 
TRI reagent (Sigma), in accordance with the manufacturer’s instructions. Media was 
aspirated off cells grown in 1 0 cm tissue culture dishes and residual media removed 
with two washes using 5ml ice-cold PBS. Cells from each dish were harvested by 
scraping in 1ml of TRI reagent per dish and transferred to a sterile eppendorf tube. 
Cells were left to stand for 5 minutes at room temperature to ensure complete 
dissociation of nucleoprotein complexes. 0 .2 ml of chloroform was then added to 
each tube and the samples vortexed for 15 seconds. The samples were then allowed 
to stand for a further 15 minutes at room temperature prior to being centrifuged at 13 
OOOg for 15 minutes at 4°C. This resulted in separation of the samples into tlii'ee 
phases: a lower red organic phase containing protein, a middle white interphase 
containing precipitated DNA and an upper colourless aqueous phase containing 
RNA. These upper phases were carefully removed, ensuring no contamination from 
the remaining phases and transfeiTed to fresh eppendorf tubes. Isopropanol (500pl) 
was added to each of the tubes containing the aqueous RNA and thoroughly mixed 
by repeated inverting. Following 5 - 1 0  minutes incubation at room temperature to 
allow maximal precipitation of RNA, samples were centrifuged at 13 OOOg for 10
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minutes at 4°C. The supernatant was then removed and the remaining RNA pellet 
was washed with 1ml of 75% ethanol made up with diethypyi'ocarbonate (DEPC)- 
treated dHgO (0.1% DEPC), thoroughly mixed into solution, left overnight at room 
temperature and then autoclaved to inactivate the remaining DEPC. The samples 
were vortexed briefly, microcentrifuged at 7500g for 5 minutes at 4^C and the 
supernatant aspirated off. Residual supernatant was removed following pulse 
microcentrifugation. Appropriate volumes of DEPC-dH^O, in the range of 10 - 30pl, 
were added to the RNA pellets and the samples were heated in a 65°C waterbath for 
1 0 - 1 5  minutes to facilitate resuspension of the RNA. RNA was stored at -70°C.
RNA concentration was detennined by UV spectrophotometry using the calculation; 
RNA concentration (pg/ml) = absorbance at 260mn x 40 x dilution factor. A ratio of 
absorbance at 260mn to 280nm in the range of 1.8 — 2 indicated the RNA samples 
were relatively free from contamination with DNA or protein.
2.5 Measuring protein concentration
The protein concentration of samples was determined using Bradford’s reagent 
(Biorad). Quantification of the colour reaction produced upon mixing 1ml of diluted 
reagent (1:4 in distilled water) with a volume of sample containing protein in the 
range o f -1 —12pg gave an indication of protein concentration. This was achieved by 
measuring the absorbance of these samples at 595mn in a UY spectrophotometer, as 
absorbance in response to increasing amounts of protein under these conditions is 
approximately linear. Absorbance readings obtained were then compared to a set of 
standards of known protein concentration using bovine serum albumin (BSA)
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measured at 595iim. A range of sample dilutions were measured and compared in 
this manner in order to obtain an average. Where sample absorbance readings fell 
outside the linear range of the standard set, appropriate dilutions were made and the 
samples re-measured.
2.6 Preparation of cDNAs
cDNAs were prepared from 3pg of RNA. Primer amiealing was carried out in a final 
volume of 24pi with 0,67 x hexanucleotide mix (Roche) (diluted in DEPC-dH^O) and 
allowed to proceed for 10 minutes before being transfered to ice. 8 pi of 5 x First 
Strand Buffer (Life Teclniologies), 4pi of O.IM DTT, 2pi of lOmM dNTP mix 
(made up in DEPC-dH20) and Ipl (200U) of Superscript II Reverse Transcriptase 
(Life Teclmologics) was added to initiate reverse transcription, which was performed 
for Ihour at 47°C before the reaction was stopped by heating at 70°C for 15 minutes. 
cDNAs were stored at -20°C
2.7 Reverse transcriptase -  Polymerase chain reaction (RT-PCR)
PCRs were carried out using a Proteus II thermal controller (MJ Research, Helena 
Bio Science). 2 pi of cDNA was amplified with 20pmol of primer, 0.5U of Taq DNA 
polymerase (Promega) in 20pl of 1 x Taq DNA polymerase buffer (Promega) 
containing 1.5mM MgCb, 0,2mM of each dNTP and l.SpCi of [a^^P] dCTP 
(lOmCi/ml, 3000Ci/mmol).
The following forward (F) and reverse (R) piimers were used:
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ARPP PO:
tRNA^"":
TFIIIC220:
p21  gene:
p21  promoter:
(F) 5’-GCA CTG GAA GTC CAA CTA CTT C-3’
(R) 5’-TGA GGT GOT CCT TGG TGA ACA C-3’
(F) 5’-GTC AGG ATG GCC GAG TGG TCT AAG-3’
(R) 5’-CCA CGC CTC CAT ACG GAG ACC AGA AGA 
CCC-3’
(F) 5’-TCC AGC GAG ACC TTC ACA CC-3’
(R) 5’-GGA TTG AGT GTT GCT GGG CT-3’
(F) 5’-CCT TCG ATA GCT CAG CTG GTA GAG CGG 
AGG-3’
(R) 5’-CGG AAT TGA ACC AGC GAC CTA AGG ATG 
TCC-3’
(F) 5’-CAC CTC CTC ATG TAG ATA CC-3’
(R) 5 ’-AG GTC TGA GTG TCC AGG AA-3 ’
(F) 5’-CCA GCC CTT GGA TGG TTT-3’
(R) 5’-GCC TCC TTT CTG TGG CTG A-3’
PCR was performed under the following cycling parameters:
ARPP PC: 95°C for 2 minutes, 18 cycles of [95°C for 1 minute, 58°C for 30 seconds, 
72°C for 1 minute], 72°C for 3 minutes.
tRNA '^^": 95*^ C for 2  minutes, 30 seconds, 25 cycles of [95°C for 30 seconds, 6 8 °C
for 30 seconds, 72°C for 20 seconds], 72°C for 5 minutes.
TRNA^^‘: 95°C for 3 minutes, 24 cycles of [95°C for 1 minute, 65°C for 30 seconds,
12^C for 15 seconds], 12°C for 5 minutes.
TFIIIC220: 95“C for 3 minutes, 20 cycles of [94°C for 20 seconds, 62°C for 30 
seconds, 72°C for 30 seconds], 72°C for 10 minutes.
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p21  gene: 95”C for 2 minutes, 30 cycles of [95°C for 30 seconds, 59°C for 30 
seconds, 72“C for 30 seconds], 72°C for 3 minutes.
p21  promoter: 95°C for 2  minutes, 35 cycles of [95°C for 1 minute, 62°C for 1 
minute, 72°C for 1 minute], 72^C for 5 minutes.
Reaction products were resolved on 7% polyacrylamide sequencing gels containing 
7M urea and 0.5 x TBE (45mM Tris, 45mM boric acid, 0.625mM EDTA pH 8.0). 
Gels were pre-run for 30 minutes at 40W in 0.5 x TBE and 2pi of each sample was 
loaded after being boiled at 95°C for 2 minutes and quenched on ice. Electrophoresis 
was carried out for a further Ihour at 40W and the gel subsequently vacuum-dried at 
80”C for Ihour before being exposed to autoradiography film in order to detect the 
radiolabelled products. Quantification of results was achieved by phosphoimaging 
(Fujix Bas 1000).
2.8 Transformation of competent cells
E.coli XL-1 Blue superconipetent cells (Stratagene) were transformed for plasmid 
storage and propagation. Cells, which were stored at -80°C and highly temperature 
sensitive, were thawed on ice to prevent loss of transformation ability. 0.4pl of (3- 
mercaptoethanol, which enhances transformation efficiency, was added to the 50pi 
of cells that were required per transfoimation reaction to give a final concentration of 
25mM. Typically 10 -  20ng of plasmid DNA was then gently mixed into the chilled 
cells. The contents were gently tapped occasionally during a 30 minute incubation 
on ice, before being heat shocked at 42°C for exactly 45 seconds and then transfeiTed
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to ice for a further 2 minutes. Cells were incubated at ?>TC for Ihour on an orbital 
shaker (225 - 250rpm) following the addition of 450pi of preheated (42°C) SOC 
medium (LB broth, 0.04% glucose, lOniM MgS0 4 , lOmM MgCh). Typically 150pl 
of the transformation mixture was then plated on LB agar (2% LB, 2% agar) plates 
containing 50pg/ml ampicillin (Amp) and the plates were incubated at 37“C 
overnight to allow growth and colony-formation of the transfoimed cells.
2.9 Preparation of plasmid DNA
For large scale plasmid DNA preparation, a single isolated bacterial colony was 
selected from a freshly-streaked plate and used to inoculate 4ml of LB medium 
containing the selective antibiotic (50pg/ml ampicillin). This was allowed to 
incubate with vigorous shaking at 37°C for ~ 6  hours to form a mini-culture and was 
subsequently used to inoculate 250ml of LB medium containing 50pg/ml ampicillin. 
Following an overnight incubation at 37°C on an orbital shaker (~300rpm), cells 
were harvested by centrifugation at 6000g for 15 minutes at 4°C and plasmid DNA 
retrieved using the QIAGEN Plasmid Maxi Kit.
The bacterial pellet was resuspended in 10ml of Buffer FI (50niM Tris pH 8.0, 
lOmM EDTA, lOOpg/ml RNase A) and then gently but thoroughly mixed with 10ml 
of Buffer P2 (200mM NaOH, 1% SDS) to initiate an alkaline lysis reaction. This 
reaction was allowed to proceed for 5 minutes at room temperature before 
neutralising the lysate by the addition of 10ml of chilled Buffer P3 (3M potassium 
acetate, pH 5.5) which subsequently resulted in foimation of a precipitate of 
potassium dodecyl sulphate. The SDS-denatured proteins and chromosomal DNA
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were co-precipitated with the detergent whilst the plasmid DNA remained in solution 
due to a lack of close protein associations. Precipitation was enlranced by a 20 
minute incubation on ice and the precipitate pelleted by centrifugation at 20 OOOg for 
30 minutes at 4°C. The supernatant containing plasmid DNA was promptly removed 
and applied to a QIAGEN-tip 500 pre-equilibrated with 10ml of Buffer QBT 
(750mM NaCl, 50mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton X-100). 
Gravity flow allowed the supernatant to pass through the anion-exchange resin to 
which plasmid DNA is able to tightly bind. The resin was then washed twice with 
30ml of Buffer QC (IM  NaCl, 50mM MOPS pH 7.0, 15% isopropanol) and the 
purified plasmid DNA was subsequently eluted with 15ml of Buffer QF (1.25M 
NaCl, 50mM Tris pH 8.5, 15% isopropanol) and precipitated with 10.5ml (0.7 
volume) of room-temperature isopropanol. This was immediately followed with a 15 
OOOg centrifugation at 4"^ C for 30 minutes. The plasmid DNA pellet was then 
washed with 70% ethanol, dried at room temperature for 5 - 1 0  minutes and 
resuspended in an appropriate volume of sterile water or TE buffer, pH 8.0 (lOmM 
Tris pH 8.0, ImM EDTA).
2.10 RNA pol III in vitro transcription assay
In vitro transcription of class III genes was reconstituted using 15-20pg of cell 
extracts to provide the basal pol III transcription components. 0.3-1.2pg His-p53 
was preincubated with cell extracts for 10 mins at 4^C. 250ng of plasmid DNA was 
then added to supply a specific pol III template and reactions were earned out in a 
25pi volume with a final concentration of 12mM HEPES pH 7.9, 60mM KCl, 
7.2mM MgCh, 0.28mM EDTA, 1.2mM DTT, 10% (v/v) glycerol, ImM creatine
65
phosphate, 0.5mM each of rATP, rCTP and rGTP and lOpCi [a-^^P] UTP 
(400mCi/mmol) (Ainershain). Transcription components were assembled on ice and 
the reaction was performed at 30°C for Ihour. Transcription was terminated by the 
addition of 250pl of IM ammonium acetate/0.1% SDS containing 20pg of yeast 
tRNA which acts as a stabiliser for the synthesised RNA. Phenol-chloroform 
extraction of the samples was performed to remove protein and DNA by adding 
250pl of a 25:24:1 ratio solution of PI1OH/CPICI3/IAA. The samples were vortexed, 
microcentrifuged at 13 OOOg for 5 minutes and 200pl of the upper aqueous layer was 
then transferred to a fresh eppendorf tube containing 750pl of 96% ethanol in order 
to precipitate the RNA. The samples were thoroughly mixed by repeated inversion, 
left at -20°C overnight before being microcentrifuged at 13 OOOg for 20 minutes to 
pellet the precipitated RNA. The supernatant was carefully removed and 750pl of 
70% ethanol was added to each sample to wash the pellet. This was also carefully 
removed to avoid dislodging the pellet and the samples were heated at 47°C for 5 -  
10 minutes to dry. 4pl of fomiamide loading buffer (98% formamide, lOmM EDTA 
pH 8.0, 0.025% bromophenol blue, 0.025% xylene cyanol FF) was added to each 
sample, which was then vortexed for 20 minutes to ensure the RNA was hilly 
redissolved. 2pi of each sample was loaded on a pre-run 7% polyacrylamide 
sequencing gel containing 7M urea and 0.5 x TBE (45mM Tris, 45mM boric acid, 
0.625mM EDTA pH 8.0) after being boiled at 95“C for 2 minutes and quenched on 
ice. Electrophoresis was perfoimed at 40W for Ihour in 0.5 x TBE before being 
dried and exposed to autoradiography film in order to detect the radiolabelled 
transcripts. Quantification of results was achieved by phosphoimaging (Fujix Bas 
1000).
66
The plasmid templates used for in vitro transcription assays were as follows: pVAi is 
a 221 bp Sall-Ball fragment of adenovirus 2 DNA containing the VAi gene 
subcloned into pUC18; pleu is a 240bp EcoRI-Hindlll fragment of human genomic 
DNA carrying a tRNA*^ ^^ ' gene, subcloned into pAT153 (White et al. 1989); and 
pRH5.7 containing the Alu sequence (White and Jackson 1992a).
2.11 Immuiioprecipition
Antibodies for immunoprécipitation experiments were coupled to protein A- 
Sepharose beads. 20pi of packed beads was used per sample and beads were washed 
twice with 1 x LDB (20mM HEPES-KOH [pH7.9], 17% glycerol, lOOmM KCl, 
12mM MgCb, O.lniM EDTA, 2niM DTT) prior to incubation with the appropriate 
antibody on a shaker for Ihour at 4°C. The beads were then washed twice with 2 x 
LDB to ensure removal of unbound antibody.
For coimmunoprecipitation reactions, typically 200 - 500pg of cell extract (made up 
to a total volume of -300pi with 1 x LDB) and/or 5-1 Opl o f in vitro translated 
protein was incubated with the prepared protein A-Sepharose beads at 4°C for 3 
hours on an orbital shaker. The beads were gently pelleted by pulse 
microcentrifugation and the supernatants carefully removed. The beads were then 
washed with 3 x LDB before the bound material was released by the addition of an 
equal volume of 2 x protein sample buffer (125mM Tris pH 6 .8 , 1% SDS, 10% [3- 
mercap to ethanol, 20% glycerol, 0.25% bromophenol blue) and analysed by SDS- 
PAGE and either western blotting or autoradiography.
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2.12 In vitro transcription-translation
Proteins were synthesized in vitro using the Single Tube Protein System 3 (STP3)-T7 
kit (Novagen) following the manufacturers protocol. Reactions were assembled on 
ice. 8 pi of STP3 T7 Transcription Mix and Ipg plasmid DNA to a final reaction 
volume of 10pi made up with nuclease-fi'ee water were incubated at 30°C for 20 
mill. Translation was carried out by adding 30pl STP3 Translation Mix, 40pCi ^^S- 
labelled Cys/Met, final reaction volume was 50pl made up with nuclease-free water. 
Reactions were gently mixed with the pipette tip and incubated at 30°C for 60 min. 
2pl of each sample was analysed via separation by SDS-PAGE. The gel was dried 
and visualized by autoradiography
The plasmids used for in in vitro transcription-translation were: pCITE.Brfl; pTBP; 
and pSBET.Bdpl (Sclmamm et al. 2000).
2.13 Separation of proteins by polyacrylamide gel electrophoresis (SDS-PAGE)
Proteins were resolved on denaturing polyacrylamide gels according to molecular 
weight by electrophoresis. Typically, 7.8% polyacrylamide resolving mini gels 
(375mM Tris pH 8.8, 0.1% SDS) were used with a stacking layer comprised of 4% 
polyacrylamide gel (125mM Tris pH 6.8, 0.1% SDS) based on the discontinuous 
buffer system described by Laemmli (Laemmli 1970). Samples were boiled for 2 
minutes in 1 x protein sample buffer (62.5mM Tris pH 6.8, 0.5% SDS, 5% P- 
niercaptoethanol, 10% glycerol, 0.125% bromophenol blue) prior to loading. 
Electrophoresis was perfonned in 1 x SDS miming buffer (0.1% SDS, 76.8mM
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glycine, lOmM Tris, pH 8.3) at an initial voltage of 70V while the bromophenol blue 
dye front moved tln*ough the stacking gel and a subsequent voltage of 140V after 
reaching the resolving gel. Electrophoresis was allowed to proceed until the dye 
front had reached the bottom of the gel, approximately 1 - 1 .5  hours.
2.14 Western blotting
Electrophoretic transfer of proteins resolved by SDS-PAGE to PVDF membrane 
was achieved using the BioRad Mini Trans-Blot Electrophoretic Transfer Cell 
system. Transfer was carried out in 1 x transfer buffer (76.8mM glycine, lOmM 
Tris, pH 8.3, 16.5% methanol) at 50V for 1 hour. Following transfer, the membrane 
was blocked in milk buffer (32.5niM Tris, 150mM NaCl, 0.2% Tween-20, 4% 
skimmed milk powder (Marvel)) for 1 hour at room temperature. Membranes were 
incubated with primary antibodies (typically a 1:1000 dilution in milk buffer) 
overnight at 4°C. Excess primary antibody was removed by washing the blot 3 times 
for 3 minutes in fresh milk buffer before incubating for Ihour at room temperature 
with the appropriate horseradish peroxidase-conjugated secondary antibody (DAKO) 
(1:1000 dilution in milk buffer). To ensure removal of excess secondary antibody, 
the blot was sequentially washed in batches of fr*esh milk buffer, 3 times for 3 
minutes, followed by 2 washes for 15 minutes. After one further 5 minute wash 
using 1 X TBS (2.5mM Tris-HCl pH 7.6, 15mM NaCl), the blot was developed using 
the enlranced chemiluminescence method (ECL, Amersham), as directed by the 
manufacturers.
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2.15 Antibodies
DO-1 anti-p53 (Pharmingen)
4286-4 anti-TFIIICl 10 (Sutciffe et al., 2000)
4c826 anti-TBP (Sutcliffe et al. 2000)
C ll anti-actin (Santa Cruz)
M19 anti-TAFi48 (Santa Cmz)
113 anti-BN51 (Ittmann et al. 1993)
128-4 anti-Brfl (Cairns and White 1998)
330-4 anti-Brfl (Alzuhem and White 1998)
1663-4 anti-B” (Sclmamm et al. 2000)
F-7 anti-HA (Santa Cruz)
p Ah 421 (Abl) anti-p53 (Calbiochem)
pAb240 (Ab3) anti-p53 (Calbiochem)
pAbl620 (Ab5) anti-p53 (Calbiochem)
pAblOS anti-SV40 Tag (Santa Cruz)
N15/C20 anti-p300 (Santa Cruz)
2.16 Primer extension
Expression levels of the transfected pol III template VA% and the CAT gene, which 
was co-transfected as an internal control for transfection efficiency, were analysed by 
primer extension. VAi (5’-CACGCGGGCGGTAACCGCATG-3’) or CAT (5’- 
CGA-TGCCATTGGGATATATCA-3’) oligonucleotides were y-^^P end-labelled 
using T4 polynucleotide kinase (PNK), For each primer extension reaction, lOpg of
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total RNA (made up to lOpl with DEPC-dHgO) were incubated at 80°C for 10 
minutes with 9pi of 5 x First Strand Buffer (Life Teclniologies) and Ipl (2.5ng) of 
the relevant probe to act as a primer. Samples were immediately transfeiTed to a 
50°C hotblock for a further 2 hours incubation. 30pl of an elongation mix (23pi 
DEPC-dHzO, 0.5pl IM DTT, 5pl 5mM dNTP mix (5mM in DEPC-dHzO), 0.5pl 
4mg/ml actinomycin D, 0.5pi RNasin, 0.5pi (lOOU) of Superscript II Reverse 
Transcriptase (Life Technologies)) was then added to the samples to initiate reverse 
transcription and the reaction was allowed to proceed for Ihour at 42°C. Reaction 
products were precipitated overnight at -20°C by the addition of 5pi of 3M sodium 
acetate and 125pi of ethanol and subsequently pelleted by microcentrifugation at 13 
OOOg for 15 minutes. Pellets were washed with 300pl of 75% ethanol and dried at 
47°C for 5 minutes before being resuspended by vortexing for 10 minutes in 4pl of 
formamide loading buffer (98% formamide, lOmM EDTA pH 8.0, 0.025% 
bromophenol blue, 0.025% xylene cyanol FF). Electrophoresis tlirough a 7M urea 
7% polyacrylamide gel was used to resolve the samples The reaction products were 
detected by overnight exposure to autoradiography film at -80°C and quantitated by 
phosphoimaging (Fujix Bas 1000).
2.17 Electrophoretic mobility shift assay (EMSA)
TFIIIC2 DNA-binding activity was determined by EMSAs which were earned out 
using ay-^^P labelled oligonucleotide containing a B-block consensus (5’-AGAGGT- 
CCTGAGTTCAAATCCCAG-3’ (RJW l) annealed to the complementary 3’ to 5’ 
strand (RJW2)). For use in EMSAs, oligonucleotides were 5’ end-labelled using T4
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polynucleotide kinase (PNK). 40ng of RJW l was assembled on ice with lOU of 
PNK in 1 X PNK buffer (Promega) and following the addition of 20pCi of [y-^^P] 
dATP (lOmCi/ml, 3000Ci/mmol) to give a total volume of 10pi, the reaction was 
performed at 2>TC for Ihour. This was stopped by heating at 65°C for 10 minutes 
and was succeeded by phenol-chloroform extraction of the PNK enzyme; achieved 
by addition of 50pi of PhOH/CHCb/IAA (25:24:1) followed by vortexing and 
microcentrifugation at 13 OOOg for 5 minutes. The aqueous layer was transferred to a 
fresh eppendorf tube and 5pi of 3M sodium acetate and 125pi of 100% ethanol 
added. After a 30 minute incubation on dry ice, the precipitated oligonucleotide was 
pelleted by microcentrifugation at 13 OOOg for 10 minutes. The supernatant was 
removed and the pellet washed by sequential addition and removal of lOOpl of 70% 
ethanol to ensure removal of unincorporated label. The pellet was then dried by 
heating at 47°C for 10 minutes before being redissolved by incubation at 30°C for 30 
minutes in 20pl of TE buffer (lOmM Tris pH 8.0, ImM EDTA). This was followed 
by heating in a hotblock at 90°C for 2 minutes in the presence of unlabelled 
complementary oligonucleotide (RJW2’) which was added in 2.5 fold excess to 
ensure that all labelled oligonucleotide was annealed. The hotblock was then turned 
off and the sample allowed to cool slowly overnight, after which, it was stored at 4°C 
until ready for use.
Each binding reaction was performed in a total volume of lOpl, with an optimal salt 
concentration of 60mM KCl and contained Ipg of poly(dl.dC) (2pi), lOOng of non­
specific or specific competitor oligonucleotide (2pl), typically 2 - 4pi of cell extract 
and 0.25 -  0.5ng of labelled probe (2pi). A pre-incubation of 15 minutes at 30°C 
was carried out prior to addition of the probe, followed by a further 15 minutes at
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30°C. Analysis of the formation of protein-DNA complexes was achieved by 
electrophoresis of samples on a pre-mn 4% nondenaturing polyacrylamide gel in 1 x 
TAE buffer (40mM Tris acetate, ImM EDTA pH 8.0) for 1.5-2 hours at 4°C. The 
gel was dried for 1.5 hours at 80°C and exposed to autoradiogiaphy film overnight at 
-70“C.
2.18 Baculoviral expression and purification of His-p53
Human and murine p53-producing recombinant baculoviruses were constructed and 
amplified by L. Wamock at the Yorkshire Cancer Research Campaign P53 Research 
Group, Department of Biology, University of York. (Molinari et al. 1996). Sj9 insect 
cells at 80% confluency in TNM-FH medium (Pharmingene) were infected with high 
titre recombinant baculovirus and harvested 3 days later. After washing four times 
with phosphate-buffered saline (PBS) the cell pellet was resuspended and lysed for 
30 min on ice in 5 ml lysis buffer (150 mM Tris-HCl, pH 9.0, 150 inM NaCl, 0.5% 
NP-40, 10% glycerol, 1 niM phenylmethylsiilfonyl fluoride, 50 pg/ml aprotinin, 
50 pg/ml leupeptin, 10 pg/ml pepstatin A and 1 niM P-mercaptoethanol). The lysate 
was centrifuged at 20 000 r.p.m. in a Sorvall SS-34 rotor at 4°C for 30 min and 
loaded on a 0.5 ml Ni-NTA agarose column (Qiagen Inc.) prewashed with lysis 
buffer, pH 7.0. The column was washed with 10 ml lysis buffer, pH 9.0, and adjusted 
to pH 7.0 with 10 ml lysis buffer, pH 7.0. The column was step-eluted by one volume 
portions of elution buffer (50 mM NaCl, 10 mM Tris-HCl, pH 7.0, and 5 mM MgCb) 
containing increasing concentrations of imidazole (50, 100, 150 and 250 mM). The 
100-150niM imidazole fractions were routinely used for analyses. Imidazole was 
removed using Centricon-10 cartridges (Amicon) by washing with 4 x LDB. p53
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protein was quantitated by Bradford assay and purity checked by SDS-PAGE and 
silver staining. A single band corresponding to p53 was observed.
2.19 HiS“p53 biiiding assay
Binding assays were carried out with His-p53 wt and His-p53 core, comprising 
residues 98-303 (Okorokov and Milner 1999). Proteins were purified as described 
above; however, after the 50mM imidizole wash, the beads were removed from the 
column and 50pi aliquots were used in each assay. His-p53 bound to Ni-NTA 
agarose was incubated with either 5pi ^^S-labelled TBP, Brfl or Bdpl or CHO 
extract containing HA-Brfl, Binding was carried out in imidizole buffer (5mM 
MgC12, 50mM NaCl, lOniM Tris-HCl pH7.0, 50mM imidizole) for 1 hour at 4°C 
with shaking in a final reaction volume of 250pl. Beads were then washed 5 x in 
TBS. Bound material was separated by elecrophoresis and visualised by either 
autoradiography or western blotting.
2.20 Expression and purification of GST-p53
GST-p53 and GST were prepared using the GST Gene Fusion System (Stratagene) in 
E. coli. BL21 (DE3) (pLys). 40ml L-broth cultures containing 50pg/ml ampicillin 
were inoculated from glycerol stocks and grown overnight at 37°C with shaking. 
Cultures were then diluted into 400ml cultures and gi'own for 2 hours until an OD of 
0.6 was reached. Cultures were then induced with O.lmM IPTG for 16 hours. 
Expressed protein was purified from bacterial lysates by precipitation with
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glutathione coated sepharose 4B beads (Phannacia). Cultures were spun in the Sorval 
High Speed Centrifuge using the SLA-30 rotor at 3000rpm for 15 min at 4°C. 
Pelleted cells were then resuspended in 9ml ice cold PBS, 1% Triton X-100, 1% 
PMSF and sonicated 2 x 20 sec at 60-80W. Samples were centrifuged at 10 OOOrpm 
for 5 min at 4°C, The supernatant was bound to 500pl packed GST-sepharose beads 
for 30 min at 4°C, with mixing. After binding, the beads were washed 2 x with 50ml 
ice cold PBS, 1% Triton X-100, and 2 x with 50ml ice cold PBS. 20pl samples were 
analysed by SDS-PAGE and stained with Coomassie blue.
2.21 GST-pulI down assays
Equal amounts of immobilised GST and GST-p53 (estimated by Coomassie staining) 
were used in the reactions. 20pi packed glutathione-sepharose beads bearing GST- 
p53 or GST alone were incubated with 5-lOpl ^^S-labelled recombinant TBP or Brfl 
in 50pl LDB. Samples were incubated on an orbital shaker for 3 hours at 4°C. Beads 
were then washed 5 x in 500pi LDB. Bound material was separation by SDS-PAGE 
and analysed by autoradiography.
2.22 Immobilised template assay
The biotinylated templates were synthesised by PCR as previously described (Panov 
et al. 2001). The plasmid pLeu was used as template. Primers used were fbiivard, 5’- 
GCTTTGCCCCATTCCTTA-3 ’ ; reverse, 5 ’-
CTTTCTGCATGTAAATAGGTGTAAC-3 ’ which was biotinylated at the 5’ end.
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PCR was performed under the following cycling parameters: 95°C for 5 minutes, 35 
cycles of [95“C for 1 minute, 58°C for 30 seconds, 12°C for 1 minute], 72°C for 3 
minutes. A 240bp product was generated.
Immobilized template DNA (20pi) was incubated with gentle agitation with 200pg 
CHO extract stably transfected with HA tagged Brfl 1 for 20 mins at 30°C. Reactions 
were perfonned in the presence or absence of wild-type His-53 or His-p53 (24-392) 
(Okorokov and Milner 1999), in LDB (final salt concentration 60mM) and lOpg poly 
dldC to a final reaction volume of 250uL Using a magnetic stand, beads were washed 
3 X with 2 reaction volumes of LDB (60mM) containing 0.003% NP-40, and 
resuspended in 20pl protein sample buffer. Bound material was separated by SDS- 
PAGE and analysed by Western blotting.
2.23 Chromatin immunoprécipitation assay
Cells were harvested, washed with ice-cold PBS, then crosslinked for 10 mins at 
37°C in 10ml 0.5% NP-40/PBS containing 1% fomialdehyde. After crosslinking, 
cells were washed with ice-cold 0.5% NP-40/PBS and incubated for 30 mins with 
40ml high salt buffer (0.5% NP-40, PBS, IM NaCl). Further washing with 0.5% NP- 
40/PBS was followed by hypotonic disruption for 30 mins in 40ml low salt buffer 
(0.1% NP-40, lOniM Tris-HCl pH 8.0, ImM EDTA, O.IM NaCl). After 
centrifugation at 500g, nuclei were obtained with 1 stroke through a 26 gauge needle 
and recentrifuged. Nuclei were resuspended in 2.7ml of low salt buffer and lysed 
with 300pl sarkosyl. Sample was transferred to a sucrose cushion (40ml low salt
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buffer/lOOmM sucrose) and spun for 10 mins at 4000g. The pellet was resuspended 
in 3ml TE, and the process was repeated. The pellet was then resuspended in 2ml TE, 
and genomic DNA was sheared by sonication (Branson sonifier 250, 10 x lOsec, 
30% duty cycle). Sonicated material was adjusted with 1/10 volume of 11 x NET 
(1.65M NaCl, 5.5mM EDTA, 5.5% NP-40. 550mM Tris-HCl pH 7.4) and 
immunoprecipitated overnight with 4pg of antibody. Protein A-sepharose beads were 
added for a further 2 hours and then recovered on polyprep columns (Biorad). The 
negative control was incubated with beads alone. After washing twice with 10ml 
RIPA buffer, 10ml of LiCl buffer (lOmM Tris.HCl, 250mM LiCl, 0.5% NP-40, 0.5% 
deoxycholate, ImM EDTA pH8.0) and 10ml TE, beads were transferred to 1.5ml 
tubes and immunoprecipitated material was eluted twice with 200pl of 1% SDS in 
TE. To isolate precipitated DNA, proteins and antibodies were degi*aded with 
proteinase K treatment overnight at 42°C. DNA was extracted twice using 400pl 
phenol/chloroform/isoamyalcohol and ethanol precipitated. Immunoprecipitated 
DNA was quantitated by PCR.
2.24 Li-Fraumeni Cells
Mutations in the p53 genes of Li-Fraumeni families were identified by direct 
genomic sequencing of all 11 exons plus the promoter region and all splice junctions 
(Varley et al, 1997a, b). Primary fibroblasts were cultured from skin biopsies 
obtained with informed consent from LFS patients and normal control individuals 
(Boyle et al. 1998). These steps were carried out at the Paterson Institute for Cancer 
Reseearch, Manchester.
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Chapter 3
Several regions of p53 are involved in repression of RNA polymerase 
III transcription
3.1 Introduction
Previously it has been demonstrated that p53 can repress transcription of pol III 
transcription both in vivo and in vitro (Chesnokov et al. 1996; Cairns and White
1998), however cm*rently the mechanism of transcriptional repression remains poorly 
understood. p53 is a complex molecule consisting of multiple domains (Ko and 
Prives 1996; Levine 1997). Transcriptional activation is mediated tlirough the acidic 
activation domain located at the N-tenninus of the protein (Unger et al. 1992), and 
the central portion of the molecule forms a sequence specific DNA-binding domain 
(Cho et al. 1994). A variety of fimctions have been mapped to the C-teiminal 
domain; these include oligomerisation (Sturzbecher et al. 1992) and stabilization of 
DNA binding activity (Hupp et al. 1992). A minimal region of eight amino acids 
located at residues 339-346 was previously found to be essential for p53 to repress 
pol II transcription (Hong et al. 2001). In addition sequence at both the N- and C- 
tennini of p53 have also been implicated in this function (Horikoshi et al. 1995), 
(Sang et al. 1994), (Subler et al. 1994). hivestigation into which regions of p53 are 
involved in repressing pol III transcription may well provide clues as to the 
mechanism by which p53 can repress pol III transcription and therefore establishes 
the aim of this chapter.
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3.2 Results
3.2.1 Expression purification and characterisation of recombinant His-p53
In order to study the mechanism by which p53 represses pol III transcription it was 
first essential to produce active recombinant p53. His-p53 was purified from Sf9 
insect cells infected with high titre recombinant baculo virus encoding either murine 
or human His tagged p53. His-p53 was then purified to near homogeneity using Ni- 
NTA agarose beads. An ovei'view of the process used to synthesise and purify His- 
p53 is shown in figure 3.1 and detailed methods are given in Chapter 2. In many 
instances, Lorna Wamock from the University of York carried out steps A-D 
(Okorokov and Milner 1999),
Purification of His tagged p53 using Ni-NTA agarose beads produced a single band 
migi'ating at approximately 53kDa on a Coomassie-stained 10% SDS-PAGE gel 
(Figure 3.2). Human His-p53 (Figure 3.2, upper panel) usually gave a greater yield of 
protein when compared to murine His-p53 (Figure 3.2, lower panel). The reason for 
this is unclear, but may reflect the stability of the two proteins.
There is evidence that wild-type p53 can both promote and suppress cell proliferation 
and it has been suggested that these opposing functions are achieved by alternative 
conformations o f the p53 protein (Milner 1994). These foims of p53 are defined by 
reactivity with tlrree monoclonal antibodies, pAb240, pAb421 and pAbl620 (Milner 
1994). Normal cell proliferation is linked to two conformational variants of p53 both 
of which are reactive with pAb421 (Figure 3.3a). The form of p53 most commonly 
detected in proliferating cells is 24071620'*’ (Figure 3.3a, left). This form coiTelates 
with the ability to suppress growth under appropriate conditions and is temied the
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Figure 3.1. Schematic overview of the steps involved in producing recombinant 
Histidine tagged p53. (A) Generation of the recombinant baculovirus transfer vector 
(Molinari et al. 1996). (B) Co-transfection of BaculoGold (Pharmingen) and the 
linerised recombinant transfer vector into Sf9 insect cells. (C) Recombination 
between the vector and the viral DNA occurs within the cell and recombinant 
baculovirus is produced. (D) The recombinant virus is harvested and amplified to 
produce a high titre stock which can then be used to infect cells for recombinant His- 
p53 protein expression. (E) Recombinant His-p53 is purified to near homogeneity 
from the cellular lysate using Ni-NTA agarose beads (Qiagen). (Figure adapted from 
Baculovirus Expression System handbook, Pharmingen).
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Figure 3.2. Purified human (panel A) and murine (panel B) recombinant His- 
p53. Molecular markers (lane 1) and 25|ul samples either before purification (lane 2) 
of His-p53 or after elution with 50nM (lane 3), lOOnM (lane 4), 150nM (lane 5), or 
250nM (lanes 6-10) imidizole. Proteins were visualised by staining with Coomassie 
Blue. The 150mM fractions were generally used.
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Figure 3.3. Recombinant p53 largely exists in an active form. (A) Schematic 
representation of the antibodies reactive with the active suppressor form of p53; 
42y /1620"^  (left panel) and the conformational form of p53; 42^/240"^ (right panel). 
(B) A significant fraction of recombinant human, but not murine His-p53, exists in 
the mutant form. 500ng of recombinant human (lanes 1-4) and murine (lane 5-8) His- 
p53 protein was irmnunoprecipitated with anti p53 antibodies pAb421 (lanes 1 and 
5), pAbl620 (lanes 2 and 6), pAb240 (lanes 3 and 7) or the antibody against SV40 
large T antigen as a negative control (lanes 4 and 8). Immunoprecipitated material 
was elecrophoresed on a 7.8% SDS-polyacrylamide gel, transferred to nitrocellulose 
and detected via Western blotting with the anti p53 antibody DO-1.
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suppressor form (Milner 1994). The p53 epitope recognised by pAb240 is cryptic on 
the suppressor fomi of wild-type p53 but is frequently exposed on mutant p53 (Hupp 
et al. 1993).
Using immunoprécipitation it was investigated which of these three conformation 
specific antibodies were reactive with both human and murine recombinant His-p53 
(Figure 3.3b). Both human and murine p53 was reactive with pAb421 (Figure 3.3b, 
lanes 1 and 5) and pAbl620 (Figure 3.3, lanes 2 and 6). In contrast to this, pAb240 
recognised only significant levels of human p53 (Figure 3.3b, lane 3). Recognition 
by the antibodies was specific since the negative control antibody against SV40 T 
antigen immunoprecipitated undetectable levels of p53 in both cases (Figure 3.3b, 
lane 4 and 8). The p53 epitope recognised by pAb240 is Requently exposed on 
mutant p53 (Hupp et al. 1992), suggesting that a substantial portion of human but 
little murine His-p53 is present in this mutant confomiation. For this reason, 
subsequent experiments were carried out using murine His-p53.
3.2.2 Recombinant His-p53 represses pol III transcription
Murine His-p53 was tested for its ability to repress pol III transcription (Figure 3.4). 
When titrated into nuclear extract, increasing amounts of His-p53 repress 
transcription of the pol III reporters Alu (lanes 2, 3 and 4, upper band) and tRNA'^ '^  ^
(lane 2, 3 and 4, lower band). This demonstrates that recombinant His-p53 can 
efficiently repress pol III transcription in vitro, thus providing a reliable tool for 
investigating the means by which p53 regulates pol III activity.
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Figure 3.4. Recombinant His-p53 represses pol III transcription. pRH5.7 (250ng) 
and pleu (250ng) was transcribed with HeLa nuclear extract (15pg) that had been 
preincubated with 0.4pg (lane 2), 0.8pg (lane 3) or 1.2pg (lane 4) of murine His- 
p53.
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3.2.3 The N-terminal 23 residues of p53 are important for repression of pol III 
transcription
In order to address which regions of p53 are required to repress pol III transcription a 
series of previously characterised His-p53 mutants (Okorokov and Milner 1999) 
were employed (Figure 3.5a). Recombinant baculovims encoding wild-type or 
mutant His-p53 was expressed in SI9 cells, as described (Okorokov and Milner
1999) and purified to near homogeneity using the polyhistidine tag (Figure 3.5b). 
When titrated into nuclear extract, wild-type p53 produced a clear repression of VAl 
(Figure 3.6, lane 3 and 4, upper panel) and Alu transcription (Figure 3.6, lane 3 and 
4, lower panel), hi contrast, no inhibition of VAl or Alu was obseiwed using an equal 
amount of mutant p53(67-363), which is missing the N-terminal 66 residues and the 
C-terminal 29 residues (Figure 3.6, lane 5 and 6). This demonstrates that the 
repression obtained with wild-type p53 is specific. It also suggests that regions 
outside the central domains of p53 contribute to repression of pol III transcription. A 
mutant p53(l-363) which is missing only the C-terminal 29 residues was found to 
retain a significant capacity to repress pol III transcription (Figure 3.6, lanes 8 and 9). 
Deletion of the N-terminal 13 residues p53(24-393), however, completely abolished 
the ability of p53 to repress either VAl (upper panel) or Alu (lower panel) 
transcription (Figure 3.6, lane 11 and 12). These results suggest that N-tenninal 
residues of p53 are important in mediating repression of pol III transcripts. It also 
suggests that the C-terminal 30 residues are unnecessary for this activity.
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Figure 3.5. Schematic representation of the His-p53 truncated constructs. (A)
The major domains of p53 are indicated. Nt, N-terminus; Ct, C-terminus; Tet, 
tetramerization domain. (B) Coomassie-stained gels of purified His-p53 proteins. 
200ng of wild-type p53 (lane 1), p53(67-363) (lane 2), p53(l-363) (lane 3) and 
p53(24-392) (lane 4) were electrophoresed on a 10% SDS-polyacrylamide gel and 
visualised by staining with Coomassie Blue.
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Figure 3.6. The N-terminal 23 residues of p53 are important for repression of 
pol III transcription. pVAl (250ng) (top panel) and pRH5.7 (250ng) (bottom panel) 
were transcribed using HeLa nuclear extract (15pg) that had been preincubated for 
10 min at 30°C in the absence (lanes 1, 4, 7, 10 and 13) or in the presence of 0.6pg or 
1.2pg of wild-type p53 (lanes 2 and 3 respectively), 0.6pg or 1.2pg of p53(67-363) 
(lanes 5 and 6 respectively), 0.6pg or 1.2pg of p53( 1-363) (lanes 8 and 9 
respectively), or 6pg or 1.2pg of p53(24-392) (lanes 8 and 9 respectively).
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3.2.4 Repression of pol III transcription by p53 can be blocked specifically using 
antibodies against the central core or C-terminal domains
Previously it has been demonstrated that preincubation of p53 with the monoclonal 
antibody DO-1 can specifically block p53-mediated repression of pol III 
transcription (Cairns and White 1998). Since DO-1 recognises residues 11-25, this 
result is consistent with the observation that the N-tenninal domain of p53 is required 
for pol III repression (Figure 3.6). A similar approach using specific antibodies 
against p53 was used to further investigate the regions of p53 required for pol III 
regulation. Antibodies against the central core (pAbl620) or the C-terminus 
(pAb421) of p53 were preincubated with the protein prior to transcription. In the 
absence of antibody p53 clearly represses VAl transcription (Figure 3.7, lane 2). 
pAblSOl recognises only human p53 and not the murine p53 used in this 
experiment. Since preincubation with pAblSOl does not perturb repression, it serves 
as a control vs non-specific effects of antibodies (Figure 3.7, lane 3). In contrast, 
preincubation with either pAh421 (Figure 3.7, lane 4) or pAbl620 (Figure 3.7, lane 
5) blocks repression of VAl. This result suggests that both the core domain and the 
C-tenninal residues of p53 may be involved in mediating repression of pol III 
transcription.
3.2.5 Double substitution at residues 340 and 344 does not affect the ability of 
p53 to repress pol III transcription
Native p53 forms a tetranier in solution and residues 325-356 are required for this 
oligomerisation (Jeffrey et al. 1995; Sturzbecher et al. 1992). A mutant version of 
full-length p53 that carries a double substitution at residues 340 and 344,
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Figure 3.7. Repression of pol III transcription by p53 can be blocked specifically 
using antibodies against the central core or C-terminal domains. pVAl (250ng) 
was transcribed using HeLa nuclear extract (15pg) that had been preincubated for 10 
min at 30°C in the presence of buffer (lane 1) or Ipg of wild-type p53 (lanes 2-5). 
Prior to use, p53 was incubated at 4°C for 2 hours with buffer (lane 2) or 0.5pg of 
pAblSOl (lane 3), pAb421 (lane 4) or pAbl620 (lane 5).
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p53(M340Q/L344R) (Figure 3.8a) (Okorokov and Milner 1999) was used to 
investigate the involvement of this region in mediating pol III repression. This 
mutant can form dimmers, but is unable to tetramerise (Davison et al. 2001). 
p53(M340Q/L344R) was expressed in Sf9 insect cells and affinity purified (Figure 
3.8b). When equal amounts were added to nuclear extract p53(M340Q/L344R) 
repressed Alu transcription as well as wild-type p53 (Figure 3.9 compare lanes 7-9 
with 3-5). This suggests that tetramerisation of p53 is not essential in order for p53 to 
repress pol III transcription.
3.2.6 Substitution 341A prevents repression of pol III transcription
To further investigate the role of tetramerisation of p53 in mediating pol III 
transcriptional repression, two single residue substitution mutants were employed. 
The p53 mutant in which residue 344 has been substituted to Alanine (344A) is 
unable to fonn tetramers and largely exists in the dimeric foiin (McLure and Lee 
1998); however, the mutant in which residue 341 is mutated to Alanine (341 A) is 
unable to fomi dimers or tetramers, and therefore exists in a monomeric (Mateu and 
Fersht 1998). The p53 null, osteosarcoma cell line SA0S2 was transfected with the 
VAl gene as a reporter for pol III activity and HSV-CAT, in which the 
chloroamphenicol acetyltransferase gene is transcribed from the basal thymidine 
kinase promoter of heipes simplex virus. This pol II transcribed gene serves as an 
internal control for transfection efficiency and RNA recovery. In addition, vectors 
encoding wild-type p53, p53(344A) or p53(341 A) were cotransfected. Expression of 
the VAl and HSV-CAT reporters were then monitored by quantitive primer 
extension assays.
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Figure 3.8. Purification of wild-type p53 and p53 (M340Q/L334R). (A)
Schematic representation of the p53 wild-type and p53(M340Q/L344R). The major 
domains of p53 are indicated. Nt, N-terminus; Ct, C-terminus; Tet, tetramerization 
domain. Sites of point mutations are indicated by crosses. (B) Coomassie-stained 
gels of purified His-p53 proteins. 200ng of wild-type p53 (lane 1) and 
p53(M340Q/L344R) (lane 2) were electrophoresed on a 10% SDS-polyacrylamide 
gel and visualised by staining with Coomassie Blue.
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Figure 3.9. Double substitutions at residues 340 and 344 do not affect the ability 
of p53 to repress pol III transcription. pRH5.7 (250ng) was transcribed using 
HeLa nuclear extract (15pg) that had been preincubated for 10 mins at 30°C in the 
absence (lanes 1, 2, 6, 10 and 11) or presence of 0.3pg, 0.6pg or 0.9pg of wild-type 
p53 (lanes 3, 4 and 5 respectively) or p53(M340Q/L344R) (lanes 7, 8 and 9 
respectively).
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Wild-type p53 clearly represses pol Ill-dependent transcription of VAl (Figure 3.10, 
lane 2, upper two panels) when compared to the empty vector control (Figure 3.10, 
lane 1, upper two panels). Transfection of p53(344A) also demonstrated a significant 
repression of VAl (Figure 3.10, lane 3, upper two panels). In contrast to this, 
p53(341 A) was unable to significantly repress pol III transcription. Western blotting 
confirmed that p53 was expressed in all transfection experiments (Figure 3.10, third 
panel). The levels of mutant p53 protein appear to be slightly higher than that of 
wild-type p53. This could be accounted for by an underloading of sample in lane 3, 
as suggested by the actin control (Figure 3.10, bottom panel). It is also possible that 
the mutations in p53 have disrupted the mechanisms normally used to control the 
levels of p53. This result demonstrates that a mutant 433A, which camiot tetramerise, 
can still repress pol III transcription in vivo', leading to the suggestion that 
tetramerisation of p53 is not an essential function to mediate pol III transcriptional 
repression. The monomeric form of p53 harbouring the substitution 341A was unable 
to repress pol III transcription, suggesting that monomeric p53 is insufficient to 
repress pol III transcription in vivo.
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Figure 3.10. Mutation 341A prevents p53 from repressing pol III transcription. 
SAOS2 cells were cotransfected with pVAl (3pg), HSV-CAT (3pg) and 2pg of 
empty vector (lane 1) or vectors encoding wild-type p53 (lane 2), p53(344A) (lane 3) 
or p53(341A). RNA and protein were harvested 48hrs after transfection. The upper 
two panels show primer extension analyses of extracted RNA using primers specific 
for VAl (upper panel) and CAT (second panel). Extracts were analysed by Western 
blotting for the expression of p53 (third panel) and actin (bottom panel).
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3.3 Discussion
Repression of pol III transcription by p53 is not attributed to one single region of 
p53. The N-terminal residues clearly play a role, since deletion of residues 1-23 
abolished the ability of p53 to repress VAl and Alu transcription in vitro (Figure 
3.6). Stein et al. also demonstrated that residues 22 and 23 are specifically involved 
in mediating repression, since substitution of these residues abolished pol III 
repression in transient transfection assays (Stein et al. 2002b). These residues are 
important in binding TFIID, a basal transcription factor required for pol II 
transcription (Chang et al. 1995; Farmer et al. 1996b; Lin et al. 1994; Lu and Levine 
1995; Thut et al. 1995b). In contrast to this, residues 13-19, which encompass 
conseiwed region I of p53, are not required for repression of VAl transcription in 
vivo (Stein et al. 2002b).
Figure 3.7 demonstrated that preincubation with pAbl620 against the core domain of 
p53 abolished the ability of p53 to repress VAl transcription in vitro. This suggests 
that the core domain may function in mediating repression of pol III transcripts. p53 
consensus binding sites are not found within pol III genes, and it is believed that 
repression by p53 occurs not tlu'ough DNA binding, but via protein-protein 
interactions. Individual deletion of conserved regions II-V, however, completely 
abolished the ability of p53 to repress pol III transcription in vivo (Stein et al. 2002b), 
suggesting that an intact central core domain is necessary for repression of pol III 
transcription. It is possible that the obseiwed lack of repression could be attributed to 
a conformational change in p53 brought about by the deletions, however point 
mutations within the core domain that are not thought to affect p53 conformation 
were shown to block the ability of p53 to repress pol III transcription (Stein et al.
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2002a). For example, a mutant in which arginine 273 had been substituted to cysteine 
was no longer able to repress pol III transcription in vivo (Stein et al. 2002a). This 
evidence further supports a role for the core domain of p53 in mediating a pol III 
transcriptional repression.
p53 largely exists as a tetramer in solution (Levine 1997), but tetramerisation of p53 
has proved not to be essential for eliciting all of its cellular functions (Tamnina and 
Jenldns 1993; Shaulian et al. 1993; Slingerland et al. 1993). Here it is demonstrated 
that a mutant canying the double substitution M340Q/L344R was able to repress pol 
III transcription in vitro (Figure 3.10). In addition transient transfection assays 
revealed that the single substitution p53 mutant 344A could still mediate repression.
In contrast, the mutant 341A was unable to repress transcription. M340Q/L344R and 
341A are reported to form dimers but not tetramers and 344A is unable to form 
dimers or tetramers. This suggests that dimérisation but not tetramerisation is f|
essential for mediating repression of pol III transcription. p53 canying an ALAL 
mutation at residues 365, 372, 379 and 387 was unable to repress pol III transcription 
in a transient transfection assay (Stein et al. 2002b). ALAL is unable to form 
tetramers but has been shown to allow dimérisation of p53 (Sturzbecher et al. 1992) 
providing a contradiction to the suggestion that tetramerisation is not essential for 
p53 to repress pol III transcription. Several distinct activities of p53 map to this 
region and at present is it not possible to draw any firm conclusions regarding the 
oligomerisation requirements of p53 in order to repress pol III transcription.
An inconsistency exists between the evidence implicating the C-teiminal domain of 
p53 in pol III transcriptional control. Transcriptional repression by p53 could be
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blocked by preincubation with antibody pAb421 that binds to residues 371-380 
(Figure 3.7) however deletion of residues 364-392 (Figure 3.6) did not impair 
repression. An ALAL quadruple substitution at residues 365, 372, 379 and 387 was 
previously shown to diminish repression of pol III transcription in vivo (Stein et al. 
2002b), as did deletion o f residues 291-329 (Stein et al. 2002b). Both binding of 
pAb421 to the C-terminus of p53 and the ALAL substitution have been shown to 
cause a structural rearrangement within p53 that activates it for DNA binding (Hupp 
et al. 1992; Marston et al. 1998). It is possible that such a rearrangement interferes 
with repression of pol III transcription. Recently it was found that residues 339-346 
within the C-terminus of p53 possess transcriptional repression activity with respect 
to pol II promoters (Hong et al. 2001). hi addition, other sequences within the C- 
temiinus have also been found to contribute to transcriptional repression of pol II 
genes (Horikoshi et al. 1995; Subler et al. 1994). On the basis of this, it is very likely 
that sequence within the C-terminus of p53 contributes to repression of pol III 
transcription.
p53 has been shown to inliibit a wide range of pol III templates (Caims and White 
1998). The only sequences shared by these genes are the promoter and terminator 
elements that are recognised by basal pol III transcription factors. p53 has been 
shown to bind to TFIIIB, a factor fundamental for the recruitment of polymerase to 
pol III templates. TFIIIB is a trimeric complex, an essential subunit of which is the 
TATA-box binding protein, TBP (Kassavetis et al. 1992; Lobo et al. 1992; Simmen 
et al. 1992; Taggart et al. 1992; White and Jackson 1992a). Previously it was 
demonstrated that functional TBP is mandatory for titration of TFIIIB to relieve p53 
mediated repression of VAl transcription in vitro (Cairns and White 1998). Both the
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N- and C-tenninal regions of p53 have been shown to interact with TBP (Horikoshi 
et al. 1995) and it is a possibility that the N- and C-tenninal regions of p53 mediate 
repression of pol III transcription thinugh interactions with TBP.
The N- and C-terminal regions of p53 have also been shown to function in mediating 
repression of pol II transcription (Horikoshi et al. 1995), (Sang et al. 1994), (Subler 
et al. 1994), and it has also been postulated that p53 mediates this repression tlnoiigh 
interactions with TBP (Horikoshi et al. 1995). It has recently been demonstrated that 
p53 represses pol II transcription through the recmitment of histone deacetylase 
complexes via the corepessor iiiSin3A (Murphy et al. 1999). mSin3A is thought to 
interact with the N- and C-teiininal regions of p53, thus providing a further possible 
mechanism by which p53 can repress pol III transcription.
In conclusion, it is clear that from these analyses that repression of pol III 
transcription by p53 camiot be attributed to one single defined region. There is 
evidence implicating both the N- and C-teimini of p53 and it appears that the core 
sequence-specific DNA binding domain also plays a role.
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Chapter 4
Loss of p53 function allows increased pol III transcription
4.1 Introduction
Mutation of the p53 gene is obsei*ved in around half of all human cancers (Hollstein 
et al. 1991). hi addition to this, it is becoming evident that many of the tumours that 
retain wild-type p53 frequently show defects in the ability to mount a p53 response 
(Vogelstein et al. 2000). This is often due to an abeiTation in a pathway responsible 
for the regulation of p53 itself. For example, the amplification of the Mdm2 gene 
has been described in some tumours types (Oliner et al. 1992) and in ceiwical 
carcinomas, a tumour associated with viral infection, p53 is directly targeted and 
inactivated by viral proteins (Vousden 1995),
The aim of this chapter was to investigate whether mutational events in the gene or 
deregulation of p53 itself can compromise its ability to regulate pol III transcription. 
Firstly it was examined what effect endogenous p53 has on pol III transcription by 
investigating the abundance of pol III transcripts in wild-type and knockout mouse 
embryonic fibroblasts (MEFs). It was then examined how the ability of p53 to 
regulate pol III transcription is influenced by inherited mutations in the p53 gene 
found in individuals with Li-Fraumeni syndrome (LFS). The consequence of 
deregulation of p53 on pol III transcription was also investigated. It was examined 
whether the viral E6 oncoprotein from Human Papillomavirus (HPV) affects the
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ability of p53 to repress pol III transcription and what consequence induction of the 
p i4^^^ tumour suppressor has on pol III transcription.
4.2 Results
4.2.1 Primary p53 knockout mouse embryo fibroblasts display elevated levels of 
pol III products
Previously it was demonstrated that fibroblasts from p53 knockout mice synthesise 
pol III products at abnormally elevated levels (Cairns and White 1998). The cells 
used in this experiment were immortalised fibroblasts and therefore have almost 
certainly undergone multiple genetic changes both in the process of immortalisation 
and through multiple passages. Using untransformed primary MEFs RT-PCR 
analysis of cDNA prepared from wild-type (Figure 4.1, lane 1) or p53 knockout 
(Figure 4.1, lane2) cells demonstrate that tRNA^^‘ (upper panel) and tRNA^^" 
(middle panel) are elevated in the knockout cells when compared with the wild-type 
controls. This effect is specific since the levels of the pol II transcribed gene 
encoding acidic ribosomal phospoprotein PO (ARPP PO) remain constant (lower 
panel). This finding adds further evidence to the belief that endogenous p53 
contributes to the control of pol III transcription.
4.2.2 Pol III transcriptional activity is often deregulated in primary fibroblasts 
from LFS patients
Sufferers of LFS, an inherited autosomal cancer syndrome, carry mutant forms of the 
p53 gene (Varley et al. 1997a). As with sporadic tumours, a variety of mutations are 
associated with this syndrome (Varley et al. 1997a). It was investigated whether the
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Figure 4.1. Primary p53 knockout mouse embryo fibroblasts (MEFs) display 
elevated levels of tRNA in vivo. RT-PCR analysis of cDNA prepared from RNAs 
extracted from wild-type MEFs (lane 1) or p53 knockout MEFs (lane 2) using 
primers for tRNA*^“ (top panel), tRNA^^ (middle panel) or ARPP PO (bottom 
panel).
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pol III machinery is deregulated in cells harbouring a variety o f these mutations 
(Table 4.1). Protein extracts were prepared from primary human fibroblasts derived 
from healthy volunteers or patients caiTying inlierited mutations in the p53 gene. 
Transcription assays were then carried out using the VAl (upper panel) and the 
tRNA^^" (second panel) genes as templates. A representative example of such 
experiments is shown in Figure 4.2. Lanes 1-4 show the pol III activity of cells 
obtained from healthy volunteers, all of which are presumed to carry only wild-type 
p53. The remaining lanes show samples from 11 Li-Fraumeni patients who have 
inlierited a mutant copy of the p53 gene. Each patient carries a different mutation in 
p53, apart from 190MA and 19MA (lanes 13 and 14) who are unrelated but carry the 
same splicing mutation (Varley et al. 2001). When compared to the normal samples 
most of the Li-Fraumeni samples display elevated pol III activity. This however is 
not always the case, as samples from patients 109MA and 163MA show only low 
levels of pol III transcription (lanes 7 and 8). The tRNA^^^‘ gene has a much weaker 
promoter than VAl and gave little or no signal in the extracts from healthy 
volunteers (Figure 4,2, lane 1-4). In concuiTence with the transcription assays earned 
out with the VAl gene, many of the Li-Fraumeni cell extracts transcribed the tRNA 
gene at higher levels (Figure 4.2, lanes 5-15) with the relative levels of VAl and 
tRNA*^ ^^ ' being similar. Again the lowest activity was observed in samples 109MA 
and 163MA (Figure 4.2, lanes 7 and 8). The exception is seen in sample 168MA 
(Figure 4.2, lane 10), where transcription of VAl is relatively much higher than that 
of tRNA^^". The activation of pol III transcription is also much more pronounced 
with VAl than tRNA^^“ in sample 196MA (Figure 4.2, lane 9). The reason for this 
difference is unclear, since the tRNA and VA genes are believed to utilize the same 
set of transcription factors (White 1998a).
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Lane
Patient
Mutation
1 Healthy volunteer wt
2 Healthy volunteer wt
3 Healthy volunteer wt
4 Healthy volunteer wt ';i
5 194MA P152L
6 138MA R175H <s;
7 109MA E180K :ï;S
8 163MA R248W 3
9 196MA T256A •;r:
10 168MA R273H 1
11 193MA Stop codon at R209 Î : ^
12 191MA Mutation in splice acceptor of intron 3 ■Î
■1
13 190MA Mutation in splice donor site of exon 3 :
14 19MA Mutation in splice donor site of exon 3
15 161MA-F L344P and loss of wt allele ■'i
'1 ,
Table 4.1. Li-Fraumeni mutations
■4
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Figure 4.2. Pol III transcriptional activity is frequently elevated in extracts of 
primary fibroblasts from LFS patients. (Upper panel) pVAl and (second panel) 
pleu were transcribed using whole cell extract (15pg) of primary fibroblasts from 
four healthy volunteers (lanes 1-4) or from 11 patients with LFS (194MA, lane 5; 
138MA, lane 6; 109MA, lane 7; 163MA, lane 8; 196MA, lane 9; 168MA, lane 10; 
193MA, lane 11; 191 MA, lane 12; 190MA, lane 13; 19MA, lane 14; 161MA-F, lane 
15). The same extracts were analysed by Western blotting for levels of p53 (third 
panel) and actin (bottom panel)
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The p5 3-interacting protein mdm2 plays a critical role in regulating the level of wild- 
type p53 in healthy cells. This is by means of a negative feedback loop in which 
increased p53 drives the expression of mdm2 (Ko and Prives 1996). Inactive p53 
mutants m e expressed at elevated levels due to their inability to induce mdni2 (Prives 
1998). Western blotting revealed that the p53 mutants are more abundant in the Li- 
Fraumeni samples than the nonnal controls (Figure 4.2, third panel). Blotting for 
actin confimied equal loading in each case (Figure 4.2, lower panel). The exception 
is provided by patient 109MA (Figure 4.2, lane 7), where the levels of p53 are 
substantially lower than those of the other mutants. This suggests that the E180K 
mutant may retain some capacity to regulate transcription, resulting in down 
regulation of the protein. It is therefore significant that pol III activity also remains 
repressed in this sample. Despite this exception, it is clear that pol III transcription is 
elevated in the majority of Li-Fraumeni samples in despite of the high levels of 
mutant p53, suggesting that naturally occurring mutations can compromise the ability 
of p53 to repress pol III transcription.
4.2,3 Pol III transcription is further deregulated upon loss of wt p53
Patients with LFS who inherit mutant p53 invariably retain one wt copy of the gene. 
However fibroblasts hom  patient 161MA-F were found to have deleted their wild- 
type p53 allele (Varley et al. 1996). This may be explained by the fact that these cells 
were obtained during surgery to remove a tumour (Varley et al. 1996). Nevertheless 
these cells remained untransfonned, like all the Li-Fraumeni fibroblasts examined in 
this study. This sample (Figure 4.2 lane 15) displayed exceptionally high pol III 
activity when compared with either the normal or heterozygous samples (Figure 4.1,
109
lanes 1-14). This observation raised the possibility that deletion of the wild-type copy 
of p53 may result in further deregulation of pol III transcription.
To test this, heterozygous cells taken from patient 19MA, were cultured tlnmigh an 
additional nine passages, which resulted in spontaneous deletion o f the wild-type 
allele. Pol III activity in this samples were found to be dramatically elevated when 
compared to the heterozygous sample (Figure 4.3, lanes 5 and 6). The same result 
was obtained with cells from patient 163MA (lanes 3 and 4). Clearly complete loss 
of wild-type p53 correlates with a substantial activation in pol III transcription. 
Western blotting confirmed that mutant p53 continues to be expressed in these cells 
(Figure 4.3, middle panel). Blotting for actin confirmed equal loading in each case 
(Figure 4.3, lower panel). The level of mutant p53 in the late passage sample 163MA 
is substantially higher than that of the heterozygous sample (Figure 4.3, lanes 3 and 
4), indicating that regulation of mutant p53 is completely abolished as expected. In 
contrast to this, levels of mutant p53 in the late passage sample of 19MA remain 
comparable to those of sample 19MA (Figure 4,3, lanes 5 and 6). The reason for this 
is unclear, but may suggest degradation of p53.
4.2.4 Oncoprotein E6 abrogates the ability of p53 to repress pol III transcription
Apart h'om mutation, p53 function can also be compromised through the action of 
various oncoproteins. One such protein is the E6 oncoprotein from Human 
Papillomavirus (HPV) (Vousden 1995), which targets p53 for degradation. It was 
tested in transient transfection assays whether the repression of pol III transcription 
mediated by p53 was affected by cotransfection of E6 from HPV-16. The p53 null.
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Figure 4.3. Deletion of wild-type p53 correlates with increased pol III 
transcriptional activity in extracts of primary fibroblasts from LFS patients.
(Upper panel) pVAl were transcribed using whole cell extract (15pg) of primary 
fibroblasts from two healthy volunteers (lane 1 and 2) or from LFS patients 163MA 
(lanes 3 and 4) and 19MA (lane 5 and 6). The cells used in lanes 3 and 5 have 
retained one wild-type copy of the p53 gene; however, the cells in lanes 4 and 6 were 
harvested at later passages and have consequently deleted the wild-type p53 allele. 
The same extracts were analysed by Western blotting for levels of p53 (middle 
panel) and actin (lower panel).
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osteosarcoma cell line SAOS2 was transfected with the VAl gene, as a reporter for 
pol III activity, and HSV-CAT, in which the chloroamphenicol acetyltransferase 
gene is transcribed from the basal thymidine kinase promoter of herpes simplex 
vims. This pol II transcribed gene serves as an internal control for transfection 
efficiency and RNA recovery. In addition, vectors encoding wild-type p53 and the 
E6 oncoprotein from HPV-16 were co-transfected. Expression of the VAl and HSV- 
CAT reporters were then monitored by quantitive primer extension assays.
Wild-type p53 clearly represses pol Ill-dependent transcription of VAl (Figure 4.4, 
lane 3, upper two panels) when compared to the empty vector control (Figure 4.4, 
lane 1, upper two panels). This effect was blocked by coexpression of E6 (Figure 4.4, 
lane 4, upper two panels). Western blotting confimied that E6 expression reduced the 
level of p53 without affecting the level of actin (bottom two panels). From this it is 
concluded that pol III activity in vivo can be influenced by E6, a well-established 
oncoprotein that can counteract the function of p53 in human tumours.
4.2.5 p i 4^ *^  ^contributes to p53 mediated repression of pol III transcription
The alternative product of the human INK4a/ARF locus p i4^^^ has the potential to 
act as a tumour suppressor by binding to and iidiibiting mdm2 (Stott et al. 1998), a 
key regulator of p53 activity. It was investigated whether an increase in endogenous 
p53 through the induction of p i4 ^ ^  affected pol III transcription. The NARF2 cell 
line stably transfected with a plasmid encoding p i4 ^ ^  was induced with IPTG. RT- 
PCR analysis (Figure 4.5a) of cDNAs prepared from RNA extracted from cells 
revealed that upon stabilization of p53 (Figure 4.5a, lane 2) through the induction of 
p l4*^^ levels of the pol III transcript tRNA^^‘ (upper panel) were reduced. This
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Figure 4.4. Repression of pol III transcription can be overcome by the E6 
oncoprotein of HPV-16. SAOS2 cells were cotransfected with pVAl (3pg), HSV- 
CAT (3pg) and 2pg of empty vector (lanes 1 and 2) or vector encoding wild-type 
p53 (lanes 3 and 4) in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of 2pg 
pJ4Q16,E6 encoding HPV-16 E6. RNA and protein were harvested 48hrs after 
transfection. The upper two panels show primer extension analyses of extracted RNA 
using primers specific for VAl (upper panel) and CAT (second panel). Extracts were 
analysed by Western blotting for the expression of p53 (third panel) and actin 
(bottom panel).
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Figure 4.5. pl4**^ induction results in decreased tRNA^^k (A) RT-PCR analysis 
of cDNA prepared from RNAs extracted from uninduced NARF2 cells (lane 1) or 
p l4 ARi- induced NARF2 cells (lane 2) using primers for tRNA^^ (top panel) or ARPP 
PO (bottom panel). (B) Western blot of uninduced (lane 1) and p l4 ^ ^  induced (lane 
2) NARF2 cells with DO-1 against p53.
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effect was specific since ARPP PO remained constant (Figure 4.5a, lower panel). 
Western blotting confirmed that p53 protein levels were increased by the induction 
of p i4 ^ ^  (Figure 4.5b, lane 2). It is unlikely that the reduction in pol III 
transcription is caused by piq^RF since co-expression of E6 from HPV-16,
which specifically targets p53, abrogates the observed decrease in pol III transcripts 
(J. Morten, unpublished results).
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4.3 Discussion
Previously it was shown that established fibroblasts from Imockout mice have 
significantly elevated pol III activity when compared with their wild-type 
counterparts (Cairns and White 1998). It has now been demonstrated that pol III 
transcripts are abnormally elevated in primary MEFs. The use of primary cells has 
the advantage over established cell lines since fewer genetic alterations will have 
occuiTed. This result clearly suggests that endogenous p53 contributes significantly 
towards the control of pol III transcription.
This study demonstrates that repression of pol III transcription can be compromised 
by mutations that commonly arise in untransfonned cells from patients with LFS. In 
addition, it is shown that the oncoprotein E6 from HPV-16 can release pol III from 
repression by p53. In contrast, induction of the tumour suppressor pl4^^^, which 
leads to an increase in p53 levels, also causes a decrease in pol III transcripts.
E6 promotes the degradation of p53 by complexing and targeting it for ubiquitin- 
mediated proteolysis (Scheffiner et al. 1993). It is therefore not surprising that E6 can 
compromise the ability of p53 to repress pol III transcription. However, it was 
important to confirm that oncoproteins such as E6 can stimulate pol III transcription. 
Mdm2, which also targets p53 for degiadation, has been shown to elicit a similar 
effect on pol III transcription (Stein et al. 2002a). Where p53 produced a specific 
repression of pol III transcription, cotransfection of wild-type hdni2 blocked this 
effect. In contrast, an hdm2 mutant with a small deletion in its p53-binding domain 
was unable to overcome the repression mediated by p53. pl4^^^ targets mdm2 (Stott
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et al. 1998). pl4*^^ can act directly to inliibit the p53-directed ubiquitin ligase 
activity of Mdm2 (Honda and Yasuda 1999; Midgley et ah 2000). Abnormal 
oncogenic signals, such as E l A and Myc, have been shown to lead to the activation 
of p53 tlirough induction of p i 4^^^ (Weber et ah 1999; Lohrum et al. 2000). In some 
cells the expression of p i4 ^ ^  also alters the subcellular localisation of mdm2, 
targeting itself and mdm2 to the nucleolus (Weber et ah 1999; Lohiaim et ah 2000). 
Under these circumstance, p53 remains in the nucleoplasm, releasing p53 from the 
inlhbitory effect of mdm2 interaction. Here it is shown that stabilization of p53 
thr ough an induction of pl4*^^ results in a decrease of pol III transcription. Both E6, 
mdni2 are major instigators in the development of human cancers. In many cervical 
carcinomas p53 is bound and inactivated by the E6 product of the HPV, and 
amplification and overexpression of the gene encoding hdm2 is observed in many 
tumour types, especially oseosarcomas and soft tissue tumours (Momand et ah 
1998). p i4^^^ has also been implicated in contributing to carcinogenesis, with the 
gene being to be deleted or methylated in many human cancers (Ruas and Peters 
1998). Collectively, the capacity of E6, hdni2 and pl4"^^ to regulate pol III 
transcription, through their action on p53, may contribute to the ability of p53 to 
suppress tumour formation.
p53 is mutated in over 50% of all human cancers (Hollstein et ah 1991). Most of 
these mutations are mis-sense point substitutions, which lie within the sequence- 
specific DNA binding region of p53 (Bullock et ah 2000). Although it appears that 
p53 represses pol III transcription tlii'ough disruption of protein-protein interactions 
(Chesnokov et ah 1996; Cairns and White 1998), certain mutations within this 
sequence-specific DNA binding domain can influence the effect of p53 on pol III
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transcription (Stein et al. 2002a). For example in SA0S2 cells, transient transfection 
of a mutant p53 in which arginine 175 is substituted to proline (R175P), originally 
derived from an anogenital tumour, was severely compromised in its ability to 
repress pol III transcription. This mutant is also partially compromised in its ability 
to transactivate the mdm2 promoter, and repress the c-fos and SV40 early promoters 
(Crook et al. 1994). R175P, however, retains the capacity to suppress the 
proliferation of SA0S2 cells (Crook et al. 1994; Ryan and Vousden 1998), 
establishing the fact that the cell cycle arrest function by p53 is unable to account for 
the observed repression of pol III transcription (Stein et al. 2002a). The mutant 
R273C was also unable to repress pol III transcription (Stein et al. 2002a). The 
mutant R18IL, which is compromised in its ability to repress various pol II 
transcribed genes (Crook et al. 1994), retains a significant capacity to repress pol III 
transcription (Stein et al. 2002a). Since the two systems respond differently to the 
R181L mutation, different structural and functional parameters may be required for 
p53 to repress pol II and pol III genes (Stein et al. 2002a).
The data from the Li-Fraumeni cells (Figures 4.1 and 4.2) support the finding that 
naturally occurring substitutions in p53 can influence the ability of p53 to repress pol 
III transcription. Furthermore, the Li-Fraumeni data have the advantage over the 
transient transfections that p53 is being expressed at physiological levels in a more 
normal cellular context. In several cases, such as 168MA, which carries a R273H 
substitution, pol III activity is elevated dramatically despite the presence of a wild- 
type allele. Other studies have also demonstrated dramatic changes resulting from the 
loss of a single wild-type allele. Heterozygous p53’^ '^ ' mice have been shown to 
develop tumours at a higher rate than their wild-type litteimates, with over 95% of
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heterozygotes having died or developed tumours by the age of two years, compared 
with only 20% of the wild-type mice (Venkatachalam et ah 1998). Inactivation of a 
single allele clearly has dramatic effects on the regulation of pol III activity. 
However, as demonstrated in Figure 4.2, loss of the remaining wild-type allele can 
result in further deregulation.
Each patient with LFS comes from a different genetic background and it cannot be 
concluded that the increases in pol III transcription obseiwed in fibroblasts from 
many of the patients can be attributed solely to the mutation of p53. hideed, cells 
from different healthy volunteers show subtle variations in pol III activity. The 
results however, are striking and suggest that naturally occurring mutations in p53 
can compromise its ability to control pol III transcription.
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Chapter 5
Mechanism of pol III transcriptional repression by p53
5.1 Introduction
p53 represses a variety of genes (Ginsberg et al. 1991; Mercer et al. 1991; 
Santhanam et al. 1991; Kley et al. 1992; Seto et ai. 1992; Sabler et al. 1992; Mack et 
al. 1993; Ragimov et al. 1993; Crook et al. 1994; Horikoshi et al. 1995; Chesnokov 
et al. 1996; Fanner et al. 1996a; Werner et al. 1996; Cairns and White 1998; 
Veifkatachalam et al. 1998; Yu et al. 1999; Sun et al. 2000; Zhao et al. 2000), 
although, at present the mechanism by which p53 elicits these effects is poorly 
understood. It is believed that p53-mediated repression of pol III transcription occurs 
via a direct mechanism. Assembly of a pol III transcription initiation complex on 
type two promoters involves a stepwise assembly of multiple transcription factors. 
The A- and B-block consensus sequences found in many o f these promoters are 
recognised by the multisubunit complex TFIIIC2. TFIIICl and TFIIIB are then 
recruited. This DNA-TFIIIC-TFIIIB complex then serves to recruit pol III to the start 
site. It is believed that p53 targets TFIIIB (Chesnokov et al. 1996; Cairns and White 
1998). It has been demonstrated by immunoprécipitation and cofractionation 
experiments that endogenous p53 and TFIIIB associate at physiological ratios. 
Furthennore when p53 is present in excess, adding purified TFIIIB can efficiently 
relieve VAl gene expression from repression by p53. TFIIIB is a trimeric complex, 
consisting of the TATA-box binding protein, TBP, Brfl and Bdpl. Previous analysis 
has demonstrated that both the N- and C-temiinal domains of p53 are important in 
mediating pol III transcriptional repression (Stein et al. 2002b). p53 is a well-
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established binding partner of TBP, and it is the N- and C-terminal domains of p53 
that contact TBP. For repression of pol Il-transcribed genes by p53, an interaction 
between TBP and p53 has been implicated (Seto et al. 1992; Liu et al. 1993; Martin 
et al. 1993; Farmer et al. 1996a; Fanner et al. 1996b; Tansey and HeiT 1997); 
however, additional interactions between p53 and TAFs are also believed to 
contribute to the effect (Farmer et al. 1996b).
Here the functional consequences of p53-TFIIIB interactions are investigated. The 
involvement of histone acetylase transferase (HAT) and deacetylase (HDAC) 
complexes in p53-mediated pol III transcriptional repression is also examined. HATs 
and HDACs contribute to the control of transcription tluough multiple mechanisms 
(Kuo and Allis 1998). For example acétylation of the basal transcription factor SLl 
has shown to play a major role in controlling expression of pol I transcription (Muth 
et al. 2001). p53 itself is subject to acétylation, a modification which results in 
stmctural changes within the protein and activation of intrinsic DNA-binding activity 
(Gu and Roeder 1997). Previous mechanistic analysis of pol II transcribed genes that 
are repressed by p53 revealed that the recruitment of HDAC eomplexes by p53, via 
the co-repressor complex mSin3A, was essential in mediating repression (Murphy et 
al. 1999).
5.2 Results
5.2.1 p53 associates with TBP and Brfl but not Bdpl
Previously it was demonstrated that endogenous p53 co fractionates with TFIIIB 
(Cairns and White 1998). Cairns and White also showed that TFIIIB
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immunoprecipitates with p53 at physiological ratios (Cairns and White 1998). To 
further investigate the association of p53 with the individual subunits of TFIIIB, His- 
p53 pull down assays were performed. 50pl of purified wild-type His-p53 and His- 
p53 (98-303) (Figure 5.1 A) was used in each binding assay. His-p53(98-303) lacks 
both TBP binding domains and is unable to repress pol III transcription (Stein et al. 
2002b), The immobilised proteins were incubated with CHO cellular extract stably 
expressing HA tagged Brfl. Following incubation and extensive washing, Western 
blotting revealed that both TBP and HA-BrH associated with wild-type His-p53 
(Figure 5.IB, bottom and middle panels). This interaction was specific since His-p53 
(98-303), which encompasses only the core domain of p53, did not bind to either 
protein (Figure 5.IB, lane 3). Bdpl did not associate with either wild-type His-p53 or 
His-p53 (98-303). This result may indicate that Bdpl cannot associate with p53. hi 
addition, it may further suggest that Bdpl is unable to associate with TBP and BrH 
in the presence of p53. To further investigate these findings, wild-type and His-p53 
(98-303) were incubated with reticulocyte containing Bdpl, Brfl or TBP labelled 
with ^^S-Met and ^^S-Cys. As expected, TBP associated with wild-type His-p53 but 
not with His-p53 (98-303). Brfl also bound to wild-type His-p53, whereas no 
significant association was observed between Brfl and His-p53 (98-303). This result 
does not suggest unequivocally that Brfl can bind directly to wild-type His-p53. It is 
possible that BrH interacts with wild-type His-p53 via another molecule contained in 
the reticulocyte. TBP may bridge the association between BrH and wild-type His- 
p53. ^^S-Bdpl did again not interact with either wild-type His-p53 or His-p53 (98- 
303). This further suggests that Bdpl is unable to associate with p53.
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Figure 5.1. Wt His-p53 binds endogenous TBP and HA-Brfl, but not Bdpl. (A)
Purification of p53 wt and p53(98-303). 50pl of packed beads binding His-p53 wt 
(lane 1) and His-p53(98-303) (lane 2) were boiled in SDS sample buffer, separated 
by SDS-PAGE and visualised by Coomassie Blue staining. (B) Wt His-p53 binds 
endogenous TBP and HA-Brfl, but not Bdpl. 200pg of CHO extract expressing HA 
tagged Brfl was incubated with His-p53 wt (lane 2) or His-p53 (98-303) (lane 3) 
bound to Ni-NTA agarose beads for 1 hour at 4°C. After extensive washing, bound 
material was separated by gel electrophoresis and visualised by Western blotting 
with antibodies 58c9 against TBP, F7 against HA and 2663-4 against Bdpl. Lane 1 
shows 10% CHO extract input. (C) Wt His-p53 binds ^^S-labelled TBP and B rfl, but 
not Bdpl. Reticulocyte lysate (5pl) containing in vitro-translated TBP (bottom 
panel), Brfl (middle panel) or Bdpl (top panel) was incubated with His-p53 wt (lane 
2) or His-p53 (98-303) (lane 3) bound to Ni-NTA agarose beads. After extensive 
washing, bound material was separated by gel electrophoresis and visualised by 
autoradiography. Lane 1 shows 5% of the input reticulocyte lysate containing in vitro 
translated protein.
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To further examine the binding between TFIIIB and p53, GST-pull down assays 
were perfonned. Equal amounts of GST-p53 and GST alone (Figure 5.2A) were 
incubated with reticulocyte containing ^^S-labelled Brfl and TBP. The results shown 
demonstrate that significantly more TBP can associate with GST-p53 than GST 
alone (Figure 5.2B, lanes 2 and 3). In addition, substantially more Brfl bound to 
GST-p53 when compared to GST alone (Figure 5.2B, lane 5 and 6). This adds 
further support to the suggestion that Brfl can interact p53. These results 
demonstrate that recombinant wild-type p53 can associate with the TFIIIB subunits 
TBP and Brfl. No association was observed between wild-type His-p53 and Bdpl. 
The results also suggest that Bdpl may be prevented from associating with TBP and 
Brfl in the presence of p53.
5.2.2 TBP relieves p53 mediated repression of pol III transcription
Since TFIIIB is targeted by p53 (Cairns and White 1998; Chesnokov et al. 1996), 
and an association exists between p53 and both TBP and Brfl, it was examined 
whether raising the concentration of TBP could reverse pol III transcriptional 
repression mediated by p53. In the absence of TBP, p53 mediates repression of Alu 
transcription in vitro (Figure 5.3, lanes 2 and 5). Titration of increasing amounts of 
TBP alleviated this repression (Figure 5.3, lane 3 and 4). In the absence of p53, 
increasing amounts of TBP had little effect on the level of Alu transcription (Figure 
5.3, lanes 7 and 8). This result suggests that TBP becomes limiting for pol III 
transcription in vitro in response to p53. However, transcription was not fully 
reconstituted by TBP, which may suggest that additional TBP is required. It is also 
possible that another transcription factor becomes limiting. Both Brfl and TBP can 
interact with p53, and it remains to be determined whether titration of Brfl in vitro
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Figure 5.2. ^®S-Iabelled TBP and Brfl bind GST-p53. (A) Coomassie-stained gel 
of purified GST and GST-p53. Molecular markers (lane 1, left and right panel) and 
purified GST-p53 (Ipg) (lane 2, left panel) or purified GST (2pg) (lane 2, right 
panel) were electrophoresed on a 7.8% SDS-polyacrylamide gel and then visualised 
by staining with Coomassie Blue. (B) ^^S-labelled TBP and Brfl bind GST-p53. ^^S- 
labelled TBP (lanes 2 and 3) or Brfl (lanes 5 and 6) were incubated with equal 
amounts of GST (lanes 2 and 5) or GST-p53 (lanes 3 and 6) for 3 hours at 4°C. After 
extensive washing with LDB, bound material was separated by gel electrophoresis 
and visualised by autoradiography. Lanes 1 and 4 show 10% ^^S-labelled TBP and 
^^S-labelled Brfl.
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Figure 5.3. Titration of recombinant TBP relieves p53-mediated repression of 
Alu transcription. pRH5.7 (250ng) was transcribed using HeLa nuclear extract 
(15|ig) that had been preincubated for 10 min at 30°C in the presence of 0.6pg of 
wild-type p53 (lanes 2-5) and 0.5pl (lanes 3 and 7) or Ipl (lanes 4 and 8) of 
recombinant TBP.
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can also alleviate p53-mediated repression of pol III activity. It was not possible to 
test this, as we have been unable to express recombinant Brfl.
5.2.3 Association of p53 with TFIIIB results in disruption of essential pol III 
transcription complex interactions
It has been shown that TBP and Brfl can associate with both wild-type GST-p53 and 
His-p53. From this it is unlikely that p53 prevents TBP-Brfl interactions within the 
TFIIIB complex. To test this, reticulocyte containing TBP and B rfl, labelled with 
^^S-Met and ^^S-Cys, were incubated together with recombinant wild-type His-p53 or 
His-p53 (98-303). Complexes were then immunoprecipitated using an antibody 
against TBP. After extensive washing, bound material was separated by 
elecrophoresis and visualised via autroradiography. Both ^^S-TBP and ^^S-Brfl 
efficiently coprecipitated in the absence of p53 (Figure 5.4A, lanes 4). 
Coprecipitation of Brfl was specific, since Brfl was not precipitated in the absence 
of TBP (Figure 5.4A, lane 3). No disruption in the amount of Brfl co-precipitating 
with TBP was observed in the presence of either wild-type His-p53 or FIis-p53 (98- 
303) (Figure 5.4A, lane 5 and 6). This result suggests that wild-type p53 does not 
dismpt the interactions formed between TBP and Brfl.
Multiple protein-protein interactions are fomied between the basal pol III 
transcription factors during initiation of transcription (Paule 1998; Geiduschek and 
Kassavetis 2001). TFIIIB foims interactions with both TFIÎIC2 and the polymerase 
itself. It was tested whether p53 could compromise the interactions between these 
factors. Using an antibody against RNA polymerase III, ^^S-labelled Brfl efficiently 
CO-precipitated in the presence but not in the absence of HeLa nuclear extract (Figure
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Figure 5.4. p53 does not prevent Brfl from binding to TBP. (A) Anti-TBP 
antibody 4c826 was used to immunoprecipitate reticulocyte containing in vitro 
translated TBP (2pi) and/or in vitro translated Brfl (5pi). His-p53 wt (0.6pg) was 
added to lane 5 and His-p53 (98-303) (0.6pg) was added to lane 6. After extensive 
washing, bound material was separated by gel electrophoresis and visualised by 
autoradiography. Lane 1 shows 10% ^^S-labelled TBP and 35S-labelled Brfl. (B) 
Values shown represent the % of ^^S-Brfl co-immunoprecipitating, compared to 
input ^^S-Brfl. Values represent the mean and standard deviation of three 
experiments.
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5.5, lanes 2 and 3). The amount of co-precipitating ^^S-Brfl was dramatically 
reduced in the presence of wild-type His-p53 (Figure 5,5, lane 4). In contrast, 
binding of ^^S-Brfl to pol III was unaffected by the addition of His-p53 that lacked 
both the N- and C-tenninal regions (Figure 5.5, lane 6). Similarly ^^S-labelled Brfl 
co-precipitated with an antibody against TFIIIC2 (Figure 5.6, lane 2). Addition of 
wild-type His-p53 resulted in a reduction in association between ^^S-Brfl and 
TFIIIC2 (Figure 5.6, compare lanes 2 and 4). Addition of His-53 (98-303) had little 
effect on ^^S-Brfl co-precipitating with TFIIIC2 (Figure 5.6, lane 6). These results 
suggest that the ability of TFIIIB to associate with TFIIIC2 and pol III is 
compromised by wild-type p53 in vitro.
5.2.4 TFIIIB but not TFIIIC2 is prevented from binding the tRNA *^"' promoter 
by wild-type p53 in vitro
Assembly of a functional pol III transcription complex on tRNA genes involves a 
stepwise assembly of tlmee factors. TFIIIC2 recognises and binds to internal 
promoter elements; this then seiwes to recruit TFIIIB, which in turn associates with 
the polymerase, situating it at the start site of transcription (Paule and White 2000; 
Geiduschek and Kassavetis 2001). The effect on this recruitment process, and 
therefore the subsequent occupancy of pol III transcription machinery on the 
tRNA '^^" gene was investigated. An immobilised template assay was employed for 
this purpose (Figure 5.7A). The tRNA^*^“ gene was amplified by PCR using specific 
primers. The reverse primer was covalently biotinylated at the 5’ end. This allowed 
the immobilisation of the tRNA gene fragment using magnetic beads coated with 
streptavidin. The resultant 3’ biotinylated fi*agment was separated by agarose gel
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Figure 5.5. p53 prevents Brfl from binding to pol III. (A) Anti-pol III antibody 
114 was used to immunoprecipitate reticulocyte containing in vitro translated Brfl 
(5pi) in the presence of lOOpg HeLa NE preincubated with His-p53 wt (Ipg) (lane 5) 
and His-p53 (98-303) (Ipg) (lane 6). After extensive washing, bound material was 
separated by gel electrophoresis and visualised by autoradiography. Lane 1 shows 
20% ^^S-labelled Brfl. (B) Values shown represent the % of 35S-Brfl co- 
immunoprecipitating, compared to input ^^S-Brfl. Values represent the mean and 
standard deviation of tluee experiments.
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Figure 5.6. p53 prevents Brfl from binding to TFIIIC2. (A) Anti-TFIIIC2 
antibody 4286-4 was used to immunoprecipitate reticulocyte lysate containing in 
vitro translated Brfl (5 pi) in the presence of lOOpg HeLa NE preincubated with His- 
p53 wt (Ipg) (lane 5) and His-p53 (98-303) (ipg) (lane 6). After extensive washing, 
bound material was separated by gel electrophoresis and visualised by 
autoradiography. Lane 1 shows 10% -labelled Brfl. (B) Values shown represent 
the % of ^^S-Brfl co-immunoprecipitating, compared to input 35S-Brfl. Values 
represent the mean and standard deviation of four experiments.
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Figure 5.7. Biotinylated Template Assay. Schematic overview of the biotinylated 
template assay protocol. The biotinylated templates were synthesised by PCR with 
the reverse primer being biotinylated at the 5’end. Biotinylated fragments were 
purified then incubated with streptavidin coated magnetic beads. Immobilised DNA 
was incubated together with cellular extract, plus or minus recombinant p53. Bound 
material was washed extensively then separated by gel electrophoresis and visualised 
by Western blotting.
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electrophoresis. The DNA fragment was then purified and checked for its ability to 
support transcription in vitro (Figure 5.8).
The plasmid pleu (250ng) (Figure 5.8, lane 1) or 250ng (lane 2) or 500ng (lane 3) of 
the purified biotinylated tRNA^^" fragment were transcribed using HeLa nuclear 
extract. Although the tRNA fragment was transcribed at a lower level when 
compared to that obtained with the plasmid pleu (compare lanes 1 and 2), 500ng of 
fragment produced a signal approaching that obtained with 250ng of plasmid 
(compare lanes 1 and 3). This shows that the tRNA fragment can support active 
transcription in vitro and can therefore be used as a tool to investigate promoter 
occupancy.
The immobilised tRNA^^" template was incubated with extract prepared from CHO 
cells stably expressing HA tagged Brfl, either in the absence, or in the presence of 
wild-type p53 or p53 (24-392). Bound material was then separated by gel 
electrophoresis and detected via Western blotting, hi the absence of p53, TFIIICllO 
(top panel), HA-Brfl (middle panel) and TBP (lower panel) could be detected bound 
to the tRNA^*^“ gene fragment (Figure 5.9, lane 2). Binding was specific, since no 
factor could be detected binding to the beads alone (Figure 5.9, lane 1). In the 
presence of increasing amounts of wild-type His-p53, the occupancy of the TFIIIB 
subunits TBP (lower panel) and HA-Brfl (middle panel) were diminished. This 
decrease was specific, since adding equal amounts of His-p53 (24-392) resulted in no 
change in occupancy. TFIIICllO (upper panel) levels remained constant in the 
presence of wild-type His-p53 (lanes 3 and 4). These results suggest that p53 
interferes specifically with TFIIIB recruitment on tRNA genes in vitro.
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Figure 5.8. Biotinylated tRNA^®“ gene fragment supports in vitro transcription.
pLeu (250ng) (lane 1) or 250ng (lane 2) or 500ng (lane 3) of the biotinylated 
tRNA^" gene fragment was transcribed in vitro using HeLa nuclear extract (15pg).
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Figure 5.9. TFIIIB but not TFIIIC2 is prevented from binding the tRNA^^“ 
promoter in the presence of wild-type His-p53. Immobilised biotinylated tRNA^^" 
gene fragments were incubated with CHO cellular extract (200jag) stably expressing 
HA tagged Brfl in the absence (lanes 2 and 5) or the presence of 2pg (lanes 3 and 6) 
or 4pg (lane 4 and 7) of wild-type His-p53 (lanes 3 and 4) or mutant p53 (p53(24- 
392)) (lanes 6 and 7). After incubation for 20 minutes at 30°C, beads were 
thoroughly washed, resuspended in protein sample buffer and separated by gel 
electrophoresis. Bound material was analysed by Western blotting with antibodies 
58c9 against TBP, F7 against HA and 4286-4 against TFIIIC 110.
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5,2.5 TFIIIB and pol III occupancy at endogenous tRNA genes is elevated 
specifically in primary p53-knockout MEFs relative to wild-type control cells
Clii'omatin immunoprécipitation, or ChIP, refers to a procedure used to determine 
whetlrer a given protein binds to a specific DNA sequence in vivo (Figure 5.10). This 
method was used to examine whether differences in promoter occupancy of pol III 
transcription complex subunits on tRNA genes in vivo could be observed between 
primary p53 Imockout mouse embryo fibroblasts (MEFs) and matched wild-type 
control cells. RT-PCR analysis has confimied that the levels of primary tRNA 
transcripts are elevated specifically in p53 knockout fibroblasts when compared to 
the wild-type controls (Figure 4.1). In addition nuclear run-on assays previously 
demonstrated a marked and specific increase in tRNA expression in p53-/- 
fibroblasts (Cairns and White 1998). First cells were grown to 80% confluency and 
DNA-binding proteins were then cross-linked to DNA with 1% formaldehyde. Cells 
were lysed by hypertonic shock and chromatin was isolated. DNA was then sheared 
into small fragments by sonication. Antibodies against TFIIIB, TFIIIC2 and pol III 
were then used to co-iminunoprecipitate DNA bound to each of these factors. In 
order to assess whether changes in occupancy were apparent between the p53 
knockout and wild-type MEFs, the DNA was amplified by semi-quantitive PCR 
using primers specific for tRNA genes. Various concentrations of DNA were used to 
ensure that the PCR reactions were in the linear range for each antibody used for 
Chip.
Chip analysis demonstrated that there was significantly more TBP present at 
tRNA'^^" (upper panel) and tRNA^ "^  ^(middle panel) promoters in p53 Imockout MEFs 
compared to wild-type control cells (Figure 5.11, lanes 5 and 6). Promoter
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Figure 5.10. Schematic overview of the Chromatin Immunoprécipitation assay 
(ChIP). (A) Cells are grown to 80% confluency then cross linked in a 1% 
formaldehyde solution. (B) Soluble sheared cliromatin is prepared through a process 
of hypertonic disruption, purification and sonication. (C) Transcription complexes 
are immunoprecipitated overnight with antibodies against the factors of interest. (D) 
hnmune complexes are extensively washed, and the cross-links between proteins and 
DNA are reversed by proteinase K treatment. DNA is purified by pheno 1-chloroform 
extraction and ethanol precipitation. (E) Amounts of co-precipitating purified DNA 
are analysed by semi-quantitive PCR and gel electrophoresis.
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Figure 5.11. TFIIIB and pol III occupancy at tRNA genes is elevated specifically 
in primary MEFs from p53-knockout mice relative to wild-type controls. (A)
Chip was carried out with antibodies against TBP (lanes 5 and 6), TFIIIC2 (lanes 7 
and 8) and RNA pol III (lanes 9 and 10) or beads alone as control (lane 3 and 4). 
Occupancy at tRNA^^" (upper panel), tRNA^^ (second panel) and TFIIIC220 genes 
(lower panel) was analysed in primary MEFs from p53+/+ (odd lanes) and p53 -/- 
(even lanes) mice, hiput DNA is shown in lanes 1 and 2. (B). Values shown 
represent the % of tRNA gene co-precipitating with factor in vivo, compared with 
the input DNA which is set at 100% for p53-/- and p53+/+ MEFs. Values represent 
the mean and standard deviation of three experiments. (C) Protein levels of TBP, 
TFIIICllO and pol III are constant in p53-knockout and wild-type MEFs. Cellular 
extracts (50pg) obtained from wild-type (lane 1) and p53-knockout (lane 2) primary 
MEFs were separated by gel electrophoresis and analysed by Western blotting with 
antibodies 58c9, against TBP (top panel), 4286-4, against TFIIICllO (middle panel) 
and BN51 against RNA pol III (bottom panel).
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occupancy of pol III is also increased on both tRNA promoters in the Imockout cells 
(Figure 5.11, lanes 9 and 10). An approximate 4-fold increase in TBP and pol III 
occupancy is obsei*ved in p53-knockout MEFs compared to the wild-type controls 
(Figure 5.1 IB). In contrast, equal amounts of TFIIIC2 were found to be associated 
with the tRNA genes (Figure 5.11, lanes 7 and 8). These effects were specific, since 
none of the factors tested were found to be associated with an internal fiagment of 
the TFIIIC220 gene (Figure 5.11, lower panel). The immunoprécipitation control, in 
which no antibody was used, revealed no backgiound binding of DNA (Figure 5.11, 
lane 3 and 4). Western blotting demonstrated that the abundance of all tlu'ee factors is 
comparable in the two cell types (Figure 5.11C). This indicates that changes in tRNA 
gene occupancy in the two cells types are not due to differences in protein amounts. 
Overall these results suggest that the observed increase in tRNA gene transcription 
observed in p53-Imockout MEFs is most probably due to the increased recruitment of 
TFIIIB and pol III to these promoters.
5.2.6 DNA-biiidiug activity of TFIIIC2 is unaffected by p53
The previous results suggest that although TFIIIB and pol III occupancy on tRNA 
genes change in response to p53, TFIIIC2 binding activity does not. To further 
investigate this finding, eletrophoretic mobility shift assays (EMSAs) were carried 
out. A promoter fragment containing a B-block consensus sequence capable of 
binding TFIIIC2 was used. This B-block oligo was incubated with cellular extract 
obtained from NARF2 cells. As previously described, these cells can be induced with 
EPTG to express Induction of p i 4 ^ ^  results in an increase in p53 levels and
a correlative decrease in pol III transcription (Figure 3.5). Several protein-DNA 
complexes were detected with extracts from either uninduced NARF2 cells (Figure
152
5.12, lanes 1 and 2) or IPTG-treated NARF2 cells (Figure 5.12, lanes 3 and 4). 
Competition experiments suggested that many of these complexes result from 
sequence-specific binding and it camiot therefore be concluded without doubt which 
complex indicates TFIIIC2 binding to the probe. It is clear though, that upon 
induction of p i4^^^ there were no changes in complex association with the 
radiolabelled oligo. A positive control using partially purified TFIIIC2 may have 
helped distinguish which complex is TFIIIC2. The result, however, still suggests that 
the decrease in tRNA gene transcription observed upon p i4 ^ ^  induction is not 
mediated by a change in TFIIIC2 binding activity.
5.2.7 HDAC activity is not required for p53 to repress pol III transcription.
Previously it has been shown that p53 can repress pol II transcription of Map4 and 
stathmin genes by recruiting histone deacetylases (HDAGs) (Murphy et al. 1999). In 
this study, the HDAC inliibitor trichostatin A (TSA) was used and was shown to 
abrogate p53-mediated repression of these genes (Murphy et al. 1999). HDAC 
complexes are recruited to chromatin, resulting in nucleosome deacetylation. The 
resulting compressed cluomatin structure occludes transcription factors from the 
DNA, resulting in transcriptional repression (Knoepfler and Eisemuan 1999). Such a 
mechanism is compatible with the discovery that TFIIIB is prevented from binding 
tRNA genes in the presence of p53 (Figures 5.9 and 5.11). Furthermore, it has been 
demonstrated that HDAC function contributes to the control of pol III transcription 
in vivo (Sutcliffe et al. 2000).
To test the possibility that HDACs contribute to pol III repression by p53, levels of 
tRNA synthesis between p5 3-Imockout and wild-type MEFs were compared in the
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Figure 5.12. DNA-binding activity of TFIIIC2 is unchanged in the presence of 
p53. EMSA using Ing of a B-block promoter fragment probe, Ipg polydl-dC, and no 
protein (lane 5) or 20pg of cellular extract from NARF2 cells (lanes 1 and 2) or 
PI4ARF induced NARP2 cells (lanes 3 and 4) Lanes 1, 3 and 5 contained 50ng of 
unlabelled probe DNA whereas lanes 2 and 4 contained 20ng of non-specific DNA 
of a similar length.
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absence and presence of TSA. p53-knockout and wild-type control MEFs were 
grown to 70% confluency and the cells were treated with 300iiM TSA for 24 hours. 
RT-PCR analysis was then perfomied on cDNA prepared from these cells. Pol III 
activity increased when wild-type MEFs were treated with TSA (Figure 5.15, lanes I 
and 3, upper two panels). This was a specific increase, since the levels of ARPP PO 
remained constant (bottom panel). In p53-knockout MEFs, the levels of tRNA 
synthesis also changed in response to TSA (Figure 5.13, lane 2 and 4, upper two 
panels). However, the differences in tRNA synthesis, upon treatment with TSA, 
remained approximately five fold in both the p53 knockout and wild-type cells 
(Figure 5.13B). From this evidence, it is unlikely that TSA-sensitive HDAC activity 
is responsible for p53-mediated repression of pol III transcription in the wild-type 
fibroblasts.
In addition to modifying chromatin structure, HDACs have also been shown to 
regulate the function of transcription factors tluough direct deacetylation. To 
investigate this possibility, it was tested in vitro, using a naked DNA template, 
whether TSA might influence p53-mediated repression of pol III transcription. When 
added to cell extracts, wild-type His-p53 produced a strong repression of Alu 
transcription (Figure 5.14, lanes 6 and 9). This repression was maintained when TSA 
was included at concentrations of 100 and 300nM (Figure 5.14, lane 7 and 8). TSA 
had little effect on pol III transcription in the absence of p53 (Figure 5.14, lanes 3 
and 4). It is therefore concluded fiom these experiments that p53 can repress pol III 
transcription efficiently via mechanisms that do not require HDAC activity.
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Figure 5.13. Repression of tRNA by p53 is maintained in the presence of TSA.
(A) RT-PCR analysis of cDNAs prepared from total RNA extracted from primary 
p53-/- MEFs (lanes 2 and 4) and matched wild-type MEFs (lanes 1 and 3) that were 
cultured in the presence (lanes 3 and 4) or absence (lanes 1 and 2) o f 300nM TSA. 
The cDNAs were PCR amplified using specific primers against tRNA^^ (upper 
panel), tRNA^^" (middle panel) or ARPP PO (bottom panel). (B) Values shown 
represent the % of tRNA PCR product relative to the wild-type MEFs in the absence 
of TSA (100%).
156
AtRNATyr
tRNALeu
ARPP PO
1 2  3 4
B1200 
1000 
8 0 0  
P  6 0 0
4 0 0
200
MEF
TSA
wt wt
+
TSA
p53
2  S
o  o1—I 5 5O  O  I rn
+ + + +
Alu #►
1 2 3 4 5 6 7 8 9  10
Figure 5.14. Recombinant His-p53 represses pol III transcription in vitro 
despite the presence of TSA. PVAl (250ng) was transcribed using HeLa nuclear 
extract (15pg) that had been preincubated for 10 min at 30°C in the absence (lane 1-5 
and 10) or in the presence of 0.6pg of wild-type p53 (lanes 6-9) and lOOnM (lanes 3 
and 7) or 300nM (lane 4 and 8) TSA.
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5.2.8 p300 stimulates pol III transcription through a p53-independent 
mechanism
As exemplified by the finding that tRNA synthesis increased in response to TSA in 
vivo, it is likely that histoire acetylase transferase (HATs) or deacetylase complexes 
(HDACs) play a role in regulating pol Iff transcription. p300/CBP transcriptional co­
activator proteins play many roles in controlling transcription mediated tlirough 
multiple mechanisms (Chan and La Thangue 2001). As well as acting as protein 
bridges, connecting transcription factors to the transcriptional apparatus, they can 
also influence clmomatin activity by acetylating nucleosomal hi stones. Other 
proteins, including p53, can be acetylated by p300/CBP (Chan and La Thangue 
2001). Previously it was demonstrated that the CBP/p300 associated factor PCAF 
acetylates TAFI68, the second largest subunit of the TATA-box-binding protein 
(TBP)-containing factor SLl. This modification resulted in stimulation of pol I 
transcription (Muth et al. 2001). It was investigated whether p300 plays a role in 
controlling pol III transcription.
The p53 null osteosarcoma cell line SA0S2 was transfected with the VAl gene as a 
reporter for pol III activity and HSV-CAT as an internal control. In addition, vectors 
encoding p300 and wild-type p53 were co-transfected. Expression of the VAl and 
HSV-CAT reporters was then monitored by quantitive primer extension assays. As 
expected, compared to the vector alone control (Figure 5.15, lane 1), transfection of 
wild-type p53 resulted in a decrease in VAl transcription (figure 5.15, lane 3). 
Cotransfection of p300 slightly relieved this p53-mediated repression (Figure 5.15, 
lane 4); however, the increase in VAl expression was comparable to that obtained by
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Figure 5.15. p300 stimulates pol III transcription through a p53-independent 
mechanism. (A) SA0S2 cells were cotransfected with pVAl (3pg), HSV-CAT 
(3pg) and 2pg of empty vector (lanes 1 and 2) or vector encoding wild-type p53 
(lanes 3 and 4) in the presence (lanes 2 and 4) or absence (lanes 1 and 3) of 2pg 
p300. RNA and protein were harvested 48hrs after transfection. The upper two 
panels show primer extension analyses of extracted RNA using primers specific for 
VAl (upper panel) and CAT (second panel). (B) Numbers represent the relative 
levels of VAl transcription.
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transfection of p300 alone (Figure 5.15, lane 2). Although the increase in VAl 
transcription mediated by p300 is marginal, it may suggest that p300 could play a 
role in stimulating pol III transcription. This result, however, suggests that the 
increase in pol III activity by p300 is not mediated tlirough p53. This result is 
preliminary and requires verification.
5.2.9 p300 but not p53 associates with tRNA genes in vivo
One possible mechanism that p300 may utilize to modulate pol III transcriptional 
activity could be tlnough the direct acétylation of clnomatin. Nucleosomes are 
associated with the coding regions of many pol Ill-transcribed genes (Paule and 
White 2000). In addition histone acétylation has been shown to facilitate the access 
of transcription factors to clnomatinised 5S rRNA promoter sequences (Lee et al. 
1993). To investigate whether p300 is associated with pol III genes, an antibody 
against p300 was used in ChIP assays. It was also tested whether p53 or the 
retinoblastoma protein RB could be found associated with tRNA templates. The 
results presented here suggest that p53 represses pol III transcription tlirough 
targeting of TFIIIB. This p53-TFIIIB interaction prevents TFIIIB associating with 
the other pol III transcription complex components. To elicit this effect, it is unlikely 
that p53 would be required to associate with the pol III gene itself. Rb also represses 
pol III transcription. This is achieved through a very similar mechanism, and again it 
is unlikely that Rb is required to associate with the pol III promoter.
As expected, TBP clearly coprecipitated with tRNA^®“ and tRNA^^ (Figure 5.16, 
lane 5, upper and middle panels). In contrast, under the conditions of this experiment, 
neither p53 nor Rb were found to associate with the tRNA genes (Figure 5.16 lanes 6
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Figure 5.16. p53 is not present at the tRNA promoter in vivo. ChIP was carried 
out with antibodies against TBP (lane 5), p53 (lane 6), RB (lane 7), p300 (lane 8) or 
beads alone as control (lane 4). Occupancy at tRNA^“ (upper panel), tRNA^^ 
(second panel) and TFIIIC220 genes (lower panel) was analysed in HeLa cells Input 
DNA is shown in lanes 1 and 2.
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and 7) A weak association, however, is observed reproducibly between p300 and the 
tRNA promoters (Figure 5.16, lane 8). This effect was specific since no association 
was observed between p300 and the TFIIIC220 control gene fragment (Figure 5.16, 
lower panel); in addition no DNA was found to co-precipitate with the negative 
control (Figure 5.16,lane 4). This result suggests that p53 and Rb are not found 
associated with tRNA genes in vivo. These findings are in agreement with the 
proposed mechanisms by which these factors elicit their effects on pol III 
transcription, since they both bind TFIIIB and prevent its recmitment to promoters. 
This assay also suggests that p300 may associate with pol III templates. To confirm 
this idea further analyses are required.
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5.3 Discussion
In order for a functional pol III transcription initiation complex to fonn, multiple 
protein-protein, and protein-DNA interactions are required. TFIIIC2 binds to internal 
promoter elements, which allows recruitment of TFIIIC 1 and TFIIIB. This TFIIIB- 
TFIIIC-DNA complex then facilitates the recruitment of pol III to the start site of 
transcription (Paule and White 2000; Geiduschek and Kassavetis 2001). p53 has 
been shown previously (Chesnokov et al. 1996; Cairns and White 1998), and in this 
study, to target TFIIIB. Such an interaction appears to result in occlusion of TFIIIB 
from the promoter both in vitro and in vivo, hi addition, functional p53 prevents 
TFIIIB from fomiing interactions with either TFIIIC2 or pol III.
Binding studies have revealed that wild-type p53 can interact with two TFIIIB 
components, TBP and Brfl. However, titration of TBP in vitro proved to be 
sufficient to at least partly restore p53-repressed Alu transcription. This finding is in 
agreement with unpublished results showing that p53-mediated inliibition of tRNA 
transcription can be reversed by transient transfection of TBP (D. Jolnison, 
unpublished results), hi addition, a TBP-E184R mutant, which is specifically 
defective for pol II transcription, was also able to rescue p53 repressed pol III 
transcription (D. Jolnison, unpublished results). In contrast, overexpression of BrH 
did not result in a reversal of p53-mediated repression (D. Jolnison, luipublished 
results). These results suggest that although p53 may fonn an interaction with Brfl, it 
is its interaction with TBP that is functionally significant for repressing pol III 
transcription. Although binding of TBP to p53 has been shown extensively, the 
functional significance o f this interaction has remained elusive (Seto et al. 1992; Liu 
et al. 1993; Martin et al. 1993; Farmer et al. 1996b; Tansey and Herr 1997).
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Overexpression of TBP in transient transfections failed to restore p53-repressed pol 
II transcription (Fanner et a l 1996b), and in this study TAFs were proposed to be 
mediating repression. The results presented here suggest that the TBP-p53 interaction 
plays an important role in controlling pol III transcription and may well establish a 
reason for this well-documented interaction.
Both the immobilised template assays and the ChIP assays demonstrated that TFIIIB 
occupancy on tRNA promoters is reduced in the presence of p53. As exemplified by 
Chip, the decrease in TFIIIB binding in wild-type MEFs compared to p53-knockout 
cells results in less pol III being recruited and consequently a decrease in pol III 
transcription. Levels of TFIIIC2 found at the tRNA genes, however, remain 
unchanged both in vitro and in vivo. These results are also consistent with the finding 
that p53 prevents association of TFIIIB with TFIIIC2 or pol III in 
coimmunoprecipitation assays. EMSA revealed that TFIIIC2 binding activity was 
unchanged in NARF2 cells upon induction of Eiclilrom and Jackson
previously reported that Brfl is specifically degraded following induction of p53 in 
the TR9-7 fibroblast cell line (Eiclhiorn and Jackson 2001). In contrast to this, no 
difference in the cellular levels o f Brfl or indeed in any of the tested pol III 
transcription components was observed between the wild-type and p53-knockout 
MEFs.
Although interactions between pol III and the transcription factors TFIIIB and 
TFIIIC2 were diminished in the presence of p53, the interaction between TBP and 
Brfl appeared to remain intact. These results also suggest that the interaction 
between Brfl and wild-type p53 in Figure 5.1 could be indirect, mediated through
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TBP. This may also help explain why TBP is sufficient to relieve p53-mediated 
repression of pol III transcription. In this study it was not possible to ascertain 
whether p53 affects the interaction of Bdpl with TBP and Brfl because Bdpl 
associates very loosely with TFIIIB and has proved to be extremely difficult to 
coimmunoprecipitate from mammalian cells (Schramm et al. 2000) and data not 
shown.
Previously it was suggested that the functional and mechanistic parameters for p53 to 
repress pol II and pol III transcribed genes might vary (Stein et al. 2002a). In 
transfected SA0S2 cells, the R181L p53 mutant remains capable of repressing the 
pol III template VAl (Stein et al. 2002a), whereas this mutant was found to have lost 
the ability to repress various pol II transcribed genes (Crook et al. 1994). Consistent 
with this, it is shown here that there are several differences in how p53 represses 
these two classes of gene. The TBP-p53 interaction plays a fundamental role in 
regulating pol III transcription, demonstrated by the finding that titration o f TBP but 
not Brfl can relieve p53-mediated repression (Figure 5.2 and D. Johnson, 
unpublished observations). Although the TBP-p53 interaction is well established, 
there has been no direct evidence implicating this interaction as relevant to regulation 
of pol II transcription (Tansey and Herr 1995; Thut et al. 1995a; Farmer et al. 
1996a). Indeed, Tansey and HeiT showed that TBP binding is not required for p53 to 
activate a pol II reporter (Tansey and Herr 1995).
p53-dependant HDAC recruitment has been shown to mediate repression of certain 
pol II transcribed genes (Murphy et al. 1999). Although HDAC activity modulates 
pol III transcription, this activity is irrespective of p53 status. Transfection of p300
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was found to stimulate VAl transcription very slightly. This effect was also found to 
be independent of p53. p53 itself can be acetylated by p300 (Gu and Roeder 1997). 
Such modifications are thought to modulate the activity of the protein. p300 may 
however play a more direct role in controlling pol III transcription. ChIP analysis 
revealed that there may be a weak association between p300 and tRNA genes. The 
CBP/p300 associated factor PCAF plays a role in controlling pol I transcription 
(Muth et al. 2001). In this case, acétylation of the basal pol I transcription factor SLl 
resulted in increased association with the rDNA promoter and an increase in pol I 
transcription. It is equally possible that components of the basal pol III 
transcriptional machinery are subject to acétylation. Transcription can be regulated 
tlnough acétylation and deacetylation of clnomatin directly (Chan and La Thangue 
2001). hr many cases, hyper-acetylation of core histone tails is associated with 
increased transcriptional activity, whereas hypo-acetylation correlates with 
transcriptional repression. Pol III transcription may be regulated by such chromatin 
remodelling effects. TFIIIC was previously demonstrated to harbour intrinsic HAT 
activity and partial inliibition of this activity coiTclates with a partial reduction in 
transcription fi'om chromatin templates (Kundu et al. 1999).
Chip analysis indicated that RB is not present on tRNA genes. This finding is 
consistent with the model in which RB represses pol III transcription tlnough its 
interaction with TFIIIB, which prevents TFIIIB interacting with TFIIIC2 and being 
recruited to a promoter (Sutcliffe et al. 2000). Collectively, the data investigating the 
mechanism by which p53 represses pol III transcription supports a similar model. In 
the absence of p53, efficient pol III transcription complexes can form (Figure 5.16a).
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Figure 5.17. Model of p53 mediated pol III transcriptional repression. (A)
Specific initiation at class III genes is dependent on the interaction between TFIIIB 
(blue) and pol III (pink); in most cases TFIIIB must be recruited to promoters 
through binding to TFIIIC2 (green). (B) p53 associates with TFIIIB and prevents it 
from interacting with pol III and TFIIIC2. In this way p53 is able to disrupt 
preinitiation complex formation and inhibit transcription.
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In the presence of functional p53, TFIIIB is targeted. p53-TFIIIB interactions prevent 
TFIIIC2-dependent recruitment of TFIIIB to pol III promoter regions. This 
ultimately leads to a decrease in pol III transcription, mediated by a reduction in 
recruitment of pol III to the start sites of genes (Figure 5.16b).
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Chapter 6
The Physiological role of p53 in controlling pol III transcription in 
response to genotoxic stress
6.1 Introduction
Although not required for normal growth and development, p53 is a key player in the 
prevention of tumour development (Ko and Prives 1996; Levine 1997). Under a 
range of physiological stress conditions p53, can induce cell cycle arrest or apoptosis 
(Ko and Prives 1996; Levine 1997). These functions serve to control DNA damage 
and protect cellular progeny from accumulating genetic mutations (Ko and Prives 
1996). Most tumours evade these defences by inactivating p53 (Hollstein et al. 
1991), In tumours that do not contain mutated p53, perturbations in the p53 
activation or response pathways often occur (SheiT and Weber 2000).
Activation of p53 is observed in response to a variety of cellular stresses. These 
include DNA damage, hypoxia and ribonucleotide depletion (Larkin and Jackson 
1999). Under nonnal physiological conditions, p53 is maintained at low levels in an 
inactive state. A variety of mechanisms exist to control p53 activity, with one of the 
most central regulators being Mdni2 (Momand et al. 1992; Oliner et al. 1993). As 
well as inliibiting the transcriptional activation function of p53, Mdm2 can also target 
p53 for proteolytic degradation (Oliner et al. 1993; Haupt et al. 1997; Kubbutat et al. 
1997b).
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Within minutes of a cell sustaining DNA damage, p53 levels can rise dramatically 
(Larkin and Jackson 1999). This is mostly achieved tlnough stabilization of p53. 
Stress can induce multiple post-translational events that have been found to modulate 
the âmction of p53 (Giaccia and Kastan 1998; Woods and Vousden 2000). These 
phosphorylation, dephosphorylation and acétylation events are believed to play 
major roles in controlling the activity of p53. The nature of the response pathway can 
vary dramatically between different cell types and different stresses (Giaccia and 
Kastan 1998; Oren 1999; Zhao et al. 2000). Serine-15 of p53 is phosphorylated in 
response to DNA damage, but not in response to aberrant oncogene signals (de 
Stanchina et al. 1998). It was also shown that p53 is phosphorylated on serine-15 in 
response to IR or UV, whereas phosphorylation of the CK2 site situated at serine-392 
is phosphorylated following UV but not IR (Blaydes and Hupp 1998; Kapoor and 
Lozano 1998; Lu et al. 1998). Although it is established that p53 can regulate pol III 
transcription, it is yet to be detennined under which physiological circumstances this 
control becomes important. It was therefore investigated whether the DNA damaging 
agent methyl methane sulfonate (MMS) could induce a p53 response that results in 
the down regulation of pol III activity.
6.2 Results
6,2.1 p53 induction in response to DNA-damage results in down regulation of 
pol III transcription.
Several forms of DNA damage have been shown to activate p53 (Larkin and Jackson 
1999). Such damaging agents include ionising radiation, radio-mimetic drugs, 
ultraviolet light and a variety of chemicals (Larkin and Jackson 1999). It was tested
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whether changes in pol III activity occur in response to the DNA damage-inducing 
agent methyl methane sulfonate (MMS). MMS is a DNA alkylating agent that has 
previously been demonstrated to provoke a p53 response. HeLa cells were gi*own to 
80% confluency then treated for two hours with 0.04% MMS. Cell extracts were then 
analysed by Western blotting for p53 expression. HeLa cells express low levels of 
p53, which can be induced upon treatment with MMS (Figure 6.1 A, upper panel). 
This induction was specific, since the levels of the actin control remained unchanged 
(Figure 6.1 A, lower panel). As exemplified by in vitro transcription assays, this 
induction correlated with a decrease in tRNA^^" transcription (Figure 6. IB). In 
addition RT-PCR analysis revealed that MMS treatment decreased synthesis of 
tRNA^^' (Figure 6.IC, top panel). It is well established that p53 can induce synthesis 
of p21. As shown in Figure 6.1C, middle panel, RT-PCR analysis revealed that MMS 
treatment of HeLa cells also resulted in an induction of p21 mRNA (Figure 6.1C, 
middle panel). These changes were specific, since the levels of ARPP PO inRNA 
were unresponsive to MMS. This result demonstiates that MMS treatment of HeLa 
cells results in induction of p53. This increase in p53 correlates specifically with an 
induction of p21 gene expression, and a repression of pol III transcription.
6.2.2 Induction of p53 by MMS specifically reduces TBP occupancy at tRNA 
genes.
Having established that MMS induces a p53 response that leads to a down regulation 
of pol III transcription, it was investigated whether changes in TFIIIB occupancy at 
pol III promoters could be detected in response to MMS. ChIP analysis revealed that 
significantly less TBP is present at tRNA^^" (upper panel) and tRNA^^*' (middle 
panel) promoters in MMS treated HeLa cells when compared to untreated cells
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Figure 6.1. Induction of endogenous p53 by genotoxic stress represses tRNA 
expression. (A) p53 levels increase following MMS treatment. Immunoblot analysis 
of untreated HeLa (lane 1) or HeLa cells treated for 2 hours with 0.04% MMS (lane 
2). 50pg protein was probed with DO-1 against p53 (upper panel) or C ll  against 
actin (lower panel). (B) tRNA^" transcription is down regulated following MMS 
treatment, pleu (250ng) was transcribed with HeLa cell extract (15pg) that had been 
untreated (lane 1) or treated with 0.04% MMS for 2 hours (lane 2). (C) p21 is 
induced following MMS treatment. RT-PCR analysis of cDNA prepared from RNAs 
extracted from untreated HeLa cells (lane 1) or HeLa cells treated with 0.04% MMS 
(lane 2) using primers for tRNA^ *^^  (top panel) p21 (middle panel) or ARPP PO 
(bottom panel).
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(Figure 6.2, lanes 4 and 9). In contrast, in response to MMS, TBP occupancy on the 
p21 promoter increased (Figure 6.2, third panel, lanes 4 and 9). p21 is a well- 
established target gene o f p53. Upon p53 induction, p21 gene expression is induced 
(El-Deiry et al. 1993). Under these circumstances increased TBP binding would be 
expected. ChIP with an antibody against p53 revealed that p53 was not detectable on 
tRNA genes, either before or after MMS treatment. This result further suggests that 
p53 does not associate with tRNA genes in vivo, hi contrast, however, p53 is found 
associated with the p21 locus after MMS treatment (Figure 6.2, third panel, lane 10). 
This is consistent with previous observations that p53 can bind to the p21 promoter 
and induce its expression (El-Deiry et al. 1993). These effects were specific, since 
none of the factors tested were found to be associated with an internal fragment of 
the TFIIIC220 gene (Figure 6.2, bottom panel). The immunoprécipitation control, in 
which no antibody was used, revealed no background binding of DNA (Figure 6.2, 
lane 3 and 8). These results are in agi’eement with the mechanism by which the p53- 
TFIIIB complex is excluded fi'om tRNA gene promoters. Firstly these results 
demonstrate that TBP occupancy on tRNA genes is reduced following MMS 
treatment. This is a specific effect, since MMS treatment, results in increased 
association of TBP with the p21 gene locus. It is again suggested that p53 does not 
associate with pol III genes, even after induction with MMS.
6.2.3 Induction of p53 by MMS results in a decrease in TFIIIC2-tRNA 
association.
To further investigate the mechanism p53 utilizes to mediate repression of pol III 
transcription in response to DNA damage, ChIP assays were earned out using 
antibodies against several components of the basal pol III transcriptional machinery.
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Figure 6.2. Occupancy of TBP at tRNA genes decreases following DNA-damage.
Chip was carried out with antibodies against TBP (lanes 4 and 9) and p53 (lanes 5 
and 10) or beads alone as control (lane 3 and 8). Occupancy at tRNA^®“ (upper 
panel), tRNA^ '^" (second panel), p21 (third panel) and TFIIIC220 genes (lower panel) 
was analysed in untreated HeLa cells (lanes 1-5) and HeLa cells treated with 0.04% 
MMS for 2 hours (lane 6-10). Input DNA is shown in lanes I, 2, 6 and 7. (B). Values 
shown represent the % of factor co-precipitating with tRNA in vivo compared with 
the input DNA which is set at 100% in each case. Values represent the mean and 
standard deviation of two experiments.
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Upon MMS treatment and induction of p53, there is significantly less TBP, Brfl and 
Bdpl present at tRNA*^^  ^ (Figure 6.3, upper panel) and tRNA^^' (Figure 6.3, lower 
panel) promoters (Figure 6.3, lanes 3, 4 and 5). Promoter occupancy of pol III is also 
decreased in response to MMS (Figure 6.3, lane 8). These findings are consistent 
with the previously detennined mechanism showing that TFIIIB occlusion fi'om pol 
III templates occurs in the presence of p53. However, TFIIIC220 and TFIIICllO 
levels also decrease in response to MMS (Figure 6.3, lanes 6 and 7). This is in 
contrast to the finding that TFIIIC2 occupancy on tRNA genes remains comparable 
in p53 knockout and wild-type fibroblasts (Figure 5.11). The immunoprécipitation 
control, in which no antibody was used, demonstrated that little background 
association of DNA was observed in either case (Figure 6.3, lane 2).
To further investigate the activity of TFIIIC2 following MMS treatment, EMSAs 
were perfomied. A promoter fragment containing a B-block consensus sequence 
capable of binding TFIIIC2 was used. After incubation of this B-block oligo with 
untreated or MMS treated HeLa cell extracts, a major TFIIIC2-DNA binding 
complex was observed (Figure 6.4 lane 2-5). Treatment of HeLa cells with MMS 
resulted in a dramatic decrease in the binding activity of this major complex. This 
result suggests that TFIIIC2 DNA-binding activity is reduced in response to MMS. 
These results imply that DNA damage induced by MMS can affect both TFIIIB and 
TFIIIC2 in order to down regulate pol III activity. However, there is no evidence 
demonstrating that these effects are mediated directly by p53.
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Figure 6.3. Occupancy of TFIIIC2 at tRNA genes decreases following DNA- 
damage. ChIP was carried out with antibodies against TBP (lane 3), Brfl (lane 4), 
Bdpl (lane 5), TFinC220 (lane 6), TFinCllO (lane 7) and RNA pol III (lanes 8) or 
beads alone as control (lane 2). Occupancy at tRNA^®“ (upper panel) and tRNA^^’’ 
(lower panel) was analysed in untreated HeLa cells (left panel) and HeLa cells 
treated with 0.04% MMS for 2 hours (right panel). Input DNA is shown in lane 1.
(B). Values shown represent the % of factor co-precipitating with tRNA in vivo 
compared with the input DNA which is set at 100% in each case.
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Figure 6.4. DNA-binding activity of TFIIIC2 is reduced upon induction of DNA- 
damage. EMSA using Ing of B-block oligo, Ipg polydl-dC, and no protein (lane 1) 
or 20pg of cellular extract from untreated HeLa cells (lanes 2 and 3) or HeLa cells 
treated with 0.04% MMS for 2 hours. Lanes 2 and 4 also contained 50ng of 
unlabelled RJWl oligo whereas lanes 1, 3 and 5 contained 20ng of non-specific oligo 
of a similar length.
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6.2.4 Single amino acid substitutions at residues 15 and 34 do not prevent p53~ 
mediated pol III transcriptional repression.
Phosphorylation of p53, in response to DNA damage, is one mechanism through 
which the activity o f p53 may be regulated. Several lines of evidence have shown 
that serine-15 and serine-37 (equivalent to serine-34 of murine p53 by sequence 
homology) of p53 are phosphorylated in response to DNA damage (Milne et al. 
1995; Shieh et al. 1997; Siliciano et al. 1997). Having established that DNA damage, 
induced by MMS, results in down regulation of pol III activity it was tested whether 
substitution of serine-15 or serine-34 could modulate the activity of p53 to regulate 
pol III transcription in vitro.
Recombinant baculovirus encoding wild-type or mutant His-p53 was expressed in 
Sf9 cells as described (Okorokov and Milner 1999), and purified to near 
homogeneity using the polyhistidine tag. When titrated into nuclear extract, wild- 
type p53 repressed Alu transcription (Figure 6.5A and B, lanes 2, 3 and 4). 
Substitution of serine-15 to alanine produced no clear difference in transcriptional 
repression by p53 (Figure 6.5A, lanes 6, 7 and 8). Titration of p53 S15D, where 
serine-15 of p53 was substituted to glutamic acid resulted in a marginal increase in 
transcriptional repression by p53 (figure 6.5A, lanes 10, 11 and 12). Substitution of 
serine-15 to alanine resulted in a slight decrease in transcriptional repression by p53, 
when compared to that obtained by wild-type His-p53. In contrast substitution of 
serine-34 of p53 to either alanine (Figure 6.5B, lanes 6, 7 and 8) or glutamic acid 
(Figure 6.5B, lanes 10, 11 and 12) resulted in no change in repression of Alu 
transcription by p53. Substitution of a serine to alanine would prevent
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Figure 6.5. Mutation at residue 15 or 34 permits efficient p53-mediated pol III 
transcriptional repression. (A) pRH5.7 (250ng) (top panel) was transcribed using 
HeLa nuclear extract (15pg) that had been preincubated for 10 min at 30°C in the 
absence (lanes 1, 5, 9 and 13) or in the presence of 0.4pg, 0.8pg or 1.2pg of wild- 
type p53 (lanes 2, 3 and 4 respectively), 0.4pg, 0.8pg or L2|iig of p53(S15A) (lanes 
6, 7 and 8) or 0.4pg, O.Spg or L2pg of p53(S15D) (lanes 10,11 and 12). (B) pRH5.7 
(250ng) was transcribed using HeLa nuclear extract (15pg) that had been 
preincubated for 10 min at 30“C in the absence (lanes 1 , 5 , 9  and 13) or in the 
presence of 0.4pg, 0.8pg or 1.2pg of wild-type p53 (lanes 2, 3 and 4 respectively), 
0.4pg, 0.8pg or 1.2pg of p53(S34A) (lanes 6, 7 and 8) or 0.4pg, 0.8pg or 1.2pg of 
p53(S34D) (lanes 10, 11 and 12).
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phosphorylation of this residue. In both cases this substitution at residues 15 or 34 
permitted pol III repression, suggesting that phosphorylation of serine-15 or serine- 
34 is not essential for p53 to repress pol III transcription. A marginal increase in p53- 
mediated pol III repression is observed when serine-15 was substituted to glutamic 
acid. This substitution has been shown sometimes to mimic serine phosphorylation. 
Phosphorylation of serine-15 has previously been reported to result in stabilization of 
p53 (Sheih et al. 1997), and this may account for this slight increase in repression. 
These results are preliminary and require further investigation. The analyses would 
particularly benefit fi'om in vivo investigation where one could be certain that p53 
was being modified correctly.
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6.3 Discussion
Although it is clear that p53 can directly repress pol III transcription, physiological 
significance of this regulatory mechanism remains unexplored. In this study, the 
regulation of p53 tlu'ough the induction of DNA damage is addressed, in the context 
of its function in controlling pol III transcription. Here it is shown that DNA damage, 
induced by the chemical alkylating agent MMS, provoked an increase in p53 levels 
that correlated specifically with a decrease in pol III activity. This finding is in 
agreement with previous observations in yeast showing that MMS treatment of cells 
resulted in a down regulation of 5S rRNA and tRNA (Ghavidel and Schultz 2001). A 
substantial repression of these genes was also observed following UV exposure 
(Ghavidel and Schultz 2001), Importantly, the authors also showed that repression of 
pol III transcription by MMS is not an indirect effect of cell cycle arrest, since MMS 
treatment fully down regulated pol III transcription in arrested cdc mutants (Ghavidel 
and Schultz 2001)
Chip analysis revealed that in response to MMS, TBP occupancy at tRNA 
promoters is decreased. This finding is in concordance with the demonstration that 
wild-type MEFs have less TBP associated with tRNA promoters when compared 
with matched p53-lmockout cells. In contrast, TBP occupancy on the p2I promoter 
region increased in response to MMS. RT-PCR analysis demonstrated that p21 gene 
expression is increased in response to MMS. Following DNA damage, p53- 
dependant G1 arrest is mediated, at least in part, through p53’s induction of p21 (El- 
Deiry et al. 1994). The findings here are therefore in agreement with this well- 
established observation. ChIP assays also revealed that whilst p53 is associated with 
the p21 promoter following MMS treatment, no detectable levels of p53 were found
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binding to tRNA genes either before or following MMS treatment. This result 
suggests that association of p53 with pol Ill-transcribed genes is not essential for p53 
to elicit repression pol III transcriptional repression. p53 binds DNA in a sequence- 
specific mamier. Such sequences are routinely found in p53 target genes, such as 
p21. p53 consensus motifs are, however, not usually located in pol III transcribed 
genes. This finding further suggests that p53 does not associate directly with pol III 
templates. Collectively the results are in agreement with the model in which p53 
represses pol III transcription tlnough targeting and subsequent occlusion of TFIIIB 
from pol III transcribed genes.
Further ChIP analysis of untreated and MMS treated HeLa cells revealed that the 
occupancy of RNA polymerase III and the TFIIIB subunits TBP, Brfl and Bdpl was 
reduced at the tRNA gene promoters. Furthermore, association of the TFIIIC2 
subunits 110 and 220 was also decreased in response to MMS. EMSA also indicated 
a reduction in TFIIIC2 DNA-binding activity following MMS treatment. These 
preliminary investigations suggest subtle differences in the mechanistic response to 
p53 and DNA damage. Ghavidel and Schultz recently demonstrated that partially 
purified TFIIIB fractions from untreated cells could fully restore pol III transcription 
in MMS-treated extracts (Ghavidel and Schultz 2001), indicating that TFIIIB was the 
sole limiting factor in these assays. In contrast fractions containing partially purified 
pol III and TFIIIC2 but not TFIIIB were inactive (Ghavidel and Schultz 2001). These 
studies were earned out in yeast, which lack p53, and therefore provides and 
explanation for the difference in results. The findings in this study are preliminary 
and certainly require further investigation. It is important to establish that the 
changes in transcription factor occupancy are promoter specific.
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Protein kinase CK2 has been implicated in mediating a cellular response to stress in 
which pol III activity is reduced. (Ghavidel and Schultz 2001). CK2 was found to 
physically associate with and inactivate TFIIIB (Ghavidel and Schultz 2001). CK2 is 
responsible for phosphorylating serine-386, located in the C-temiinus of p53 (Hall et 
al. 1996). Blocking phosphorylation of this residue, tlu'ough an alanine substitution, 
was shown to reduce the ability of p53 to repress expression from the c-fos promoter. 
This effect was specific since mutation of serine-386 did not affect the ability of p53 
to activate p21 gene expression (Hall et al. 1996). It would be interesting to ascertain 
whether this mutation could affect the ability of p53 to repress pol III transcription.
Post-translational modifications are believed to rapidly and effectively regulate p53 
in response to DNA damage. Treatment of cell lines expressing p53 with the 
phosphatase inhibitor okadaic acid was found to result in an increase in p53 
phosphorylation and increased levels of p53 protein (Zhang et al. 1994). Multiple 
lines of evidence have demonstrated that p53 is phosphorylated in vitro both in the 
N- and C-terminal regions by a number of different kinases (Larkin and Jackson 
1999). The DNA-dependant protein kinase (DNA-PK) has been demonstrated to 
phosphorylate p53 in vitro at serine-15 and 37 (equivalent to serine-34 of murine p53 
by sequence homology) (Lees-Miller et al. 1990; Shieh et al. 1997). ATM kinase was 
also shown to phosphorylate serine 15, whereas ATR kinase was capable of 
phosphorylating both serine-15 and 37 (Banin et al. 1998; Camman et al. 1998; Lakin 
and Jackson 1999; Tibbetts et al. 1999). Whether these modifications have direct 
relevance in vivo remains controversial, but the effects of DNA damage on such 
modifications are becoming apparent. Phospho-peptide mapping revealed that 
phosphorylation of mouse p53 at serine-34 occurred in response to UV (Milne et al.
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1995). Serine-15 was also identified as a site on p53 that was phosphorylated in 
response to DNA-damage induced by UV or IR (Shieh et al. 1997; Siliciano et al. 
1997). It is unclear at present whether covalent modification of p53 contributes to its 
control of pol III transcription. Mutation of serine-15 or serine-34 of murine p53 had 
little effect in modulating p53-mediated pol III transcription in vitro. In vitro 
phosphorylation o f serine-15 of p53 has been shown to inhibit the interaction of p53 
with Mdm2 (Shieh et al. 1997), and it has been proposed that phosphorylation of 
serine-15 of p53 may be important in controlling the half-life and transcriptional 
activity of p53 in response to DNA-damage (Larkin and Jackson 1999). In this 
model, p53 is targeted for ubiquitin-mediated degradation in the undamaged cell by 
interacting with Mdm2. Upon DNA damage, p53 becomes phosphorylated on serine- 
15 and no longer interacts with Mdm2 (Shieh et al. 1997; Siliciano et al. 1997). This 
therefore results in a decrease in Mdm2 dependant degradation. Consistent with this 
model, substitution of serine-15 with glutamic acid (a residue that sometimes mimics 
serine phosphorylation) resulted in slight stabilisation of p53 in vivo (Ashcroft et al. 
1999). The precise role of serine-15 is however unclear (Dumaz et al. 2001). Co­
transfection of Mdm2 with p53 was shown to abrogate p53-mediated pol III 
transcriptional repression (Stein et al. 2002a). Therefore it is likely that 
destabilisation of the Mdm2-p53 interaction, tlu'ough phosphorylation of Serine-15, 
may result in a p53-mediated repression of pol III activity.
Multiple residues in p53 have been reported to undergo phosphorylation. As well as 
aforementioned N-terminal residues, multiple C-terminal residues are believed to 
undergo modification. For example, CK2, PKC and Cdks have been demonstrated to 
phosphorylate the C-terminal regulatory domain of p53. Such phosphorylation events
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have been shown to activate p53 sequence-specific DNA binding in vitro (Hupp et 
al. 1992; Hupp and Lane 1994; Takenaka et al. 1995; Wang and Prives 1995). Both 
N and C-terminal domains of p53 are important in eliciting p53-mediated repression 
of pol III transcription (Stein et al. 2002b). It is therefore possible that modifications 
within these regions modulate the activity of p53 with respect to its control of pol III 
gene expression.
p53-mediated pol III repression may seiwe a critical role in cells with DNA damage. 
It could serve to divert cellular resources bom transcription to DNA repair and other 
processes required to maintain viability while the damaged cell is repaired (Ghavidel 
and Schultz 2001). In yeast, it was demonstrated that DNA repair is inliibited by pol 
III transcription (Abousseklrra and Thoma 1998). In this situation repression of pol 
III activity, by p53, may allow adequate access of the repair machinery to damaged 
DNA. In damaged cells, it is also possible that p53-independent effects contribute to 
the down-regulation of pol III activity. It is also very likely that multiple mechanisms 
may exist to repress pol III transcription, depending on which form of cellular stress 
is elicited.
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Chapter 7
Conclusions, discussion and future work
The formation of productive mammalian transcription initiation complexes on tRNA 
gene promoters, involves the binding of TFIIIC2 to the intragenic promoters, 
followed by the recruitment of TFIIIB and TFIIICl to the complex via interactions of 
these factors with TFIIIC2. This TFIIIB-TFIIIC-DNA complex then serves to recruit 
Pol III to the start site of transcription via contacts between TFIIIB and pol III (Paule 
and White 2000; Geiduschek and Kassavetis 2001). The mechanism utilised by p53 
to repress pol III transcription involves binding and inactivation of TFIIIB 
(Chesnokov et al, 1996; Cairns and White 1998). p53 can interact directly with the 
TFIIIB subunit TBP. Association between Brfl and p53 has been observed, although 
at present it camiot be concluded whether this is a direct interaction or mediated 
through another molecule such as TBP. The consequences of such interactions are 
clear, however. Association of p53 with TFIIIB results in diminished interactions 
between TFIIIB, TFIIIC2 and pol III, It is unlikely that p53 can disrupt prefoimed 
interactions between these factors, since assembly of TFIIIB into a preinitiation 
complex, was shown to confer substantial protection against the inliibitory effects of 
p53 (Cairns and White 1998). p53 evidently prevents formation of functional 
preinitiation transcription complexes, hi the presence of wild-type p53, less TFIIIB 
and consequently pol III subunits were found to be associated with tRNA^^" genes in 
vitro. To ascertain the effect of the p53-TFIIIB associations on transcription factor 
occupancy of tRNA genes in vivo ChIP assays were employed. Transcription factor 
occupancy in non-stressed p53^^ cells was compared to that of p53'^‘ cells.
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Reproducibly, it was found that in the presence of wild-type p53, less TFIIIB and pol 
III subunits were associated with the tRNA genes. The decrease in TFIIIB and pol III 
recruitment was not due to a decrease in the cellular concentrations of these 
transcription components. Eichom and Jackson previously reported that Brfl is 
specifically degraded following p53 induction in the TR9-7 fibroblast cell line. In 
contrast there were no discernable differences in the levels of Brfl in the p53^^ and 
p53'^* cells. Unlike the changes observed for TFIIIB and pol III, the occupancy of 
TFIIIC2 was unaffected by p53. This suggests that TFIIIC2 is able to stably associate 
with tRNA gene promoters in vivo in the absence of TFIIIB. Similar results have 
been obtained using ap53 inducible cell line (D. Johnson, unpublished results).
The possibility that p53 might disrupt the TBF-Brfl interaction was investigated. 
Drl represses pol III transcription when overexpressed in vitro or in yeast cells via 
such a mechanism (White et al. 1994b; Kim et al. 1997). In contrast, p53 appears to 
be unable to disrupt the TBP-Brfl interaction. It remains a possibility that the p53 
may prevent the association of Bdpl with the TBP-Brfl complex. Bdpl associates 
very loosely with TFIIIB (Schramm et al. 2000) and consequently this has prevented 
examination of this interaction.
Although direct binding of p53 to TBP has been demonstrated in many studies, the 
biological relevance of this interaction to p53-mediated transcriptional regulation has 
been unclear (Seto et al. 1992; Liu et al. 1993; Martin et al. 1993; Tansey and Herr 
1995; Farmer et al. 1996a; Fanner et al. 1996b). Tansey and Herr (1995) identified 
substitutions in TBP that prevent its binding to p53 in vitro but do not compromise 
its ability to support p53-mediated activation of an RNA pol II reporter in vivo.
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Repression of pol II transcription has also been shown to involve molecular 
interactions that are distinct from those with TBP (Farmer et al. 1996b). 
Overexpression of TBP in transient transfections failed to rescue pol II 
transcriptional repression by p53 (Fanner et al. 1996b). In contrast, increasing 
amounts of recombinant TBP could reverse p53 mediated transcriptional repression 
in vitro. Furthennore, p5 3-mediated inliibition of tRNA transcription can be reversed 
in vivo by TBP (D. Jolmton, unpublished results). The TBP-E248R mutant is also 
able to rescue p53 repressed pol III transcription. This mutant renders TBP 
specifically defective for pol II transcription (Bryant et al. 1996), which suggests that 
the TBP-mediated increase in pol III transcription does not require changes in pol II 
activity. In contrast, overexpression of Brfl could not reverse p5 3-mediated 
repression of pol III gene expression in vivo. At present this experiment cannot be 
carried out in vitro due to our inability to produce significant quantities of 
recombinant Brfl. These observations however provide evidence that the p53-TBP 
interaction is of functional significance for pol III regulation.
A requirement for TBP binding is also consistent with the fact that pol III repression 
involves both the N- and C-tenninal domains of p53. Both these regions contact TBP 
(Liu et al. 1993; Horikoshi et al. 1995). The data presented in chapter 3 demonstrate 
that the N-terminal region of p53 is essential for pol III transcriptional repression in 
vitro. This region encompasses the transcriptional activation domain of p53 and has 
been shown to interact with several proteins, including TBP. Mutation of residues 22 
and 23, within the N-terminal region of p53, has been previously demonstrated to 
severely reduce the ability of p53 to repress pol III transcription in a transient 
transfection assay (Stein et al. 2002b). Chesnokov et al. (1996) also demonstrated the
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importance of these residues in mediating pol III repression. Mutation impaired the 
ability of p53 to bind to TFIIIB and hence down regulate pol III activity both in vitro 
and in vivo. These residues are important in binding TFIID, a function that 
contributes to the regulation of pol II templates (Lin et al. 1994; Chang et al. 1995; 
Lu and Levine 1995; Thut et al. 1995b; Farmer et al. 1996a; Farmer et al. 1996b). 
Deletion of residues 13-19 permitted efficient repression of VAl, when compared to 
wild-type p53 (Stein et al. 2002b). Clearly efficient repression of pol III transcription 
by p53 requires N-terminal sequence that includes residues 22 and 23 but excludes 
residues 13-19.
The C-temiinal portion of p53 also contributes to pol III transcriptional repression. 
Although deletion of the 30 C-temiinal residues did not affect the ability of p53 to 
repress VAl and Alu transcription in vitro, preincubation of wild-type p53 with an 
antibody raised against residues 371-380 clearly blocked transcriptional activity. 
Further evidence implicating the C-terminus in pol III transcriptional repression was 
obtained by transient transfection assays. A p53 mutant lacking the C-terminal 102 
residues of p53 was unable to repress VAl expression in vivo (Stein et al. 2002b). 
Additionally, a p53 mutant carrying a quadruple substitution (ALAL) in residues 
365, 372, 379 and 387, was unable to repress pol III transcription in a transient 
transfection assay (Stein et al. 2002b). This mutant has constitutive DNA-binding 
activity, and can efficiently transactivate pol II transcription and induce a G1 arrest 
or apoptosis (Marston et al. 1998). This result therefore supports the idea that the C- 
terminal region is involved in mediating pol III transcription repression. It also 
provides an important demonstration that repression obseiwed in vivo is not an 
indirect effect of cell cycle aiTest. Residues 339-346 were reported to possess
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independent transrepression activity with respect to pol II reporters (Hong et al. 
2001). It is possible that this region contributes to the pol III response.
It has also been found that the central core domain of p53 is involved in pol III 
transcriptional repression, hidividual deletions of conserved regions II-V have been 
shown to abolish the ability of p53 to repress VAl gene expression (Stein et al. 
2002b). In agreement with these observations, preincubation of wild-type p53 with 
pAbl620, which binds the central core domain, abolishes the ability of p53 to repress 
pol III gene expression in vitro. It is perhaps unexpected that the sequence-specific 
DNA binding domain of p53 is required for pol III repression, since consensus p53 
binding sites are not found in pol III transcribed genes. p53 was undetectable at 
tRNA promoters using ChIP assays. It would be interesting therefore to establish the 
role played by this domain in controlling pol III activity. An obvious possibility is 
that deletions or antibody binding may have interfered with the conformation of the 
p53 molecule. It is also possible that TFIIIB, or an as yet unidentified cofactor, 
which may contribute to regulation, might interact with this region. Further 
experiments will be required to distinguish these possibilities.
p53-mediated repression of pol I transcription also involves a direct interaction 
between p53 and the TBP-containing SLl complex (Zhai and Comai 2000). In this 
instance, p53 binding to SLl prevents its association with the pol I transcription 
component UBF. It is therefore possible that p53-mediated repression of pol 
transcription involves a mechanism similar to that used for pol III, where p53 
directly targets TBP within the SLl complex.
I
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A mechanism distinct from that described here is used by p53 to repress expression 
of the pol II transcribed genes, Map4 and stathmin. p53 binds to the recognition 
sequences within these promoters and recruits a corepressor complex containing 
HDACs that mediate transcriptional silencing (Murphy et al. 1999). TSA, a potent 
inliibitor of HD AC activity, enhances pol III transcriptional activity; this finding is 
consistent with previous observations (Sutcliffe et al. 2000). This effect, however, 
appears to be independent of p53. Consistent with this result, ChIP assays show that 
p53 is not bound to the tRNA genes in vivo. Mechanistic differences between p53~ 
mediated pol II and pol III repression are supported by their distinct responses to a 
leucine substitution at p53 residue 181 (Stein et al. 2002a). In transfected SA0S2 
cells, the R181L p53 mutant remains capable of repressing VAl gene expression but 
has lost the capacity to repress pol II templates such as the SV40 early promoter 
(Crook et al. 1994; Stein et al. 2002a).
Mutations in the p53 tumour suppressor gene occur in about 50% of all human 
tumours, making it the most frequent target for genetic alterations in cancer 
(Hollstein et al. 1991). Inlierited mutations in p53 can give rise to LFS, a familial 
cancer predisposition in humans (Vaiiey et al. 1997b). A wide variety of mutations 
can be associated with this inlierited disease (Varley et al. 1997a). It is shown here 
that the pol III activity of samples prepared form several Li-Fraumeni patients are 
substantially elevated when compared to samples obtained from healthy volunteers. 
Further deregulation of pol III activity was also observed upon deletion of the wild- 
type p53 gene. RT-PCR analysis of primary p53 knock-out fibroblasts has 
demonstrated that endogenous p53 contributes significantly towards the control of
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pol III transcription in vivo. The study of LFS patients provides further insights into 
the function of endogenous p53 at physiological concentrations.
Since each of the patients in the LFS study has a different genetic backgi'ound, it
cannot be concluded that the elevated pol III transcriptional activity results solely
from changes in p53. Evidence from transient transfection assays do, however,
demonstrate that naturally occurring p53 mutations can compromise its ability to
repress pol III transcription (Stein et al. 2002a). The p53 R175P mutant, originally
obtained from an anogenital tumour, was severely compromised in its ability to
repress VAl gene expression in vivo (Stein et al. 2002a). This mutant retains the
ability to suppress proliferation of SA0S2 cells, providing further evidence that the
cell cycle arrest function of p53 is insufficient to mediate a pol III transcriptional
repression. Substitution R273C, within a highly conserved region of the DNA-
binding domain, completely abolishes the ability of p53 to repress VAl transcription
in SAOS2 cells (Stein et al. 2002a). This mutant is also completely inactive towards
various pol II promoters (Crook et al. 1994). Another mutant which is also inactive
towards various pol II promoters is R181L (Crook et al. 1994). This mutant was
nearly as active as wild-type p53 in repressing pol III transcription (Stein et al.
2002a). Although p53 appears to repress pol III transcription tlirough protein-protein
interactions with TFIIIB, rather than direct binding to DNA at a class III gene site, it
was unclear whether mutations within the sequence specific DNA-binding domain of
p53 would perturb its repression function. Clearly however, the data establish that
.regulation of pol III transcription can be influenced by substitutions within the 
central domain. In many cases these effects may be explained by conformational 
changes within the molecule. Arginine 273 is a DNA contact site within p53 (Cho et
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al. 1994). Mutation at this site is not thought to affect p53 conformation, suggesting 
that conformational changes camiot fully account for perturbations in p53 function. 
This therefore implies that the core domain of p53 may be directly involved in 
regulating pol III transcriptional activity.
The p53 R175H substitution accounts for -6%  of the missense mutations identified 
in human cancers (Greenblatt et al. 1994). When compared with other p53 mutants it 
is found to be the most tumourigenic in a variety of assays (Finlay et al. 1989; 
Dittmer et al. 1993); it is also associated with an extremely poor prognosis in human 
cancer victims (Goh et al. 1995). This mutant has not only lost the ability to repress 
pol III transcription, but actually displays a capacity to stimulate expression of VAl 
when transfected into SAOS2 cells (Stein et al. 2002a). The mechanistic basis of this 
stimulation remains unclear at present, although there are precedents for such 
behaviour. For example, the promoter of the gene encoding the insulin-like growth 
factor I receptor is repressed by wild-type p53, but stimulated by certain tumour- 
derived p53 mutants (Werner et al. 1996).
Apart from mutation, p53 function can be compromised by the action of various 
oncoproteins. p53 is bound to and inactivated by the E6 product o f HPV in many 
cervical carcinomas (Wemess et al. 1990; Vousden 1995). As expected, 
cotransfection of E6 abrogates p53 mediated repression of pol III transcription in 
SA0S2 cells. Mdm2 and its human counterpart hdm2 are cellular oncoproteins that 
can also bind to and inactivate p53 (Momand et al. 1992). Amplification and 
overexpression of the gene encoding hdm2 is observed in many tumour types, 
especially osteosarcomas and soft tissue tumours (Momand et al. 1998). As with E6,
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cotransfection of hdm2 was found to counteract the specific repression of pol III 
transcription by p53 (Stein et al. 2002a). In contrast, an hdm2 mutant with a small 
deletion in its p53-binding domain (residues 59-89) was unable to overcome 
repression (Stein et al. 2002a). Both E6 and hdni2 promote the degiadation of p53 
through ubiquitin-mediated proteolysis (Scheffher et al. 1993; Haupt et al. 1997; 
Kubbutat et al. 1997b), and it is therefore not surprising that these oncoproteins 
deregulate pol III transcription. Nevertheless it was important to confirm that E6 and 
hdm2 stimulate pol III transcription, since both are important aetological agents in 
the development of specific types of human cancer.
Extensive northern analysis of 80 tumour specimens representing 19 types of cancer 
revealed that 7SL RNA, a pol III product, is abnormally abundant in every tumour 
analysed relative to healthy tissue fiom the same patient (Chen et al. 1997a). hi 
addition, in situ hybridisation of lung, breast and tongue carcinomas revealed 
increased levels of pol III transcripts in neoplastic cells relative to the surrounding 
healthy tissue (Chen et al. 1997a; Chen et al. 1997b). In a significant number of 
cases, the consistent deregulation of pol III in transformed cells may be provided by 
deregulation of p53. Cun'ently it is estimated that p53 function is compromised in 
over 80% of human tumours (Lozano and Elledge 2000). Derepression of pol III can 
be expected in a high proportion of these cases.
Under normal cellular conditions, p53 does not interfere with cell cycle progi'ession 
or cell survival; however, in response to cellular stresses such as hypoxia, 
ribonucleotide depletion and exposure to genotoxins, p53 is rapidly induced (Oren 
1999). Under such circumstances, reducing cellular biosynthesis through a reduction
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in pol III transcription may be important for maintaining cell viability. Reducing the 
production of rRNA and tRNA might be particularly beneficial when ribonucleotide 
pools are depleted. Indeed, such conditions have been shown to trigger a p53- 
dependent repression in pol III activity (A. McLees and R. J. White, unpublished). 
Furthermore a specific block in rRNA processing and hence ribosome production has 
been shown to trigger a p53-mediated reversible aiTest (Pestov et al. 2001).
The DNA-damaging agent MMS was shown to induce a p53 response that coiTclates 
with a reduction in pol III transcription. The mechanistic basis of this repression 
remains unclear. The data presented here demonstrate that less TBP is found 
associated with tRNA promoters in response to MMS. This is a promoter specific 
decrease, since more TBP was detected at the p21 locus following treatment. These 
findings are in agreement with the situation in the p53 Icnockout and wild-type cells. 
In contrast, levels of TFIIIC2 were also found to be diminished in response to MMS. 
These studies are, however, preliminary and require vital controls. It is necessary to 
show that the changes in factor occupancy are promoter specific and not the result of 
a cell cycle arrest.
It is entirely possible that different mechanisms are employed by p53 to down 
regulate pol III activity in response to different stresses. Stress causes p53 to 
accumulate rapidly, primarily due to its stabilization. It also triggers a complex series 
of phosphorylation and acétylation events (Hupp et al. 1992; Giaccia and Kastan 
1998; Sakaguchi et al. 1998; Oren 1999). The nature of the response pathways and 
the modifications they induce can vary dramatically between different cell types and 
distinct kinds of stress (Giaccia and Kastan 1998; Oren 1999; Zhao et al. 2000). For
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example, serine 15 of p53 is phosphorylated in response to DNA damage, but not in 
response to abeiTant oncogenic signals (de Stanchina et al. 1998). Substitution of 
serine 15 to glutamic acid, a residue that can mimic a serine phosphorylation, 
resulted in a marginal increase in pol III transcriptional repression in vitro. Although 
this modification may enhance the activity of p53 with respect to controlling pol III 
transcription, it was not essential for its function since mutation to alanine also 
permitted efficient pol III repression.
It remains to be detennined whether acétylation of p53 modulates its function with 
respect to pol III transcriptional control. Inhibition of HDAC activity with TSA 
permitted pol III repression in vitro, suggesting that in this system acétylation or 
deacetylation events do not play a major role in controlling pol III activity by p53. 
Transfection of p300 appeared to slightly increase pol III activity, although this 
effect seemed to be independent of p53. This result requires confoiination, although, 
if  substantiated, it may suggest that the pol III apparatus is subject to acétylation that 
may enliance its activity. Indeed, a weak association between p300 and tRNA 
promoters was observed in ChIP analysis. It is entirely possible that p300 may play a 
role reminiscent to that in the pol I system, where acétylation of the basal pol I 
transcription factor SLl results in increased association with the rDNA promoter, 
and an increase in pol I transcription (Muth et al. 2001).
A variety of mechanisms may contribute to the deregulation of pol III activity found 
in a wide range of transfoimed cell lines and tumour samples. The pol III specific 
transcription factor TFIIIC2 is frequently overexpressed in ovarian carcinomas 
(Winter et al. 2000). Furthermore, clinically important tumour vimses, such as
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hepatitis B virus and human T-cell leukaemia virus type I can increase pol III activity 
specifically (Aufiero and Sclmeider 1990; Wang et al. 1995; Gottesfeld et al. 1996; 
Wang et al. 1997). Like p53, the tumour suppressor retinoblastoma protein, RB, has 
been shown to dowiuegulate pol III activity through its interaction with TFIIIB. This 
interaction prevents TFIIIB associating with TFIIIC2 and pol III, thereby inliibiting 
pol III transcription. This function is compromised by a number of mutations that 
arose naturally in human carcinomas (White et al. 1996; Brown et al. 2000; Sutcliffe 
et al. 2000). In addition, tliree viral oncoproteins, E7, El A and SV40 large T antigen, 
can bind to RB releasing pol III from repression (Lamiinie et al. 1999; Sutcliffe et al. 
1999) (White et al. 1996). hi a high proportion of cancers, the function of RB is 
compromised due to its hyperphosphorylation; this can be caused by overexpression 
of cyclin D or loss of p i 6, a specific inliibitor of cyclin D-dependent kinases (Hunter 
and Pines 1994; Bates and Peters 1995). Such hyperphosphorylation has been shown 
to prevent RB from interacting with TFIIIB in vivo (Scott 2001). Clearly, loss of RB 
function tlirough a variety of mechanisms may contribute to pol III deregulation in a 
range of transfoimed cell types (Brown et al. 2000). It is highly likely that, like the 
loss of RB function, deregulation of p53 may contribute to elevated pol III activity 
found in many tumour types.
At present there is no direct evidence that p53 can achieve growth restraint by 
regulating pol III transcription. It is however a possibility, given the clear data 
showing that p53 directly targets pol III transcription. It is unquestionable that 
growth can be prevented when the synthesis of rRNA or tRNA becomes limiting. It 
is however necessary to establish under what physiological conditions this becomes
206
important, and whether loss of such functions during tumour development may 
contribute an important step towards neoplastic growth.
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